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Abstract 




The aim of the study was to clarify the occurrence, and etiological and prognostic factors of 
primary fallopian tube carcinoma (PFTC). We studied the sociodemographic determinants 
of the incidence of PFTC in Finland and the role of chlamydial infections and human 
papillomavirus infections as risk factors for PFTC. Serum tumor markers were studied as 
prognostic factors for PFTC. We also evaluated selected reproductive factors (parity, 
sterilization and hysterectomy) as risk or protective factors of PFTC. The risks of second 
primary cancers after PFTC were also studied. 
 
The age-adjusted incidence of PFTC in Finland increased from 1.2 per 1,000,000 in 1953–
57 to 5.4 per 1,000,000 in 1993–97. The incidence rate was higher in the cities, but the 
relative rise was higher in rural areas. Women in the two highest social classes showed a 
1.8–fold incidence compared with those in the lowest. Women in agriculture and those not 
working outside the home showed only half the PFTC incidence of those in higher 
socioeconomic occupations.  
 
Pretreatment serum concentrations of hCGβ, CA125 and TATI were evaluated as prognostic 
markers for PFTC in a study including 60 patients. Elevated hCGβ values (above the 75th 
percentile, 3.5 pmol/L; OR 2.49, 95% CI 1.22–5.09), stage (OR 2.47, 95% CI 1.21–5.02) 
and histology (OR 2.71, 95% CI 1.26–5.83) were strong independent prognostic factors for 
PFTC. 
 
Chlamydial and human papillomavirus (HPV) infections were studied in two separate 
seroepidemiological case-control studies with 78 PFTC patients. The incidence of women 
with positive HPV or chlamydial serology was the same in PFTC patients and in the control 
group and was not found to be a risk factor for PFTC. 
 
The effects of parity, sterilization and hysterectomy on the risk of PFTC were studied in a 
case control-study with 573 PFTC cases from the Finnish Cancer Registry and ten age-
matched controls from the Finnish Central Population Register. In multivariate analysis 
parity was the only significant protective factor as regards PFTC, with increasing protection 
associated with increasing number of deliveries (OR for 1 or 2 deliveries 0.63, 95% CI 
0.44–0.91; and for > 3 deliveries 0.32, 95% CI 0.19–0.52). In univariate analysis 
sterilization gave borderline protection against PFTC (OR 0.58, 95% CI 0.33–1.00) and the 
protective effect increased with time since the operation. The OR for PFTC after previous 
Abstract 
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breast cancer was 1.69 (95% CI 1.08–2.67) and after other cancers, 1.23 (95% CI 0.79–
1.91). 
 
Finally, the possible risk of a second primary cancer after diagnosis and treatment of PFTC 
in a cohort of 2084 cases from 13 cancer registries followed for second primary cancers 
within the period 1943–2000 was studied. In PFTC patients, second primary cancers were 
36% more common than expected (SIR 1.36, 95% CI 1.13–1.63). The SIR for second cancer 
(all sites combined) was highest if the time since PFTC was more than 10 years, if age at 
PFTC diagnosis was less than 60 years or the year of PFTC diagnosis was before 1984. 
Significant increases were detected for non-lymphoid leukemia (SIR 3.7, 95% CI 1.0–9.4), 
for bladder cancer (2.8, 95% CI 1.0–6.0), for colorectal cancer (1.7, 95% CI 1.0–2.6), for 
breast cancer (1.5, 95% CI 1.1–2.2) and for lung cancer (1.8, 95% CI 0.9–3.2). Significant 
risks were detected for colorectal cancer during the second to fifth year after PFTC 
diagnosis, for non-lymphoid leukemia during the second to tenth year and for breast cancer 
after follow-up of 10+ years. The excess of colorectal and breast cancers after PFTC may 
indicate common effects of earlier treatments, or they could reflect common effects of 
lifestyle or genetic, immunological or environmental background. 
 
In conclusion, the incidence of PFTC has increased in Finland, especially in higher social 
classes and among those in certain occupations. Secretion of hCGβ reflects the 
aggressiveness of this cancer. Serum hCGβ is a good prognostic marker and elevated levels 
reflect a worsened prognosis. The study findings suggest that PFTC is a disease with a 
multi-etiological background. Parity is a clear protective factor, as is previous sterilization, 
whereas factors other than infectious ones will have to be determined as possible risk factors 
of this disease. After PFTC there is a risk of second primary cancers, especially non-




          
Introduction 





Primary fallopian tube carcinoma (PFTC) is one of the rarest carcinomas of the female 
genital tract and therefore it has been poorly studied. Because the incidence of PFTC has 
been increasing (Clayton et al. 2005) and the true incidence is probably underestimated 
(McMurray et al. 1986), there is a need for clinical study of its occurrence, and possible risk, 
prognostic and protective factors. 
 
Primary fallopian tube carcinoma resembles ovarian cancer. The fallopian tube and ovary 
both develop from the Müllerian duct in organogenesis, the two diseases have a similar 
pattern of spread, they are diagnosed and treated similarly and the prognosis is also alike. 
However, in some aspects they behave differently. The earlier lymphatic spread of PFTC 
has been emphasized in many studies (Baekelandt et al. 1993). There are no studies on the 
prognostic significance of tumor markers other than CA125, no studies on the connection 
between chlamydial or human papillomavirus infections and PFTC, nor any studies on the 
effects of parity, earlier hysterectomy or sterilization on the risk of PFTC. Nor have second 
primary cancers occurring after PFTC been studied. The present study was designed to 
clarify these aspects. 






REVIEW OF THE LITERATURE 
1. OVERVIEW AND HISTORICAL ASPECTS 
Primary fallopian tube carcinoma was first described by Renaud in 1847. According to 
Ricci, a case recorded by Renaud is in an unpublished manuscript in the library of the Royal 
College of Surgeons (Ricci 1945). Later it was reported by Rokitansky in 1861, but it was 
Orthmann who described PFTC as its own disease entity in 1886 (Orthmann 1888). In 1898 
Falk used cul-de-sac puncture to aspirate the contents of a carcinomatous tube adherent to 
the pelvic peritoneum, and made the first preoperative diagnosis of PFTC (Southwood 
1956). So far, fewer than 2500 cases have been reported in different studies worldwide, most 
of the reports being case-reports. 
 
Primary fallopian tube carcinoma is a rare disease, constituting about 1% of female genital 
tract malignancies (Nordin 1994). The incidence rate of PFTC is 14% higher among 
Caucasian women (including Hispanics) than in African Americans (Rosenblatt et al. 1989). 
During the period 1995–99 the SEER program reported an age-adjusted incidence rate of 
3.3/1,000,000 among Caucasian women (National Cancer Institute 2001). In Denmark, the 
incidence rate around 1980 was 2.9/1,000,000 (Pfeiffer et al. 1989). So far, the incidence 
rates over longer time periods have not been studied. Little is known about the epidemiology 
of PFTC. The risk and protective factors have been regarded as being similar to those of 
ovarian cancer. From epidemiological studies on ovarian cancer it is known that parity, use 
of oral contraceptives (OCs), breast-feeding, sterilization and hysterectomy are protective 
factors, whereas early age at menarche and late age at menopause are risk factors, and age, 
infertility and infertility treatments may be risk factors to some extent (Irwin et al. 1991; 
Hankinson et al. 1993; Hankinson et al. 1995; Riman et al. 1998; Auranen et al. 2005). 
Furthermore, women with a family history of breast/ovarian cancer have an increased risk of 
ovarian cancer (Narod 2006). 
 
Two-thirds of PFTC patients are postmenopausal. The mean age of PFTC patients varies in 
different studies, being 60–69 years. The association with low parity (nulliparity in 17–45% 
of PFTC patients) (Eddy et al. 1984; Rosenblatt et al. 1989; Hellstrom et al. 1994) and the 
high incidence of histological and/or gross evidence of old pelvic inflammatory disease 
(PID) has been reported in many articles (Peters et al. 1988; Demopoulos et al. 2001). An 
initial connection between PFTC and tuberculous salpingitis was reported by Gungor et al. 
(2003), but no other precise infectious agent has been verified. 






2. CLINICAL FEATURES 
2.1. Symptoms and signs 
The most common presentation of PFTC is postmenopausal vaginal bleeding and discharge 
(50–60%), followed by abdominal pain (30–49%) and abdominal mass (12–75%) 
(Ajithkumar et al. 2005; Clayton et al. 2005). Abdominal pain may be colicky because of 
forced tubal peristalsis. In 1916, Latzko called attention to a triad of intermittent profuse 
serosanguinous vaginal discharge, colicky pain relieved by discharge, and abdominal or 
pelvic mass, reported to present in 15% of PFTC patients. Hydrops tubae profluens – a 
pathognomic feature – implies intermittent discharge of clear or blood-tinged fluid 
spontaneously or on pressure, followed by shrinkage of the adnexal mass. However, this 
occurs in only 5 to 9 % of the patients (Nordin 1994; Ajithkumar et al. 2005). Many PFTC 
patients are asymptomatic and a delay between the first symptoms and diagnosis appears to 
be common. Symptoms connected to PFTC in different studies (Nordin 1994; Alvarado-
Cabrero et al. 1999; Baekelandt et al. 2000; Obermair et al. 2001; Benoit and Hannigan 
2006) are presented in Table 1. 
 
Table 1. Symptoms connected to PFTC 
Presenting symptom %
 
Postmenopausal or abnormal vaginal 
bleeding  35–60
Abdominal pain 30–49
Abnormal Pap smear 10–36
Pelvic mass felt clinically 12–61
Abdominal distension 14–23
Latzko triad  15
Hydrops tubae profluens 5–9
Urinary urgency 8
Acute abdomen  5
 
2.2. Diagnosis 
Correct preoperative diagnosis of PFTC is reported in 0.3–15% of cases (Alvarado-Cabrero 
et al. 1999; Santana et al. 2003; Ajithkumar et al. 2005). It has been speculated that when 
compared with ovarian cancer, PFTC would be more often diagnosed at an earlier stage 
owing to abdominal pain secondary to tubal distension (McMurray et al. 1986; Peters et al. 
1988; Gadducci et al. 2001). However, there are no real studies on this issue. In 10% to 36% 






of patients, abnormal cervical cytology in Pap smear tests representing adenocarcinoma is 
detected (Peters et al. 1988; Rahimpanah and Reid 2000; Obermair et al. 2001) and in 31% 
of the patients endometrial curettage shows adenocarcinoma (Baekelandt et al. 2000). 
 
Ultrasonography in the diagnosis of PFTC is of limited value. There are some reports of 
adnexal masses with sausage-shaped structures with a cogwheel appearance inside, separate 
from the ovaries and uterus, but the exact nature of the lesion was not depicted before the 
operation (Kol et al. 1990; Yuen et al. 2002; Haratz-Rubinstein et al. 2004). Transvaginal 
color Doppler ultrasonography was an improvement, showing low vascular impedance and 
neovascularization, especially in papillary protrusions in the fallopian tubes (Kurjak et al. 
1998). A study with three-dimensional power Doppler ultrasonography was even more 
accurate, showing arteriovenous shunts, microaneurysms, tumoral lakes, blind ends and 
dichotomous branching in all 5 PFTC cases (Kurjak et al. 2000). Some case reports of exact 
diagnoses with computed tomography (Santana et al. 2003) or with magnetic resonance 
imaging (MRI) exist (Mikami et al. 2003; Takagi et al. 2003; Hosokawa et al. 2006). 
Usually, PFTCs show as small cystic or solid masses that typically are sausage-shaped in 
MRI. 
 
Niloff et al. pioneered research into tumor markers of PFTC in 1984. They described 
elevated CA125 levels in four patients with PFTC, associated with recurring disease (Niloff 
et al. 1984). Circulating levels of CA125 are increased in 65–80% of PFTC patients 
preoperatively (Takeshima et al. 1997; Baekelandt et al. 2000; Hefler et al. 2000). 
Concentrations of CA125 have been reported to be elevated in 20% of cases of stage I 
disease and in 75%, 89% and 100% in cases at stages II, III and IV, respectively (Takeshima 
et al. 1997). 
2.3. Histopathology 
Normal fallopian tube walls are constructed of three layers: the outer serosa layer, the 
muscularis containing an outer thinner longitudinal layer and an inner circular muscular 
layer, and the mucosa. The mucosal lining is composed of at least three types of cells: 
ciliated cells, the wave of which is directed towards the uterus, and nonciliated cells, i.e. 
secretory cells and intercalary (peg) cells that may be a variant of the secretory cells. Below 
the surface epithelium there are often stromal cells that can undergo decidual differentiation, 
e.g. in pregnancy. The epithelial cells undergo changes during the menstrual cycle in 






response to changes in hormone levels, particularly those of estrogen (Ross et al. 2002). 
Fallopian tube carcinomas spread to adjacent organs, the peritoneum and regional lymph 
nodes. In many cases carcinomas involve both the tube and the ovary and it may be difficult 
to determine the organ of origin. In order to be regarded as a primary fallopian tube 
carcinoma the main tumor has to lie within the tube or its fimbrial end, a transition from 
benign to malignant epithelium should be visible and the ovaries/uterus should be normal or, 
if not, the condition must be clearly different from the fallopian tube lesion (Tavassoli et al. 
2003). In 10–25% of patients both fallopian tubes are affected (Sedlis 1978; Yoonessi 
1979). 
 
The majority of fallopian tube malignancies are adenocarcinomas. The most common 
histological subtype is serous adenocarcinoma (50–80% of cases), followed by 
endometrioid, mucinous and other subtypes including clear cell, transitional and 
undifferentiated variants (Alvarado-Cabrero et al. 1999; Baekelandt et al. 2000). Rare types 
of cancers include sarcomas, germ cell tumors, lymphomas and malignant müllerian tumors 
(Coppleson 1992). There is no generally agreed grading system for fallopian tube 
carcinoma. The three-tiered system employed is based on the extent of the solid component 
and cellular atypia. 
2.4. Staging 
In 1991, the International Federation of Gynecology and Obstetrics (FIGO) established a 
staging classification for PFTC (Table 2). The distribution of different stages in different 
studies is summarized in Table 3. 
Table 3.   Distribution (%) of clinical stages (0–IV) in patients with PFTC  
        
Reference Year  n*       
    0 I  II   III  IV  
Eddy et al. 1984 71 6 20 27 34 13
Peters et al. 1988 115 34 23 22 3
Hellström et al.  1994 128 1 56 23 14 6
Rosen et al. 1998 143 42 19 26 12
Wolfson et al. 1998 72 33 28 33 6
Rauthe et al. 1998 37 46 19 32 3
Baekelandt et al.  2000 151 6 27 21 34 11
Hefler et al. 2000 53 30 13 47 9
Gadducci et al. 2001 88 24 24 49 3











































































































































































































































































































































































































































































































































































































































































































































































































































































































2.5. Comparison of characteristics of PFTC and ovarian cancer 
Primary fallopian tube carcinoma and epithelial ovarian cancer resemble each other in many 
ways. In Table 4 these characteristics are summarized (Peters et al. 1988; Hellstrom et al. 
1994; Pectasides et al. 1994; McGuire et al. 1996a; McGuire et al. 1996b; Rosen et al. 1998; 
Wolfson et al. 1998; Baekelandt et al. 2000; Hefler et al. 2000; Gadducci et al. 2001; Kosary 
and Trimble 2002; du Bois et al. 2003; Ozols et al. 2003; Trimbos et al. 2003; Pectasides et 
al. 2006).   
 
Table 4.  Frequency (%) of characteristics of PFTC and EOC* 
  PFTC EOC 
Histology   
  Serous 50–80 52–80 
  Endometrioid  8–50 13–24 
  Mixed  4–17  3–9 
        Undifferentiated  8–11  1–2 
  Clear cell  2  4–12 
  Transitional 11  1–2 
  Mucinous  3–8  2–20 
Grade   
  1 15–20  8–20 
  2 20–30 30–38 
  3 50–65 48–54 
Stage   
  I 20–56 12 
  II 17–27  9–11 
  III 14–49 63–67 
  IV  3–13 14–17 
Overall 5-year 
survival 22–57 50–82 
*EOC= epithelial ovarian cancer 
2.6. Natural course and the pattern of spread 
Because of its frequently observed cardinal symptoms, i.e. painful tension in the tubes and 
an abnormal discharge of serous fluid, 17-56% of cases of PFTC are at stages I and II at 
diagnosis compared with ovarian carcinomas, in which two thirds are at stages III and IV at 
diagnosis. However, there are suggestions that advanced carcinoma of the tubes could be 
misdiagnosed as ovarian adenocarcinoma (Benedet et al. 1977), which would account for 
the lower incidence of advanced stages of the disease at diagnosis. The pattern of spread of 
PFTC has long been considered to be similar to that of ovarian carcinoma, with 






intraperitoneal spread being the most frequently encountered (Wolfson et al. 1998). There is 
often intraperitoneal spread before the invasion of the ovaries. When direct invasion and 
transluminal spread occurs, it involves the serosae of the ovaries, uterus and intestines 
(Sedlis 1978). Lymph node involvement appears to be more common in PFTC than in 
ovarian carcinoma. The major lymphatic channels of the fallopian tube drain to the para-
aortic nodes, whereas the medial portion occasionally drains via the lymphatics of the round 
ligaments to the inguinal region. Lymph node involvement occurs in 42 to 59% of PFTC 
patients, with almost equal involvement of para-aortic and pelvic nodes (Klein et al. 1994; di 
Re et al. 1996). 
2.7. Associated pathologies and hereditary risk of PFTC 
In 11 to 15% of PFTC patients there has been another malignancy before the diagnosis of 
PFTC (Alvarado-Cabrero et al. 1999; Baekelandt et al. 2000; Carcangiu et al. 2004; Clayton 
et al. 2005). In the study by Alvarado-Cabrero, 11 of 103 cases (11%) had had an earlier 
breast cancer. This study suggested that the association between breast and gynecological 
malignancies was a result of their similar hormone-responsiveness. Baekelandt et al. (2000) 
detected eight breast cancers, two cancers of the colon, and twelve second gynecological 
cancers among 151 PFTC patients. In a study by Aziz et al. (2001) an increase in the risk of 
ovarian cancer (RR = 2.2) and of early-onset breast cancer (RR = 2.4) was observed in the 
first-degree relatives of patients with PFTC. Altogether, 11% of PFTC patients were 
BRCA1 mutation carriers and 5% carried BRCA2. The authors suggested that PFTC should 
be considered to be a clinical component of the hereditary breast-ovarian cancer syndrome, 
and it may be associated with BRCA1 and BRCA2 mutations (Aziz et al. 2001). The 
frequency of proliferative lesions of the tubal epithelium is increased in BRCA1 mutation 
carriers (Carcangiu et al. 2004). Leeper et al. found three PFTC cases in a study in which 
they examined fallopian tubes in 30 patients with BRCA1 or BRCA2 gene mutations, or a 
family history indicating susceptibility to ovarian and breast cancer (Leeper et al. 2002). In 
2005, Cass et al. reported a 43% rate of BRCA mutations in PFTC patients (11/28 BRCA1 
and 1/28 BRCA2). Those with BRCA mutations were also younger than those with sporadic 
PFTC (Cass et al. 2005). For comparison, the rate of BRCA mutations among ovarian 
cancer patients is 3 to 10% (Dorum et al. 1999; Malander et al. 2004).  






2.8. Survival and prognostic factors 
Because PFTC is rare and treatment modalities vary between different countries, survival 
rates also fluctuate widely. Lymphangial spread at early stages is typical of PFTC and 
worsens the prognosis. Five-year overall survival rates vary between 22 and 57%. Survival 
rates according to different stages are summarized in Table 5. 
2.8.1. Stage 
In almost all studies concerning prognostic factors, stage has been significant (Table 5): 
patients with PFTC who have local disease survive better than those with advanced stages. 
For patients with stage I disease, the depth of tumor infiltration in the tubal wall and 
intraoperative tumor rupture are of independent prognostic significance (Baekelandt et al. 
2000). The absence of closure of the fimbriated end of the fallopian tube has been of 
marginal significance as regards worse prognosis (Alvarado-Cabrero et al. 1999).  
2.8.2. Size of the residual tumor 
Residual tumor size is a very strong prognostic factor. In most studies residual tumor size 
has been divided into two groups: more or less than 1–2 cm  (Peters et al. 1988; Rosen et al. 
1999; Baekelandt et al. 2000; Gadducci et al. 2001). Patients with stage III-IV disease are 
reported to have a 5-year survival rate of 55% with a residual tumor size of less than 1 cm, 
compared with 21% for those with a larger residual tumor (Gadducci et al. 2001) (Table 6). 
2.8.3. Grade 
The prognostic significance of tumor grade is controversial. In most studies grade of the 
tumor is marginally prognostic, remaining non-significant in statistical analyses (Hellström 
et al. 1994; Hefler et al. 2000; Gadducci et al. 2001). However, in a study by Rosen and co-
authors, grade was an independent prognostic factor: grade I tumors were associated with a 
5-year survival rate of 58%, grade II, 47% and grade III tumors, 33% (p = 0.03) (Rosen et 
al. 1999). In a study carried out by Gadducci et al. the overall 5-year survival rate was 45% 
as regards grade III tumors and 80% as regards grade I-II tumors (p = 0.0038) (Gadducci et 
al. 2001). 
2.8.4. Histology 
The effect of histological subgroup on the prognosis of PFTC patients has also been 
investigated in some studies, but no statistically significant differences have been detected 
























































   



















   










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































et al. better prognosis of patients with endometrioid versus serous or transitional carcinomas 
correlated with the lower average stage of the former, and was not observed when the 
analysis was restricted to stage I and IIa cases (Alvarado-Cabrero et al. 1999).  
2.8.5. Age 
The prognosis of PFTC patients over 60 years of age (compared to younger patients) is 
worsened in nearly half of the studies (Peters et al. 1988; Wolfson et al. 1998; Alvarado-
Cabrero et al. 1999; Baekelandt et al. 2000; Hefler et al. 2000). 
2.8.6. Lymph node status and ascites 
Studies of primary lymph node status during operation as a prognostic marker are sparse. In 
one study from Italy lymph node metastasis and positive peritoneal cytology were predictive 
for worse prognosis of PFTC in univariate analysis (Cormio et al. 1996). In another study 
from Italy, patients with a negative lymph node status had a median survival (MS) of 76 
months, compared with only 33 months in patients with node metastases (di Re et al. 1996). 
In Heflers study lymph node involvement was not associated with survival, nor was it 
correlated with pre-treatment CA125 level (Hefler et al. 2000). In the study of Peters the 
presence of ascites was a marker of a poor prognosis (Peters et al. 1988). 
2.8.7. Hydrosalpinx-like appearance 
Closure of the fimbriated end of the fallopian tube and its possible effect on the prognosis of 
PFTC has been debated. Theories on the spread of malignant cells through the open 
fallopian tube to the peritoneal lining and its effect on survival have been presented. 
Absence of closure of the fimbriated end has been associated with shorter survival. In a 
study by Alvarado-Cabrero and co-workers (1999) and in another by Baekelandt et al. 
(2000), a hydrosalpinx-like appearance affected 5-year survival, the rates being 63% and 
37% (p=0.0227), when present (in 30% of the patients) and absent, respectively (Baekelandt 
et al. 2000). 
2.9. Treatment 
Surgery is the definite primary treatment and it involves total abdominal hysterectomy with 
bilateral salphingo-oophorectomy, infracolic omentectomy and appendectomy. Pelvic and 
para-aortic lymphadenectomy and, depending of the extent of the disease, careful debulking 
is obligatory. Obtaining a sample for peritoneal cytology at the beginning of laparotomy is 
important (DiSaia and Creasman 2002). 






Because of the rarity of the disease, prospective controlled trials of treatment regimens have 
been impossible to conduct. In earlier decades radiation therapy (RT) was the traditional 
adjuvant therapy for PFTC. It has been given in different forms: external whole abdominal 
or pelvic radiation, treatment with intraperitoneal isotopes, and vaginal and uterine 
implantation (Nordin 1994). Today RT should no longer be used except for palliation of 
specific symptoms, because of its low efficacy and a high rate of serious complications 
(Baekelandt et al. 2000; Gadducci 2002). As adjuvant therapy, pelvic RT has not improved 
survival and a large proportion of patients with whole abdominal RT will develop 
recurrences outside the abdominal cavity and will also have severe gastrointestinal 
complications (Baekelandt et al. 2000). 
 
Regarding chemotherapy (CT), again because of the rarity of the disease, very few data are 
available. Because of the high risk of distant metastases even after complete surgical 
resection, adjuvant therapy is usually suggested, even among patients with early disease. An 
exception is patients with carcinoma confined to the tube, not penetrating the serosal surface 
and without intraoperative tumor rupture. Such patients may not require adjuvant treatment 
(Baekelandt et al. 2000). The current CT lines are summarized in Table 7 (Gadducci 2002, 
Pectasides et al. 2006). 
 
Table 7. Chemothereapy of PFTC 
Stage   Treatment 
Ia-Ib, optimal surgical staging, no pre- or 
intraoperative rupture 
No further treatment 
Ia-Ib, suboptimal surgical staging, pre- or 
intraoperative rupture 
Paclitaxel (175 mg/m2)-carboplatin (AUC 5-
6) every 3 weeks for 3–6 cycles 
Ic-IV Paclitaxel (175 mg/m2)-carboplatin (AUC 5-
6) every 3 weeks for 6–8 cycles 
For relapse and for second-line therapy  
  Patients who failed paclitaxel-based      
  chemotherapy 
Docetaxel (75–100 mg/m2)-carboplatin (AUC 
5) every 3 weeks  
  Platinum- and paclitaxel-resistant disease Liposomal doxorubicin (50 mg/m2) every 4 
weeks  
  Topotecan (1.5–2.0 mg/m2) a day for 3–5 
days every 3 weeks 
 
 






2.10. Tumor markers as diagnostic and prognostic factors in PFTC 
2.10.1. General aspects 
Tumor markers are substances that can be identified in body fluids (serum and urine) and 
tissues and are used for diagnosis, follow-up and as prognostic markers among patients with 
cancer. They can be divided into three categories: 1) oncodevelopmental antigens, 2) cancer-
associated antigens, and 3) tumor markers representing biochemical and metabolic 
alterations, usually as a reaction of the host against the tumor. Tumor markers may also be 
classified as tumor-specific markers, organ-specific markers and reaction products against 
cancer or cancer-associated metabolic changes. Many tumor-associated antigens are 
oncofetal, such as carcinoembryonic antigen (CEA), alphafetoprotein (AFP) and human 
chorionic gonadotropin (hCG). Cancer-associated antigens may be defined as substances 
that are either newly acquired during the neoplastic process or that reflect augmentation of 
certain, usually undetectable, normal cell antigens. The first cancer-associated antigens were 
characterized in 1956 by Whitebsky, many of them being markers of ovarian cancer (Rose et 
al. 1956). A large number of cancer-associated antigens and oncodevelopmental antigens 
associated with ovarian cancer have been identified since then; today the most commonly 
used are cancer antigen 125 (CA125), hCG, TATI and AFP. Only CA125 as a tumor marker 
of PFTC has been studied earlier. 
2.10.2. Carcinoma antigen 125 (CA125) 
CA125 is a cancer-associated antigen defined by a murine monoclonal antibody (OC125, 
IgG1) which was produced by immunizing mice with an ovarian serous cystadenocarcinoma 
cell line, OVCA433 (Bast et al. 1981). 
 
The antigen has been detected in tissues derived from coelomic epithelium in the embryo 
and adult, including the pleura, pericardium, peritoneum, fallopian tube, endometrium and 
endocervix. Outside this lineage, CA125 has also been detected in tracheobronchial 
epithelium and glands, amnion, amniotic fluid, milk, cervical mucus and seminal fluid 
(DiSaia and Creasman 2002). 
 
Serum concentrations of CA125 are measured by immunoradiometric assay, introduced by 
Bast et al. in 1983. They suggested a 35 U/ml cut-off value for normal controls (Bast et al. 
1983). Niloff et al. were the first to describe elevated CA125 levels in PFTC (Niloff et al. 






1984) and Lootsma-Miklosova et al. were the pioneers in monitoring changes in CA125 
levels during treatment and recurrence (Lootsma-Miklosova et al. 1987). In 1990, Rosen et 
al. studied pre- and postoperative concentrations of CA125 in PFTC and in contrast to their 
earlier experiences with ovarian cancer, they did not find a correlation with prognosis, but a 
trend for a positive correlation between FIGO stage and preoperative CA125 values was 
observed (Rosen et al. 1994). In a study among 40 PFTC patients in Norway, there were 
strong correlations between preoperatively elevated CA125 levels and more advanced 
disease, and the presence of residual disease (Baekelandt et al. 2000). In the same year 
Hefler et al. studied the clinical value of assay of serum CA125 in PFTC and reported that 
serum CA125 is an additional independent prognostic factor of disease-free survival (DFS) 
and overall survival (OS) in patients with the disease (Hefler et al. 2000). The studies 
mentioned above are the only ones conducted concerning CA125 and PFTC. 
2.10.3. Human chorionic gonadotropin beta 
Human chorionic gonadotropin (hCG) is a glycoprotein consisting of two polypeptide 
subunits, i.e. the α- and β-subunit. Luteinizing hormone (LH) and hCG mediate their activity 
through the same receptor. The latter is produced by placental trophoblasts and it is a very 
good marker for monitoring pregnancy. Placental and trophoblastic tumors nearly always 
produce hCG, but it is also secreted in non-trophoblastic malignancies. Serum from many 
patients with non-trophoblastic tumors contains hCG immunoreactivity, which with a few 
exceptions consists of the free β-subunit of hCG (hCGβ). The subunits lack hCG activity but 
hCGβ has been shown to enhance the growth of tumor cells in culture by preventing 
apoptosis (Butler et al. 2000). The half-times of hCG and hCGβ differ, being longer for 
hCGβ than for hCG. For hCG the rapid half-time is 4 hours and the slow one 2.2 days. In 
contrast, hCGβ has a slow half-time of about 8 days and a rapid one of about 1 hour 
(Korhonen et al. 1997). This is very important to know when studying the percentual values 
of serum hCG and hCGβ in the follow-up of trophoblastic diseases. In Finland hCGβ in 
serum is quantified by means of a time-resolved immunofluorometric assay (Alfthan et al. 
1988), with a detection limit of 0.5 pmol/L. 
 
Elevated expression of hCGβ in serum, urine or tumor tissue is a strong indicator of poor 
prognosis in many non-trophoblastic tumors, such as colorectal (Lundin et al. 2001; 
Louhimo et al. 2002), ovarian (Vartiainen et al. 2001) and renal cell carcinoma (Hotakainen 
et al. 2002; Hotakainen et al. 2003). Elevated serum levels of hCGβ correlate with excretion 






of the core fragment of hCGβ (hCGβcf), a degradation product of hCGβ passing into the 
urine (Alfthan et al. 1992). Elevated urinary levels of the core fragment of hCGβ reflect a 
worsened prognosis in vulvar and cervical carcinoma (Carter et al. 1994; Carter et al. 1995). 
In ovarian carcinoma, the 5-year survival rate was found to be 80% if serum hCGβ levels 
were normal, compared with 22% when they were elevated (Vartiainen et al. 2001). 
2.10.4. Tumor-associated trypsin inhibitor (TATI) 
Tumor-associated trypsin inhibitor is a low molecular weight (6 kDa) trypsin inhibitor, 
which was initially isolated from the urine of a patient with ovarian cancer (Stenman et al. 
1982). The mean serum concentration of TATI in healthy individuals is 11 µg/L. It is 
rapidly cleared from the circulation by renal excretion, with a half-life of 6 minutes (Marks 
and Ohlsson 1983). Therefore, renal failure causes increased concentrations of TATI in the 
serum. It is expressed in several healthy tissues, especially in the gastrointestinal and 
urogenital tracts. 
 
Levels of TATI in serum are increased in many benign conditions, e.g. pancreatitis, and in 
patients with severe injury and inflammatory disease. However, in patients with pelvic 
inflammatory disease, TATI concentrations start to increase only when serum levels of C-
reactive protein (CRP) are clearly increased (Paavonen et al. 1989). Cancers originating 
from gastrointestinal and urogenital tissues often produce TATI. The increase is caused by 
production by the tumor, but an acute-phase reaction induced by tissue destruction 
associated with cancer invasion most likely contributes to the increased TATI concentrations 
seen in advanced disease. The strongest expression occurs in mucinous ovarian tumors, both 
benign and malignant (Halila et al. 1988; Koivunen et al. 1991). In mucinous ovarian cancer 
45% of the cases already have increased TATI concentrations at stage I and the figure is 90–
100% in stage IV disease. In non-mucinous cancers, TATI concentrations are elevated in 
high-grade tumors. Increased serum concentrations occur in 50–60% of patients with stage 
III-IV disease, and in these patients, an increased value before therapy is an independent 
prognostic factor for adverse outcome (Venesmaa et al. 1994). 
2.11. Chlamydia trachomatis infection as a risk factor 
2.11.1. Microbiology and clinical gynecological manifestations of chlamydiae 
Chlamydiae are obligate intracellular gram-negative bacteria that replicate in membrane- 
bound vacuoles (inclusions) in the cytoplasm of eukaryotic cells. Chlamydiae can be divided 






to four species: C.trachomatis, C.pneumoniae, C.psittaci, and C.pecorum. Chlamydiae are 
able to induce a variety of humoral and cell-mediated immune responses. Chlamydiae 
require living hosts for their replication because they lack many biosynthetic capabilities. 
Chlamydia has a very unique life-cycle with an extracellular infective elementary body (EB) 
and a non-infective intracellular reticulate body (RB) (Grayston and Wang 1975). The EB 
attaches to and enters the host cell. The chlamydial cell is surrounded by an envelope that 
consists of an outer membrane and an inner cytoplasmic membrane. The most prominent 
component of the chlamydial outer membrane of the EB is the major outer membrane 
protein (MOMP) (Caldwell et al. 1981; Wang et al. 1985), also found in the RB, comprising 
about 60% of the protein content. The MOMP plays a role in adhesion of Chlamydia to host 
cells. 
 
Chlamydia trachomatis (CTR) species is divided into 18 human serotypes A, B, Ba, C, D, 
Da, E, F, G, H, I, Ia, J, K L1, L2, L2a and L3 (Grayston and Wang 1975). Serotypes A–K 
primarily infect columnar epithelium, causing mucosal infections. Serotypes B, Ba, C and 
D–K cause chlamydial urogenital infections as well as inclusion conjunctivitis, transmitted 
from the genital tract to the eye. 
 
Infection with CTR is the one of the most common sexually transmitted infections (STIs), 
causing 90 million new infections each year worldwide. Acute genital tract infections 
include urethritis, cervicitis, salpingitis, endometritis and pelvic inflammatory disease (PID) 
– the major cause of tubal factor infertility and ectopic pregnancy. No long-lasting 
protective immunity against CTR develops during acute infections. Repeated or persistent 
infections, which provide an opportunity for long-term stimulation of the host with 
chlamydial antigens, result in tissue damage. Heat shock proteins (Hsps), found in 
chlamydial cell walls, play a crucial part in this damage. 
2.11.2. Serological diagnosis of C. trachomatis infection 
The micro-immunofluorescence (MIF) test and enzyme-linked immunoassays (EIAs) 
(Närvänen et al. 1998) are the serological methods for diagnosing chlamydial infections. 
The MIF test has been regarded as the golden standard for epidemiological research and is a 
sensitive and most specific method (Wang and Grayston 1970). 






2.11.3. Chlamydia and gynecological cancer 
Repeated or chronic chlamydial infection increases the likelihood of severe consequences. 
Chlamydial infection evokes both humoral and cell-mediated immune (CMI) responses. 
Chlamydial HSP60 may have an anti-apoptotic effect during persistent infection (Dean and 
Powers 2001). The accumulation of HSP60 in the cytoplasm of actively replicating cells 
may interfere with the apoptotic pathway. The concomitant expression of viral oncoproteins 
and/or the presence of mutations may lead to the ability to survive apoptotic stimuli, loss of 
replicative senescence, uncontrolled proliferation and finally neoplastic transformation (Di 
Felice et al. 2005). Studies connecting chlamydial infection and gynecological cancer are 
presented in Table 8 (Risch and Howe 1995, Koskela et al. 2000, Anttila et al. 2001, Wallin 
et al. 2002, Ness et al. 2003, Smith et al. 2004). 
 
Table 8. Studies on Chlamydia trachomatis and gynecological cancer 
Study Study design Result 
Koskela et al.  2000 Prospective seroepidemiologic case-
control study 
Risk of SC, OR 2.2 (95% CI 1.3–3.5);* 
Anttila et al.  2001 Seroepidemiologic case-control study All serotypes increased the risk of SCC 
and serotype G most strongly, OR 6.6 
(1.6–27)* 
Wallin et al.  2002 Population-based prospective case-control 
study 
RR of cervical cancer 17.1 (2.6–∞)* 
Smith et al.  2004 Serologic case-control study Increased the risk of SCC among HPV-
positive women, OR 1.8 (1.2–2.7) 
Risch, Howe 1995 Case-control study History of PID increased the risk of 
ovarian cancer, OR 1.5 (1.1–2.1)* 
Ness et al.  2003 Seroepidemiologic case-control study Women with higher levels of C. 
trachomatis antibodies to serovar D had 
a 90% greater probability of having 
ovarian cancer, p = 0.05 * 
*Adjusted for human papillomavirus (HPV); SC = squamous cell 
carcinoma  
2.12. Human papillomavirus infection as a risk factor 
2.12.1. HPVs 
Papillomaviruses are small, non-enveloped, double stranded DNA viruses. The genome is 
circular and contains approximately 7900 base pairs (Chen et al. 1982). The genome of HPV 
contains approximately eight opening reading frames (ORFs), which are transcribed from a 






single DNA strand. The ORFs code for two late structural proteins (L1 and L2) and six early 
(E) proteins. The protein coat (capsid) is composed of 72 capsomers consisting of L1 and L2 
proteins. The role of the capsid is to protect the genome and to target cellular surface 
receptors involved in infection. The L1 protein can become assembled to virus-like particles 
(VLPs) when expressed in eukaryotic cells (Kirnbauer et al. 1992). These do not contain 
viral oncogenes and are not infectious (Kirnbauer et al. 1994). 
 
To date, over 200 HPV types have been identified and approximately 40 types infect 
mucosal epithelia and are called genital HPVs (de Villiers et al. 2004). These types are 
further divided into high-risk types (cell transformation) and low-risk types (benign warts). 
Fifteen HPV types are classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68, 73 and 82), three are classified as probable high-risk types (26, 53 and 66) and 12 are 
classified as low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and CP6108) (Munoz et 
al. 2003). The HPV binds to specific cell surface receptors and after attachment it enters the 
cell. Once the virus has penetrated the epithelium it establishes itself in the basal layers, 
where cell proliferation begins. When the infected cell divides, viral DNA is distributed in 
both daughter cells; in one that migrates upwards to start differentiation, and in the other that 
continues to divide in the basal layer. That cell becomes the reservoir for viral DNA, and 
explains the ability of HPV infection to persist for many years (Stubenrauch and Laimins 
1999). 
2.12.2. Epidemiology of genital HPV infections 
Every year, about 400 million new HPV infections occur worldwide (WHO). Estimates of 
the population prevalence of HPV infection among women around the world range from 2% 
to 44% (Bosch and de Sanjose 2003). The life-time risk of HPV infection is high, the 
cumulative risk at three years of any HPV infection being 44% for women earlier being 
negative for HPV and 26% for detecting a type not present in the first positive sample 
(Woodman et al. 2001). Most HPV infections are transient, 80–90% spontaneously 
regressing in 2 years (Evander et al. 1995). Persistent infection with high-risk HPV is a 
major risk factor for cervical neoplasia and a cause of cervical cancer (Walboomers et al. 
1999). 
2.12.3. HPV serology 
HPV serology is an important epidemiological tool for the assay of past and present HPV 
infections and for prediction of HPV-associated cancers. A serological assay based on HPV 
virus-like particles that correlates with type-specific detection of HPV infection, as 






determined by detection of the viral genome, was established in 1994 (Kirnbauer et al. 
1994). Nowadays, an enzyme-linked immunosorbent assay (ELISA) is used, employing a 
monoclonal antibody against human immunoglobulin G (IgG) and a goat anti-mouse IgG 
horseradish peroxidase conjugate. The sensitivity of HPV serology has been reported to be 
50 to 75% (Kirnbauer et al. 1994; Kjellberg et al. 1999) and specificity for the sexually 
transmitted HPV types, 95–99% (Dillner et al. 1996). The natural history of the HPV serum 
antibody response is well known. Seroconversions against HPV16 capsids have been seen 
concomitantly with or within a few months following acquisition of HPV16 DNA 
(Wikstrom et al. 1995; af Geijersstam et al. 1998) and IgG antibody levels have been found 
to be stable over time even after more than a decade of follow-up (af Geijersstam et al. 
1998). This is in line with the fact that IgG seropositivity to oncogenic genital HPVs 
strongly correlates with the lifetime number of sexual partners (Carter et al. 1996), but does 
not correlate with the number of recent partners (Wang et al. 2000), which would have been 
correlated if seropositivity had had more limited stability over time. We know that it is 
women with persistent type-specific positivity that are at increased risk of developing 
invasive cervical cancer (Wallin et al. 1999). 
2.12.4. HPV and gynecological cancer 
HPV infection is well established as an important factor in the pathogenesis of cervical 
neoplasia (Bosch et al. 2002). In 1983 the first isolation of an oncogenic virus type (HPV16) 
from cervical cancer was reported (Durst et al. 1983). An association has also been detected 
as regards vulvar and vaginal carcinomas (Madeleine et al. 1997; Daling et al. 2002). 
 
HPV involvement in cancers of the upper genital tract (endometrial and ovarian cancers) has 
also been investigated, but the results have been highly controversial and are based mainly 
on DNA detection in tissue samples (Fujita et al. 1995; Czerwenka et al. 1996; Hording et 
al. 1997; Zimna et al. 1997; Chen et al. 1999; Hisada et al. 2001; Ip et al. 2002; Wu et al. 
2003; Yang et al. 2003). There is only one serological study on HPV antibodies and the risk 
of endometrial and ovarian cancer and PFTC (Hisada et al. 2001). Studies concerning 
gynecological cancers and HPV are presented in Table 9. 
3. ASSOCIATION BETWEEN PFTC AND SELECTED REPRODUCTIVE FACTORS 
3.1. Effect of parity on gynecological cancer 
Studies on parity and its influence on hormone-dependent gynecological cancers have 
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Whittemore et al. 1992a; Lambe et al. 1996; McPherson et al. 1996), but only one earlier 
study has reported parity data on PFTC (Nordin et al. 1994). These investigators found a 
nulliparity rate of 27% and a mean parity of 1.7 among PFTC patients in a review including 
all articles and case reports published in the English literature from 1973 to 1992, but no 
study has been carried out to study the real effect of parity on PFTC. 
 
Increasing parity lowers the risk of ovarian cancer, especially that of epithelial ovarian 
cancer (Whittemore et al. 1992a; Adami et al. 1994; Hinkula et al. 2006). Each full-term 
pregnancy diminishes the risk by 15 to 20% (Adami et al. 1994; Risch et al. 1994), the 
greatest protection being associated with the first term pregnancy (Whittemore et al. 1992a). 
The influence of age at first birth on ovarian cancer has been unclear (Riman et al. 1998). 
Some investigators have found a reduction of risk with older age at first birth and last birth 
(OR 0.57; 95% CI 0.36–0.90) (Titus-Ernstoff et al. 2001; Whiteman et al. 2003) or a risk 
increase with younger age at first pregnancy (OR 1.4, 95% CI 1.1–1.8), younger age at last 
pregnancy and with longer time since last pregnancy (Cooper et al. 1999). Other 
investigators have found a risk increase with older age at first birth (RR 4.18, ages 35–39 
years, 95% CI 1.98–8.79) (Negri et al. 1991; Mogren et al. 2001). A recent study in Finland 
did not reveal any significance of age, but the incidence of ovarian cancer was 36% smaller 
among grand multiparous (GM) women compared with average Finnish women (Hinkula et 
al. 2006). In that study, parity above five births did not provide any additional protection 
versus that associated with 5 births. 
 
Nulliparity and/or nulligravidity have been consistently associated with an increased risk of 
endometrial cancer (Salmi 1979; Parazzini et al. 1991; McPherson et al. 1996). In a study by 
Hinkula et al. in Finland, a large number of births, relatively old age at first delivery, a long 
birth period and a short premenopausal delivery-free period reduced the risk of 
postmenopausal endometrial cancer among GM women, emphasizing the protective role of 
progesterone and the stimulatory role of estradiol in the hormonal background of 
endometrial cancer (Hinkula et al. 2002). 
 
Cervical adenocarcinoma constitutes up to 20% of all cervical cancers (Vesterinen et al. 
1989; Leminen et al. 1990; Castellsague et al. 2006). Risk factors for this cancer have been 
regarded as being similar to those of endometrial cancer (Salmi 1979), but HPV infection 
appears to be the key risk factor for this cancer, as for cervical squamous cell cancer, HPV 
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type 18 being the most prominent among cervical adenocarcinomas (Leminen et al. 1991; 
Castellsague et al. 2006). Nulliparity has been considered to be a risk factor for cervical 
adenocarcinoma, whereas multiparity, especially among HPV-positive women, has been 
considered to be a risk factor for squamous cell carcinoma (Leminen et al. 1991; Munoz et 
al. 2002; Hinkula et al. 2004), these findings showing the difference in etiological factors 
between these two cancers. 
 
Early first pregnancy and multiparity are known to reduce the risk of breast cancer, probably 
as a result of the hormonally induced differentiation of breast cells and the corresponding 
reduction in the number of susceptible cells (Mogren et al. 2001). Childbirth is followed by 
a short-term increase in the risk of breast cancer, followed by a long-term protective effect 
(Mogren et al. 2001). 
 
Taken together, parity has various effects on the risk of different gynecological cancers, 
which could in part be explained by the hypotheses of incessant ovulation (Fathalla 1971) 
and raised gonadotropin (Cramer and Welch 1983). All gynecological cancers are members 
of the family of hormone-dependent cancers and birth may affect risk through hormonal 
influences. The incessant ovulation theory accords with the observed protective effect of 
interrupted ovulation as a result of increased parity, oral contraceptive use, or breast-feeding 
(Whittemore et al. 1992b). The gonadotropin hypothesis asserts that ovarian cancer is 
principally caused by high levels of gonadotropin that increase estrogen production and 
ovarian surface epithelial proliferation and malignant transformation. Pituitary secretion of 
gonadotropin generally increases during adulthood, but decreases during pregnancy; thus the 
protective effects of later childbirth are consistent with this hypothesis. One possible 
explanation for the pregnancy-reducing effect on the risk of ovarian cancer could be the high 
levels of progesterone during pregnancy, that induce apoptosis of transformed epithelial 
cells (Rodriguez et al. 1998). Pregnancy-dependent clearance of ovarian cells that have 
undergone malignant transformation was suggested by Adami et al. (Adami et al. 1994). 
Endometrial cancer risk may also be reduced by pregnancies through mechanical shedding 
of cells that have undergone malignant transformation (Lambe et al. 1999). 
3.2. Sterilization 
As early as in 1934 the first gynecologic laparoscopy was performed by Ruddock (Filshie 
1999). The spring clip was first developed by Hulka and Clemens in 1974 and in the same 
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year research on the Filshie clip started and it was used in humans in 1975 (Filshie 1988). In 
the 1970s, the popularity of sterilization increased dramatically, because of legislation and 
attitudes. It also became easily available as a result of new surgical approaches, such as 
minilaparotomy and laparoscopy. In Finland sterilization became possible on request in 
1970, and in 1985 the law changed, being more liberal. The frequency of sterilization has 
varied in recent decades in Finland, being 1560, 12 934 and 5906 sterilizations per year, 
respectively, in 1975, 1991 and 2003 (Figure 1). Part of this variation can be explained by 

















Figure 1. The annual number of registered sterilizations and hysterectomies in Finland, 1975–2003 
3.2.1. Sterilization and gynecological cancers 
Sterilization is a common gynecologic procedure, which appears to reduce ovarian cancer 
risk, but no studies on the association between sterilization and PFTC have been performed. 
The risk reduction concerning ovarian cancer has varied between 10 and 80% and the 
protective effects last for ten to twenty-five years (Table 10). There are several theories for 
the relationship between sterilization and ovarian cancer, including the screening effect 
(Weiss and Harlow 1986), a decrease in uterine growth factors that could be involved in 
ovarian cancer development (Riman et al. 1998), the effect of retrograde menstruation 
(Green et al. 1997), changes in blood flow to the ovaries (Hankinson et al. 1993) that could 
have an influence on plasma hormone levels and ovarian function, and blockage of exposure 
to ascending environmental agents, such as talc (Cramer et al. 1982). Convincing evidence 
that tubal ligation reduces the risk of ovarian cancer in BRCA1 mutation carriers was 
presented in a study by Narod et al. (Narod et al. 2001), where the OR for ovarian cancer in 
BRCA1 carriers with tubal ligation was 0.39 (95% CI 0.22–0.70), but in BRCA2 carriers no 
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The risk of other gynecological cancers after tubal sterilization still remains controversial. 
Endometrial cancer studies have revealed modestly increased (Rosenblatt and Thomas 1997) 
or decreased (Castellsague et al. 1996; Kjaer et al. 2004) risks after sterilization, or no 
change at all (Lacey et al. 2000). In the recent Danish study (Kjaer et al. 2004), the 
occurrence of cervical cancer was slightly lower and the CIN3 changes higher; findings 
most likely pointing to cervical screening at the time of surgery. 
 
The risk of breast cancer after sterilization has been recently studied as part of the Nurses` 
Health Study. A modest protective association was observed at a time when the unipolar 
electrocautery method was commonly used. Unipolar electrocautery destroys more tissue 
than other methods and might therefore destroy blood supply of fallopian tubes and ovaries, 
providing some support for an association between lower lifetime exposure to hormones and 
a decreased risk of breast cancer (Eliassen et al. 2006). Some earlier studies revealed 
increased (Irwin et al. 1988), decreased (Kreiger et al. 1999; Calle et al. 2001), or unchanged 
(Brinton et al. 2000) risks of breast cancer. 
3.3. Hysterectomy and ovarian cancer 
Hysterectomy is one of the most frequent gynecological operations performed in women 
(Luoto et al. 1994). In 1987–1992 57,519 hysterectomies were performed in Finland 
(Vuorma et al. 1998) and the increase in the age-adjusted incidence rate was 12%, being 
380/100,000 females in 1992. In 2003, 5892 hysterectomies were performed in Finland 
(Figure 1). Hysterectomy rates are slightly higher in Finland than in other Nordic countries 
(Luoto et al. 1994; Settnes et al. 1996). Of all women undergoing hysterectomy, 24% in 
1987 and 28% in 1992 were over 50 years of age. Uterine fibroids were the most common 
reason for this operation in women over 45 years of age (Vuorma et al. 1998). 
 
There are studies on the risk of ovarian cancer among women with a previous hysterectomy 
with or without salpingo-oophorectomy, but no studies on the risk of PFTC. Most studies 
have revealed a diminished risk of ovarian cancer after a previous hysterectomy (mean OR 
0.57; range 0.2–0.9) and the protective effect has varied with time since hysterectomy and 
according to age at which the procedure had been performed (Booth et al. 1989; Irwin et al. 
1991; Whittemore et al. 1992a; Hankinson et al. 1993; Green et al. 1997). The studies are 
shown in Table 11. The theories behind these effects mimic the theories behind the effect of 
sterilization. 
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4. SECOND PRIMARY CANCERS AFTER FIRST PRIMARY GYNECOLOGICAL 
CANCERS 
The number of cancer survivors is rising because of earlier detection improved treatment 
and supportive care. In the United States the number of cancer survivors has tripled since 
1971 and is growing by 2% every year (Travis 2006a). In Finland the number of new cancer 
cases has tripled since 1953 (Pukkala et al. 2006a). The 5-year relative survival rate among 
female cancer patients in Finland between 1996 and 2000 was 65%, and for males it was 
56% (Pukkala et al. 2006a). In 1998, 15% of new cancer cases reported to the US SEER 
(Surveillance, Epidemiology, and End Results) program were second primary malignancies, 
and the number of second primary cancers is still increasing. Because of better survival, it 
has become important to validate the late effects of cancer itself and its therapy. They can be 
a consequence of late effects of different treatments (RT and CT) or they can reflect the 
effects of lifestyle (tobacco, alcohol, diet) or genetic, hormonal, immunological or 
environmental background of the diseases. 
 
Secondary leukemias represented the first reported carcinogenic effects of cancer treatment 
(Travis 2002). Nowadays solid tumors comprise the largest proportion of second primary 
tumors. Therapy-associated malignancies can be divided to RT- and CT-associated tumors. 
Radiotherapy induces bone-marrow malignancies and solid tumors, the most sensitive 
organs being the breast and thyroid (Travis 2006a). Other cancers occasionally associated 
with radiation are those of the lung, stomach, colon, esophagus, bladder, ovary, brain and 
liver. The latency period of therapy-associated solid tumors is usually long, typically ten 
years or more (Travis 2002). The cancer type of concern in relation to CT is mainly 
leukemia, which is characterized by short latency. The question of the extent to which CT 
can induce solid tumors remains unresolved, but they have shown a dose-dependent 
relationship with the prior administration of cytotoxic drugs. Recent studies have shown a 
relationship between lung and bladder cancer after using chemotherapeutic drugs to treat 
Hodgkin’s lymphoma (Travis et al. 1995; Travis et al. 2002) and bone sarcomas after using 
alkylating agents for childhood cancer (Hawkins et al. 1996). 
 
There are many studies concerning second malignancies after first primary malignancies of 
the female genital system (Boice et al. 1985; Curtis et al. 1985; Storm and Ewertz 1985; 
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second primary cancers after these cancers are in part related to radiotherapy, in part to CT 
(especially leukemia and bladder cancer) and in part to genetic factors and to life-habits 
(smoking, HPV infections) or hormonal factors. An increased incidence of second cancers 
of the abdominal organs (colon, rectum, kidney, bladder, ovaries) has been observed. 
 
In a study of second cancers after primary ovarian cancer, the standardized incidence ratio 
(SIR) was 1.28 for all second cancers, and significant risk increases were detected for 
cancers of the colon, rectum, breast, bladder and eye. For leukemia, 7- to 9-fold increases 
were detected (Travis et al. 1996). The overall risk was sustained with time. Following RT 
alone, excesses of solid tumors increased with time, being two-fold after 15+ years. For CT, 
the risk of solid tumors was elevated within a 5- to 9-year interval. Genetic and reproductive 
factors have been considered to explain the excess of breast and colorectal cancers among 
ovarian cancer survivors (Curtis et al. 1985; Storm and Ewertz 1985). 
 
Second cancers after cervical cancer are mostly related to RT, and the risk remains high 
even 40 years after initial diagnosis. Cancers of the rectum, vagina, vulva, bladder and 
ovary, and leukemia, have been regarded as radiation-induced, whereas second primary 
cancers of the lung and bladder among cervical cancer patients have been associated with a 
common smoking etiology (Kleinerman et al. 1995; Ohno et al. 2006). Cervical cancer 
patients have been reported to experience a reduced risk of subsequent breast cancer, 
possibly as a result of ovarian removal or ablation by RT (Boice et al. 1985). 
 
No studies of second primary cancers after PFTC have been performed. 
 
5. CONCLUSIONS 
Studies on PFTC are quite few and the study materials are often small. PFTC behaves 
similarly to ovarian cancer in many ways and it has also been treated similarly. Treatment 
guidelines are mostly based on studies of ovarian cancer. The etiological factors and 
possible risk or protective factors and prognostic factors are mostly unknown. In this study 
we tried to clarify these aspects. 
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AIMS OF THE STUDY 
 
The present study was undertaken to investigate the occurrence of PFTC and to elucidate the 
risk and prognostic factors associated with it. 
 
 
The specific aims of the study were: 
 
1. to elucidate the incidence and the sociodemographic determinants of PFTC (I) 
 
2. to investigate the effects of parity, sterilization, hysterectomy and previous cancer on the 
risk of PFTC (V) 
 
3. to study specific tumor markers as prognostic factors of PFTC (II) 
 
4. to evaluate the impact of earlier Chlamydia trachomatis infection on the risk of PFTC 
(III) 
 
5. to evaluate the impact of earlier human papillomavirus infection on the risk of PFTC 
(IV) 
 
6. to elucidate the incidence of second primary cancers after PFTC (VI) 
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MATERIALS AND METHODS 
These studies were undertaken during 2000–2006 with the approval of the Ethics Committee 
of the Department of Obstetrics and Gynecology, HUCH Hospital Area, Hospital District of 
Helsinki and Uusimaa, and with permission of the Ministry of Health and Social Affairs. 
1. STUDY MATERIAL 
A summary of the study material is presented in Table 12. 
 
 
Table 12. Study material     
Study  n cases Mean 
age 




Source of material 
I 485    1953–1997 
Finnish Cancer Registry linked with 
Population Census data  
II 91 61   1985–2003 Patient registry and Serum Bank of the 
Department of Obstetrics and 
Gynecology, HUCH Hospital Area  
III 79 61 156 61 1985–2000 Patient registry and Serum Bank of the 
Department of Obstetrics and 
Gynecology, HUCH Hospital Area  
IV 78 62 156 64 1985–2000 Patient registry and Serum Bank of the 
Department of Obstetrics and 
Gynecology, HUCH Hospital Area  
V 573  5473  1975–2004 Finnish Cancer Registry linked with 
HILMO and CPR 
VI 2084       1943–2000 Thirteen cancer registries in Europe, 
Australia, Canada and Singapore 
Total 3390  5785  1953–2004 
   HILMO= Hospital Discharge Registry, CPR=Central Population Registry 
 
1.1. Study I 
The research on the incidence of PFTC in Finland included all patients (n = 485) who were 
diagnosed as having had PFTC and who were reported to the Finnish Cancer Registry in 
1953–1997. More than 99% of all cancer cases have been reported to the Finnish Cancer 
Registry (Teppo et al. 1994). An official census of the Finnish population was organized by 
Statistics Finland in 1970 (Central Statistical Office of Finland, 1974). The questionnaire 
included information on occupation, which was coded into more than 400 occupational  
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categories on the basis of education, occupation, industrial status, and industry groupings 
(Central Statistical Office of Finland, 1974; Rauhala 1966). Four social classes were defined 
as follows: 
I Managers and other higher administrative or clerical employees, farmers owning more 
than 50 hectares of land; 
 
II Lower administrative or clerical employees, small-scale entrepreneurs, farmers owning 
15–49.9 hectares of land; 
 
III Skilled and specialized workers, farmers owning 5–14.9 hectares of land; 
 
IV Laborers, farm and forestry workers, institution inmates, farmers owning < 5 hectares of 
land, retired persons whose former occupation was unknown. 
 
The data from the Finnish Cancer Registry was linked with the Population Census data 
electronically using personal unique identifiers as the key. Every Finn has had a personal 
identification code since 1967. 
1.2. Study V 
All women having had PFTC in 1975–2004 were selected (n = 573) from the Finnish 
Cancer Registry. Ten age-matched (± 1 month) female controls were selected from the 
Finnish Central Population Registry (CPR) for each PFTC patient (n = 5473). The control 
subjects had to be alive at the time of diagnosis of the PFTC patients. The dates of birth of 
children of PFTC patients and control subjects were collected from the CPR. Data on 
sterilization, hysterectomy (Figure 1) and salpingectomy (n = 8) were obtained from the 
Hospital Discharge Registry (HILMO) which has operated since 1967 and is maintained by 
the National Research and Development Centre for Welfare and Health (STAKES). The 
Registry contains summary information on patients discharged from all public and private 
hospitals. 
1.3. Studies II–IV 
Ninety-one consecutive patients treated for PFTC at the Department of Obstetrics and 
Gynecology in HUCH Hospital Area during the period 1985–2000 were collected for 
studies II–IV. Patient data were retrieved from the records and listed on a form with 105 
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different sections. The patients had not received chemotherapy prior to surgery. Staging was 
performed according to FIGO criteria and pelvic and para-aortic lymphadenectomy was 
performed whenever indicated. The patients were followed up as regards recurrence and 
survival until February 14, 2003. 
 
Archival serum samples stored since 1986 were used in the study. The samples were stored 
at -20 0C until analysis. 
 
In study II there were 60 preoperative serum samples available, in which hCGβ, CA125 and 
TATI were measured. We studied the overall survival of patients with and without 
preoperative hCGβ data in order to exclude selection bias; the survival rates did not differ 
from each other. Neither did the distribution of stage, grade, tumor size, size of the residual 
tumor and histological type differ between the groups. 
 
Postoperative serum samples were available from 79 PFTC patients for study III and from 
78 for study IV. Control serum samples were collected from female patients from Helsinki 
City Maternity Hospital, operated upon because of a benign gynecological disease (91 for 
study III and 90 for study IV). Study III included 65 control samples which were archival 
serum samples from patients coming to an examination for a benign colon disease (30 
controls) or which were from female employees at HUCH Hospital Area (35 controls), and 
study IV included 66 control archival samples (35 from female employees, 12 from patients 
operated upon because of benign ovarian cysts and 19 from patients seen for a benign colon 
disease). All controls selected fulfilled the necessary criteria: matched age at serum 
sampling (±5 years), and no cancer diagnosis. 
1.4. Study VI 
This study was a multi-center study with data from 13 different cancer registries in Finland, 
Denmark, Sweden, Norway, Iceland, Scotland, Spain, Slovenia, Canada (British Columbia, 
Manitoba and Saskatchewan), Australia and Singapore, coordinated by the International 
Agency for Research on Cancer (IARC). From these registries 2084 women with a first 
PFTC were detected. Patients for whom the first primary cancer diagnosis and death were 
recorded at the same time, or who had two first primary cancers recorded simultaneously 
were excluded (8%). 
 Materials and Methods 




2.1. Statistical analyses 
2.1.1. Studies I and VI 
In study I the cancer records of the Finnish Cancer Registry from 1971–1995 for persons 
born in 1906–1945 were linked with the census data. A total of 268 PFTC cases were found 
(all being a part of the total sample), for which information on social class and occupation 
were available from the population census. The incidence rates, age-standardized to the 
world population, were calculated by calendar period and urbanization level of the place of 
residence.  
 
The expected numbers of cases were calculated by multiplying the stratum-specific number 
of person-years by the respective calendar period and birth cohort-specific incidence rate of 
all Finnish women. Standardized incidence ratios (SIRs) were the ratios of the observed to 
the expected number of cases. Confidence intervals were defined with the assumption that 
the observed number of cases followed a Poisson distribution. 
 
In study VI all cases of PFTC were followed up from the date of first diagnosis (1943–2000) 
to the date of second primary cancer (1943–2000), date of death, date of migration or end of 
follow-up (1992–2000). The number of second primary cancers observed was compared 
with the expected number of cancers calculated from accumulated person-years and rates 
among females specific for each registry and five-year age and calendar-periods. The SIRs 
were stratified for time since PFTC diagnosis, for calendar-period of PFTC and for age at 
PFTC diagnosis. Poisson regression analysis was carried out as regards selected cancer sites 
to quantify the independent risk ratios (RRs) related to each variable. 
2.1.2. Studies II–V 
Analyses were performed with software packages SPSS (mostly v. 12.0), Stata 8.0 
(www.stata.com) and/or Survo MM (www.survo.fi). Two-tailed p-values below 0.05 were 
considered statistically significant. 
 
The χ2 test was used to compare categorial variables between patients with serum marker 
measurements and those without (study II) and to compare differences in seropositivity of 
different HPV types between cases and controls (study IV). The probability of survival was 
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analyzed by using the Kaplan-Meier method (study II). In the analysis of overall survival, 
death due to any cause was defined as an event, but when analyzing disease-free survival 
(DFS), the event was relapse. 
 
For evaluating prognostic factors for PFTC, univariate and multivariate Cox regression 
analyses were used (studies II–V). 
2.2. Laboratory analyses 
All serum samples were stored at -20 0C until analyzed. Serum samples for the analyses in 
study II were preoperatively collected and in studies III and IV they were collected 




Table 13. Characteristics of assays used for laboratory analyses. 
Factor Principle of assay Source of reagents 
hCGβ Fluoroimmunoassay In-house method1 
CA125 Immunol1® Immunoanalyzer 
Immunoradiometric assay 
Bayer, Tarrytown, N.Y., USA 
TATI Radioimmunoassay Orion Diagnostica, Espoo, Finland 




Washington Research Foundation, Seattle, 
WA, United States 
 peptide EIA ANILabsystems, Helsinki, Finland 
C. pneumoniae  
IgG 
MIF Washington Research Foundation, Seattle, 
WA, United States 
HPV IgG EIA using VLP capsid protein 
as antigen 
HVP16: Lab.of Cellular Oncology, NCI, 
NIH, Bethesda, USA; HPV6 and 11: Merck 
Research Laboratories, West Point, PA, 
USA; HPV31 and 33: Vienna Medical 
School, Austria; HPV18: GlaxoSmithKline 
Biologicals in Rixensart, Belgium 
HSV-2 IgG EIA EIA, Biokit SA, Spain 
1Alfthan et al. 1988, C. trachomatis = Chlamydia trachomatis 
EIA= enzyme immunoassay 








The main results are summarized in Table 14 and presented in the text; details are given in 
the separate original publications. 
 
 
Table 14. Summary of the results of the study on PFTC. 
  
Factor Protective effect Risk factor Other results 
Social class 
  
Incidence higher in 
upper social classes 
 
Urban/rural areas in 
Finland 
  Incidence higher in 
the cities, relative rise 











  Incidence higher 







Parity               ++  Protection higher 
with increasing 
number of deliveries 
Previous sterilization               +   
Previous hysterectomy                -                -  
Serum hCGβ   A high value is a 
marker of worsened 
prognosis 
 
Chlamydia trachomatis               -               -  
Human papillomavirus               -               -  
Second primary cancers   SIR* for second 
primary cancers 1.4 
(95% CI 1.1–1.6), 
especially to breast, 
colorectal, bladder, 
lung cancer and NLL 
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1. INCIDENCE AND SOCIODEMOGRAPHIC DETERMINANTS OF PFTC (I) 
The incidence of PFTC increased during the study period. It was highest among upper social 
classes and in the cities. 
 
The age-adjusted incidence of PFTC in Finland increased from 1.2/1,000,000 in 1953–57 to 
5.4/1,000,000 in 1993–1997, indicating a 4.5-fold increase corresponding to a 7-fold 
increase in the absolute number of new cases. In 1993–1997 108 new cases of PFTC were 
registered at the Finnish Cancer Registry. 
The incidence was most pronounced in the oldest age groups. During 1953–67 the peak 
incidence was observed in the age group 50–54 years, whereas during 1983–97 the 
incidence was highest between 60 and 64 years of age. In rural areas, the incidence was 




Figure 2. Incidence rates per 1,000,000 of primary fallopian tube cancer in different areas in Finland 
expressed in 15-year periods from 1953–97, adjusted for age to the world standard population. Main 
cities: Helsinki, Tampere, Turku. Numbers of cases in each category are shown. 
 
 
There were 268 PFTC cases diagnosed in 1971–1995 among women born in 1906–45, for 
which information on social class and occupation were available from the Population 








Table 15. Number of women born between 1906 and 1945 in the cohort in 1970; and observed 
and expected numbers and standardized incidence ratios (SIRs) of primary fallopian tube 
carcinomas observed during 1971-1995 among women, by social class. 
Social 
class Observed Expected SIR (95% CI)2 Women in Cohort (n) 
        
I 25 20 1.27 (0.81-1.87) 88 737 
II 95 74 1.28 (1.04-1.57) 405 654 
III 114 128 0.89 (0.74-1.06) 595 805 
IV 34 46 0.73 (0.51-1.02) 177 474 
Total 268 268 1.00 (Reference) 1 267 670 
 
The incidence was high in various occupations in health care, technical, physical and social 
science, humanistic and artistic work as well as in administrative and clerical work. In 
specific occupations, increased risks of PFTC were observed among private secretaries (SIR 
4.4, 95% CI 1.4–10), nurses (SIR 4.0, 95% CI 2.1–7.0), hairdressers and barbers (SIR 3.9, 
95% CI 1.3–9.2), and bookkeepers and accountants (SIR 3.6, 95% CI 1.6–7.1). In contrast, 
low SIRs were observed among women in farming, fishing and forestry work as well as 




Table 16. Observed number of cases and standardized incidence ratios (SIRs) with 95% confidence 
intervals (CIs) for PFTC in the main occupational categories from 1971 through 1995,among women 
born from 1906 through 1945. 
 
Occupation                                                                         Observed                        SIR (95%CI) 
 
"Academic" work*                                                                    37                              1.63 (1.15-2.25) 
Administrative and clerical work                                              35                              1.60 (1.12-2.23) 
All economically active persons                                             180                              1.11 (0.96-1.28) 
Transport and communications                                                   6                              1.09 (0.40-2.37) 
Whole population                                                                    268                              1.00 (0.88-1.12) 
Services                                                                                     32                              1.00 (0.69-1.42) 
Sales professions                                                                       16                              0.98 (0.56-1.59) 
Industrial and construction work                                               27                              0.95 (0.63-1.38) 
Economically inactive**                                                           88                              0.83 (0.66-1.02) 
Farming, forestry and fishing                                                    27                              0.79 (0.52-1.14) 
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2. EFFECTS OF PARITY, STERILIZATION, HYSTERECTOMY AND A PREVIOUS 
CANCER (V) 
Parity gave the strongest protection against PFTC and the protection got stronger by number 
of deliveries, whereas a previous sterilization procedure gave a mild protection. A previous 
hysterectomy did not give any protection. 
Parity 
In univariate analysis the OR for parity was 0.54 (95% CI 0.39–0.75) when compared with 
nulliparous women. The older age (≥ 35 years) at first birth was also protective (Table 17). 
In multivariate analysis, parity was the only significant protective factor. The protective 
effect increased with increasing number of deliveries: OR for 1–2 deliveries 0.63, 95% CI 
0.44–0.91; and for ≥ 3 deliveries 0.32, 95% CI 0.19–0.52 (Table 18). 
Sterilization, hysterectomy and a previous cancer 
In univariate analysis the protective effect of a previous sterilization was of borderline 
significance (OR 0.58, 95% CI 0.33–1.00) and the effect increased among those who were ≤ 
40 years at the time of sterilization (OR 0.30, 95% CI 0.11-0.84) and a longer time since the 
procedure also gave protection (OR 0.29, 95% CI 0.11-0.79). The OR for an earlier 
hysterectomy in univariate analysis was 1.14 (95% CI 0.66-1.98). A previous cancer was a 
significant risk factor for PFTC (OR 1.69, 95% CI 1.08–2.67), especially a previous breast 
cancer (OR 1.69, 95% CI 1.08–2.67) (Table 17). 
 
In multivariate analysis sterilization did not reduce significantly the risk of PFTC (OR 0.74, 
95% CI 0.42–1.30). PFTC patients had undergone hysterectomy more often than the 
controls (OR 1.27, 95% CI 0.73–2.21). Previous breast cancer increased the risk, but non-
significantly (OR 1.63, 95% CI 0.70–3.77) (Table 18). 
 
3. TUMOR MARKERS AS PROGNOSTIC FACTORS OF PFTC (II) 
Twenty-three percent of the patients presented stage I-II disease. Eighty percent of the 
carcinomas were of serous type. Preoperative serum concentrations of hCGβ, CA125 and 
TATI were elevated in 37%, 90% and 20% of the cases, respectively. In survival analysis, 
the overall and disease-free 5-year survival rate was 33%. When analyzing disease-free 5- 
year survival rates, the most important prognostic factors were size of the residual tumor 
Results 




Table 17. Univariate analysis of anamnestic factors associated with PFTC. 
 Cases Controls OR 95% CI 
  n (%) n (%)   
All women 565  5473    
 No previous cancer 519 (91.9) 5151 (94.1) 1.00 Reference 
 Previous cancer 46 (8.1) 322 (5.9) 1.42 1.03 - 1.98
       
Type of previous cancer       
      No previous cancer 519  5151  1.00 Reference 
      Breast cancer 23  135  1.69 1.08 - 2.67
      Other cancer 23  187  1.23 0.79 - 1.91
Women born 1925+ 375  3587    
No sterilization 360 (96.0) 3357 (93.6) 1.00 Reference 
Sterilization 15 (4.0) 230 (6.4) 0.58 0.33 - 1.00
Age at sterilization       
      No sterilization 360  3357  1.00 Reference 
      < 40 years 4  115  0.30 0.11 - 0.84
      ≥ 40 years  11  115  0.85 0.45 - 1.61
Time since sterilization       
      No sterilization 360  3357  1.00 Reference 
      < 10 years 11  108  0.93 0.48 - 1.81
      ≥ 10 years  4  122  0.29 0.11 - 0.79
Women born 1936+ 189  1764    
No hysterectomy 173 (91.5) 1633 (92.6) 1.00 Reference 
Hysterectomy 16 (8.5) 131 (7.4) 1.14 0.66 - 1.98
Age at hysterectomy       
      No hysterectomy 173  1633  1.00 Reference 
      < 45 years 9  63  1.36 0.66 - 2.79
      ≥ 45 years 7  68  0.95 0.42 - 2.12
Time since hysterectomy       
      No hysterectomy 173  1633  1.00 Reference 
      < 10 years 9  102  0.84 0.41 - 1.69
      ≥ 10 years 7  29  2.19 0.93 - 5.16
No deliveries 51 (27.0) 280 (15.9) 1.00 Reference 
Women with deliveries 138 (73.0) 1484 (84.1) 0.54 0.39 - 0.75
Age at first birth       
      No deliveries 51  280  1.00 Reference 
      < 35 years 135  1428  0.52 0.37 - 0.74
      ≥ 35 years 3  56  0.30 0.09 - 1.00
Parity       
      No deliveries 51  280  1.00 Reference 
      1-2 deliveries 111  994  0.62 0.44 - 0.89
      3 or more deliveries 27  490  0.30 0.18 - 0.49
CI = confidence Interval OR = odds ratios     
Results 




Table 18. Odds Ratios (ORs) in multivariate analysis of factors associated with PFTC (189 cases, 1764 
controls). 
  Cases, n Controls, n OR 95% CI 
Parity     
     No deliveries 51 280 1.00 Reference 
     1-2 deliveries 111 994 0.63 0.44-0.91 
     3 or more deliveries 27 490 0.32 0.19-0.52 
     
No sterilization 174 1539 1.00 Reference 
Sterilization 15 225 0.74 0.42-1.30 
     
No hysterectomy 173 1633 1.00 Reference 
Hysterectomy 16 131 1.27 0.73-2.21 
     
     
No previous breast cancer 182 1727 1.00 Reference 
Previous breast cancer 7 37 1.63 0.70-3.77 
        
CI = confidence interval   
 
(p = 0.013) and stage (p = 0.014). Size of the residual tumor strongly influenced overall 5-
year survival, the survival rate for patients with residual tumor of < 1 cm being 51%, 
compared with only 20% among patients with residual tumor of ≥ 1 cm (p = 0.003). In 
patients with serous carcinoma, the overall 5-year survival rate was 37%, compared with 
17% in those with other tumor types (p = 0.023). 
 
When studying tumor markers as prognostic factors and in survival analyses, we used the 
75th percentile for all markers. The overall 5-year survival rate was 38% when serum hCGβ 
concentrations were below the 75th percentile (< 3.5 pmol/L) and 18% when it was higher (p 
= 0.052) (Figure 3), disease-free survival rates being 38% and 20%, respectively (p = 
0.014). 
We also evaluated the prognostic value of the tumor markers CA125 and TATI. High levels 
of CA125 (above the 75th percentile [1017 kU/L]) predicted shorter survival times compared 
with serum levels below that, the overall 5-year survival rates being 14% and 39%, 
respectively (p = 0.009). Disease-free 5-year survival rates were not significantly different. 
Elevated serum TATI values were sparse and were not of prognostic significance as regards 
survival. 
Results 
  53 
 
 
Figure 3. Preoperative serum hCGβ concentrations and overall survival of PFTC patients (n = 60). 
 
In univariate analysis serum hCGβ concentration (p = 0.019), stage III–IV disease (p = 
0.020), stage IV disease (p = 0.025) and size of the residual tumor (p = 0.019) were all 
associated with DFS, while the size of the residual tumor (≤ 1 cm) (p = 0.004), serum 
CA125 > 1017 kU/L (p = 0.012) and stage IV (p = 0.018) were significantly associated with 
OS. When all the variables were fitted as multiple variables in the same model, only hCGβ 
(RR 2.80, p = 0.043) and the histology of the tumor (RR 3.17, p = 0.013) were independent 
prognostic factors for OS and only hCGβ was an independent prognostic factor for DFS (RR 
3.07, p = 0.041). In a backward stepwise model, hCGβ (RR 2.49, p = 0.012), stage IV (RR 
2.47, p = 0.012) and histology (RR 2.71, p = 0.010) emerged as independent prognostic 
factors (Table 19). 
 
Table 19. Significance of prognostic factors when fitted in Cox backward stepwise regression model  










☼Variables included in the model: grade, S-CA125, S-TATI, age, size of the residual tumor. 
Overall survival  




























hCGβ < 3.5 pmol/L
hCGβ > 3.5 pmol/L
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4. IMPACT OF PAST CHLAMYDIAL INFECTION ON THE RISK OF PFTC (III) 
The effect of a past chlamydial infection was studied in a retrospective serologic case-
control study. The study did not reveal any risk effect of a previous chlamydial infection on 
PFTC. A summary of the characteristics of PFTC patients is shown in Table 20. 
 
































 n = Number of patients 
 
Parameter n (%) 
Stage   
    I 11 (14) 
    II 12 (15) 
    III 40 (51) 
    IV 15 (19) 
    No data 1 (1) 
Grade   
    1 7 (9) 
    2 20 (25) 
    3 45 (57) 
   No data 7 (9) 
Histological type   
    Serous 57 (72) 
    Anaplastic 13 (16) 
    Carcinosarcoma 5 (7) 
    Endometrioid 1 (1) 
    Clear cell 1 (1) 
    Unknown 2 (3) 
Tumor size (cm)   
    <2 7 (9) 
    2 - 5 14 (18) 
    5 -10 19 (24) 
    >10 36 (45) 
    No data 3 (4) 
Residual tumor size 
(cm)   
   None 28 (35) 
   <0.5 2 (3) 
    0.5 - 1.0 1 (1) 
    1 - 2 4 (5) 
    >2 30 (38) 
    Peritoneal   carcinosis 10 (13) 
    No data 4 (5) 
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Seropositivity to different Chlamydia trachomatis serovars and to C. pneumoniae did not 
differ between patients and controls, seropositivity varying from 13.9% to 21.5% in PFTC 
patients and from 10.3% to 21.8% in control subjects. The overall prevalence of CTR IgG 
antibodies to one or more serotype pools in PFTC patients and controls was 20% and 16%, 
respectively (p = 0.42). When analyzing the relationship between CTR or C. pneumoniae 
IgG antibodies versus PFTC, no association was detected (Table 21). The presence of serum 















Table 22. Risk of PFTC by number of positive C.trachomatis serotype 
pools in PFTC patients and controls: univariate analysis 








n (%)    OR* 95%CI** p-value
0 63 (80) 131 (84)  1.0   
1    3 (4)      5 (3)  1.2 0.3–5.4 0.7 
2    5 (6)      9 (6)  1.1 0.4–3.6 0.8 
3   8 (10)    11 (7)  1.5 0.6–3.9 0.4 
Total 79 (100) 156 (100)       
*OR= odds ratio, **CI= confidence interval 
   
   
 
Table 21. Odds ratios calculated by conditional logistic regression analysis of 
PFTC associated with different C. trachomatis serovars and with C. 
pneumoniae 
 OR 95% CI* 
C.trachomatis 
serotype pools   
        CHIJ  1.6 0.7–3.5 
        BED  1.4  0.6–3.2 
        GFK  1.1 0.5–2.4 
C.pneumoniae  1.0 0.5–1.9 
* CI = confidence interval   
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5. THE IMPACT OF HPV INFECTION ON THE RISK OF PFTC ( IV ) 
In our study none of the seroprevalences of different HPV types differed between PFTC 
patients and controls (Table 23), nor did the rates of seropositivity to more than one HPV 
type differ between cases and controls. 
 
 
Table 23. Seropositivity to different HPV types, C.trachomatis and 
HSV-2 in 78 PFTC patients and 156 controls 
  Cases n (%) Controls n (%) p-value
HPV   
      HPV6 8    (10) 15  (10) 0.88
      HPV11 10  (13) 17  (11) 0.66
      HPV16 17  (22) 33  (21) 0.91
      HPV18 5    (6) 8    (5) 0.69
      HPV31 11  (14) 21  (13) 0.89
      HPV33 8    (10) 17  (11) 0.88
C. trachomatis 14  (18) 28  (18) 0.90
HSV-2 19  (24) 34  (22) 0.60
 
 
To study the possible effect of a papillomavirus infection with more than one HPV type, we 
analyzed seropositivity to one or more HPV types. Seropositivity to multiple HPV types did 
not increase the risk of PFTC (Table 24). All HPV-specific risk estimates of PFTC were 
non-significant. 
Table 24. Adjusted odds ratios of PFTC by seropositivity to high- low-risk HPV types 
Seropositivity to Seropositivity   
one or more of to Number of   
 HPV 
16/18/31/33 HPV6/11 Cases Controls OR    (95% CI)☼  
0 No 47 91     1.00   (reference)  
0 Yes 5 12 0.80  (0.27–2.42)  
1 No 14 28 0.96  (0.40–2.02)  
1 Yes 2 7 0.57  (0.11–2.85)  
2 to 4 No 6 13 0.88  (0.32–2.46)  
2 to 4 Yes 4 5 1.44  (0.37–5.61)  
☼Adjusted for seropositivity to herpes simplex virus type 2 and C. trachomatis  
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6. SECOND PRIMARY CANCERS AFTER PFTC (VI) 
The time since PFTC was an important factor when analyzing the risk of second primary 
cancers. There were 118 cancer cases observed after 2084 previous cases of PFTC (SIR 1.4, 
95% CI 1.1–1.6). Elevated SIRs were seen for non-lymphoid leukemia (3.7, 95% CI 1.0–
9.4), bladder (2.8, 95% CI 1.0–6.0), lung (1.8, 95% CI 0.9–3.2), colorectal (1.7, 95% CI 
1.0–2.6) and breast cancer (1.5, 95% CI 1.1–2.2) (Table 25). The SIR for a second cancer 
(all sites combined) was highest if the time since PFTC diagnosis was 10+ years, age at 
PFTC diagnosis < 60 years, or the year of PFTC diagnosis was before 1984 (Table 26). 
 
For breast cancer, a significantly elevated SIR of 2.3 (95% CI 1.2–3.8) was seen at more 
than 10 years after the diagnosis of PFTC. In multivariate analysis also, there was an 
indication of an increase of breast cancer cases 10+ years after PFTC, compared with shorter 
follow-up times. 
 
For colorectal cancer, a significant increase (SIR 2.1, 95% CI 1.3–4.9) was detected during 
the second to fifth year after PFTC diagnosis (Table 26). If PFTC was diagnosed before the 
age of 60 years, the RR of colorectal cancer tended to be high (combined SIR of age 
categories < 50 and 50–59 years 2.2; 95% CI 1.1–4.0). Multivariate analysis gave essentially 
the same result: RR 1–4 years after PFTC was 3.3 compared with follow-up of 10+ years 
(95% CI 1.0–11) and RR related to PFTC diagnosed at ages 60+ years or in 1991+ 
compared with younger ages or earlier calendar periods was also lower. 
 
In multivariate analysis concerning the remaining cancers combined (after exclusion of 
breast and colorectal cancers) there was some indication of a higher risk related to PFTC 
diagnoses before 1984. Elevated risks after PFTC were also detected for non-lymphoid 
leukemia during the second to tenth year after PFTC diagnosis (four cases, SIR 6.9, 95% CI 
1.9–17.8) and for bladder cancer in follow-up at 5+ years (seven cases, SIR 4.2, 95% CI 
1.4–9.7)
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Table 25. Observed numbers of subsequent primary cancer cases after PFTC 
among 2084 women. Standardized incidence ratios (SIRs) and 95% confidence 
intervals (CIs) are shown. 
Cancer site (ICD-9) Observed
 
SIR 95 % CI 
     
  All malignant (140-208)                         118 1.4 1.1 - 1.6 
      
  Oral cavity, pharynx (140-149) 2 1.5  0.2 - 5.6 
  Esophagus (150)   1 1.3  0.0 - 7.3 
  Stomach (151)   3 0.7  0.2 - 2.2 
  Small intestine (152) 1 3.5      0.1 - 20 
  Colorectal (153,154)  20 1.7  1.0 - 2.6 
      Colon (153)  13 1.7  0.9 - 2.9 
      Rectum (154) 7 1.7  0.7 - 3.5 
  Liver (155.0,155.1)   0 -  0.0 - 5.0 
  Gall bladder, bile ducts (156)  3 1.9  0.4 - 5.5 
  Pancreas (157)  4 1.3  0.4 - 3.3 
  Peritoneum (158)   0 -      0.0 - 28 
  Lung (162)   11 1.8  0.9 - 3.2 
  Bone (170)   0 -      0.0 - 34 
  Soft tissue sarcoma (171)   1 2.5      0.1 - 14 
  Melanoma of skin (172)   1 0.4  0.0 - 2.5 
  Other neoplasm of skin (173)   9 1.5  0.7 - 2.9 
  Breast (174)   33 1.5  1.1 - 2.2 
  Cervix uteri (180) 2 0.7  0.1 - 2.4 
  Corpus uteri (182) 2 0.3  0.0 - 1.3 
  Other female genital (179,184) 2 1.8  0.2 - 6.7 
  Bladder (188,189.3-4)   6 2.8  1.0 - 6.0 
  Kidney (189.0-2,189.5-9)  2 0.9  0.1 - 3.1 
  Brain, nervous system (191-192)   0 -  0.0 - 3.3 
  Thyroid gland (193)   2 2.3  0.3 - 8.3 
  Hodgkin's disease (201) 0 -      0.0 - 15 
  Non-Hodgkin's lymphoma (200,202) 2 0.9  0.1 - 3.1 
  Multiple myeloma (203)   1 0.8  0.0 - 4.4 
  Leukemia (204-208)   5 2.6  0.8 - 6.0 
      Lymphoid (204)  1 1.2  0.0 - 6.5 
      Non-lymphoid (205-208) 4 3.7 1.0 - 9.4 
  Others 5 1.2 0.4 - 2.7 
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Table 26. Observed numbers (Obs) and standardized incidence ratios (SIRs) for second primary cancer 
among 2084 women with an earlier first PFTC, by age and calendar period at PFTC diagnosis and by 
time since PFTC diagnosis. 
   Cancer site (ICD-9) 
Factor  All malignant (140-208)       Female breast (174)      Colorectal (153,154)  
 Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI 
Age at PFTC diagnosis        
<50 26  1.6  1.0-2.4 7  1.4  0.6-2.8 4  2.3  0.6-5.9 
50-59 39  1.5  1.1-2.1 12  1.8  0.9-3.0 7  2.2  0.9-4.5 
>60 53  1.2  0.9-1.6 14  1.4  0.8-2.4 9  1.3  0.6-2.5 
Calendar period of PFTC diagnosis       
<1975 46  1.5  1.1-2.0  11  1.6 0.8-2.9  8  1.8 0.8-3.6  
1975-1983 31  1.5 1.0-2.1  9  1.8 0.8-3.4 5  1.7 0.6-4.0 
1984-1990 24  1.2  0.8-1.8  7  1.3 0.5-2.7 5  2.0 0.6-4.6 
1991+ 17  1.1 0.6-1.7 6  1.3 0.5 -2.9 2 1.0 0.1-3.5 
Time since PFTC diagnosis (years)       
<1 15  1.2  0.7-2.0 5  1.5  0.5-3.4 2  1.2  0.2-4.4 
 1-4 42  1.5  1.1-2.0 9  1.2  0.5-2.3 10  2.7  1.3-4.9 
 5-9 17  1.0  0.6-1.5 5  1.1  0.4-2.6 2  0.8  0.1-3.0 
10+ 44  1.6  1.2-2.2 14  2.3  1.2-3.8 6  1.5  0.5-3.2 
        
Discussion 




Less than 2500 cases of PFTC have been described worldwide. A commonly occurring 
problem is how to differentiate PFTC from ovarian carcinoma. The WHO has classified 
these tumors as follows: a malignant epithelial tumor of the fallopian tube must be located 
macroscopically within the tube or its fimbriated end, and the uterus and ovary must either 
not contain carcinoma or, if they do, it must be clearly different from the fallopian tube 
lesion. Malignant epithelial ovarian tumors originate from the ovarian surface epithelium or 
its derivates (Tavassoli et al. 2003). Ovarian and fallopian carcinomas behave similarly in 
many ways and they are treated under similar guidelines. 
 
Epidemiology is the study of diseases in populations of humans, specifically how, when and 
where they occur. Epidemiological research is aimed at determining what factors are 
associated with diseases (risk factors), and what factors may protect people against disease 
(protective factors). Epidemiological studies can show that a risk factor is associated 
(correlated) with a higher incidence of disease in the population exposed to that risk factor. 
 
One of the major aspects in the present study was to elucidate the occurrence of PFTC in 
Finland and to study possible risk factors, such as previous Chlamydia trachomatis infection 
or HPV infection. Possible protective factors such as parity, previous sterilization and 
hysterectomy were also studied. As prognostic factors of PFTC (factors that can be used to 
estimate recovery and survival), serum tumor markers were studied. We also wanted to 
clarify the behavior of this disease by exploring its tendency to express hCGβ. 
 
Risk and protective factors have different biological mechanisms through which they finally 
affect the development of cancer. They can promote tumorigenesis by inducing genomic 
changes. They can affect cytokinetics, e.g. by inhibiting apoptosis or by promoting 
angiogenesis. 
The incidence of PFTC (I) 
Incidence refers to the number of new cases developing during some specific time interval. 
The incidence of PFTC was clarified using Finnish Cancer Registry and Population Census 
data. The age-adjusted incidence increased more than 4-fold during the whole study period, 
being 5.4/1,000,000 at the end and it was highest in the oldest age groups, as is 
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understandable because of the change in population structure: in 1950 6.7% of the Finnish 
population was over 65 years of age, compared with 15.6% in 2003 (Statistics Finland, 
demographic statistics). The projected figure for the population over 65 years of age in 2040 
will be 27%, which could indicate a rapid rise in the incidence of PFTC. There are only two 
other studies reporting the incidence of PFTC, the SEER program rates in the United States 
(3.3/1,000,000 among Caucasian women) being lower than our respective rates (National 
Cancer Institute 2001). The rates in Denmark (2.9/1,000,000) resemble our rates around 
1980 (Pfeiffer et al. 1989). The peak incidence occurred between the ages of 60–64 years, 
whereas in the United States, the peak incidence has been highest between the ages of 70–74 
years. 
 
In our study the incidence of PFTC was highest in the main cities, but the relative rise was 
higher in rural areas than in the cities, perhaps reflecting the adoption of urban lifestyle 
factors in rural areas. Part of the variation between these areas could be explained by 
changes in parity. The lower incidence rates in rural areas and among workers in the fields 
of farming, forestry and fishing could reflect the influence of environmental and lifestyle 
factors in the etiology of PFTC. It may also reflect differences in availability of health care 
services between rural and urban areas. The differences in incidence among women in 
different occupations are difficult to explain, but part of the variation may be explained by 
real occupational exposures. 
 
The incidence rate of PFTC was greatest in higher social classes, as is also the case among 
breast and endometrial cancer patients, but not as clearly among ovarian cancer patients in 
Finland (Pukkala 1995; Robert et al. 2004). This may reflect the effect of lower parity in 
higher social classes. 
 
A proportion of the rise in incidence may be explained by better diagnostic criteria as 
regards PFTC and attentiveness of pathologists in classifying between ovarian cancer and 
PFTC even when only small biopsies are available. In our studies, a large proportion of the 
PFTC patients had stage III disease, a situation that differs from that in many earlier studies 
(Peters et al. 1988, Hellström et al. 1994, Baekelandt et al. 2000). This may reflect the 
attentiveness of our pathologists in differential diagnostics between ovarian cancer and 
PFTC, even in later stages. The rise of incidence of PFTC in Finland goes in line with the 
rise of incidence in ovarian cancer, the rise of latter being much lower though (Figure 4).   
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Figure 4. The incidence rates of PFTC and epithelial ovarian cancer (EOC) in Finland, 1958–2004 
(Finnish Cancer Registry). Incidence rates / 100,000 
 
In conclusion, the incidence rate increased in Finland during the follow-up years. The 
incidence rates were highest among higher social classes, in some occupations and in the 
main cities, perhaps reflecting in part an effect of occupational exposure, in part an effect of 
lifestyle habits and in part an effect of parity. The results may predict ever increasing 
incidence rates, as the levels of higher social classes today seem to predict the average level 
in the whole population in the future (Pukkala 1995). 
Parity, sterilization and hysterectomy as protective factors as regards PFTC (V) 
The present study clearly indicates the protective effect of parity on the risk of PFTC. There 
are no earlier studies in which the effect of parity on the risk of PFTC has been evaluated, 
but the present findings correlate with the results of studies on ovarian cancer. Ovarian and 
tubal carcinomas share many features. In organogenesis they both develop from the 
Müllerian duct and are histologically nearly identical; hence it is logical to compare the 
results with those of studies on ovarian cancer. Several studies on ovarian cancer have 
revealed a similar protective effect of parity (Whittemore et al. 1992a; Adami et al. 1994; 
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Risch et al. 1994; Albrektsen et al. 1996; Riman et al. 1998), the most recent study being 
from Finland (Hinkula et al. 2006). In a large analysis in the U.S. a 40% reduction in the risk 
of ovarian cancer was found as regards first full-term pregnancy and each birth after the first 
incurred another 14% decrease (Whittemore et al. 1992a). In the study carried out by 
Hinkula et al. an increase from five to eight births did not increase the protection against 
ovarian cancer (Hinkula et al. 2006). Earlier studies have revealed varying results 
concerning the age at first or last birth on the risk of ovarian cancer. Some studies have 
revealed an increased risk of ovarian cancer at an older age at first birth (Booth et al. 1989), 
and some a decreased risk (Whittemore et al. 1992a; Purdie et al. 1995; Cooper et al. 1999; 
Titus-Ernstoff et al. 2001). Some revealed no association between the age at first birth and 
ovarian cancer (Risch et al. 1994; Hankinson et al. 1995). In the present study, older age at 
first birth gave more protection against PFTC than age of < 35 years at first birth and the 
protective effect of deliveries became stronger with increasing number of deliveries.  
 
There are several theories concerned with trying to explain the influence of age at first birth 
on the risk of ovarian cancer. The hypotheses are largely based on the gonadotropin 
hypothesis and on the incessant ovulation hypothesis. Pituitary secretion of gonadotropins 
generally increases during adulthood, but decreases during pregnancy. The protective effects 
of later childbirth are consistent with the gonadotropin hypothesis. Adami et al. suggested a 
theory based on pregnancy-dependent clearance from the ovaries of cells that have 
undergone malignant transformation (Adami et al. 1994). One possible explanation for the 
reducing effect of pregnancy on the risk of ovarian cancer could be the high levels of 
progesterone during pregnancy that induce apoptosis of transformed epithelial cells 
(Rodriguez et al. 1998). We have to keep in mind that all these studies concern ovarian 
cancer, but because the endothelial lining of the fallopian tube is hormonally reactive, both 
cancers could behave in a similar way, even though in the fallopian tube there is no 
ovulation trauma.  
 
In the current study we found a reduced risk of PFTC after sterilization in univariate 
analysis. The effect became stronger with time since the procedure and with younger age of 
the patients at the time of the operation. There are no earlier studies on the effect of 
sterilization on the risk of PFTC. Our results are in accordance with those of most studies 
conducted concerning ovarian cancer (Table 10). However, in the present study, in 
multivariate analysis the protective effect did not reach statistical significance. 
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In our study sterilizations occurring more than half a year before the PFTC diagnoses (or the 
corresponding day for controls) were included to obtain reliable data on the effect of 
previous sterilization on the risk of PFTC. In addition, we excluded women with an 
operation code for unilateral or bilateral salpingectomy before the day of PFTC diagnosis. 
Reliable data on sterilizations were available from 1975. We included women born after 
1925 in sterilization analyses, assuming that a sterilization procedure is no longer necessary 
for women aged 50 years or more. With these criteria, the reliability of our data is good and 
the analysis appropriate. Our data were not adjusted for menarche, menopause or use of oral 
contraceptives, all of them being possible confounding factors. 
 
In the present study hysterectomy did not give any protection against PFTC. On the 
contrary, it was a risk factor (though insignificant) in univariate analysis, showing increasing 
risk with time since operation and with younger age at operation. We cannot explain this 
result, but the study material was small concerning previous hysterectomy (n = 16). To 
verify this finding, future research is needed with a larger amount of material. Hysterectomy 
data were available from 1986 and only events occurring more than half a year before the 
diagnosis of PFTC were used. In addition, only women born after 1936 were included to 
ensure that all hysterectomies during the analysis period would have been registered. The 
absence of the same confounding factors as for analyses concerning sterilization was also a 
limitation of this analysis. 
 
Our study also involved analysis of the effect of a previous cancer on the risk of PFTC. The 
cancer cases were collected from the Finnish Cancer Registry and linked with CPR data. In 
univariate analysis, a previous cancer, especially breast cancer, was a risk factor of PFTC, 
but the data were not significant in multivariate analysis. Previous studies indicate that 
BRCA1 and BRCA2 mutations are more common among PFTC patients than in the normal 
population (Aziz et al. 2001; Cass et al. 2005). On the other hand, protective factors such as 
the long-term protective effect of parity on breast cancer risk and PFTC risk may be similar 
(Ewertz et al. 1990; Hinkula et al. 2001). 
 
In conclusion, parity is a clearly protective factor as regards PFTC, showing an increasing 
effect with increasing number of deliveries, perhaps reflecting a hormonal background for 
the disease. Further studies are needed to resolve the mechanism behind this association. 
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Serum hCGβ as a prognostic factor of PFTC (II) 
In serum, hCGβ concentrations are elevated in many non-trophoblastic malignancies 
(Alfthan et al. 1992; Carter et al. 1994; Carter et al. 1995; Gillott et al. 1996; Vartiainen et 
al. 2001; Hotakainen et al. 2002; Louhimo et al. 2002; Louhimo et al. 2004a; Louhimo et al. 
2004b) and also in some trophoblastic diseases (Stenman et al. 1985). Low levels of hCG 
and hCGβ are also expressed in many benign pancreatic, colorectal and gastric diseases 
(Alfthan et al. 1992; Louhimo et al. 2001). 
 
In the present study levels of the tumor markers hCGβ and CA125 were elevated in serum 
and they were both markers of decreased OS, but only elevated serum hCGβ values were 
associated with worsened DFS. Levels of hCGβ, and stage and histology were all of 
significant prognostic value as regards OS in multivariate analysis. Serum TATI 
concentrations were only sparsely elevated and were not of prognostic value for survival. 
 
The serum concentration of CA125 has previously been shown to behave as a prognostic 
marker for PFTC (Hefler et al. 2000) when using the 75th percentile cut-off value, which in 
their study was 756 kU/L. On the basis of that study, we also used the 75th percentile cut-off 
value, which in our study was 1017 kU/L. In our study the CA125 level correlated strongly 
with stage of the disease and it was therefore not an independent prognostic factor for DFS, 
although the RR in univariate analysis was similar to that reported by Hefler et al. (2000). 
 
The results of the current study suggest that serum hCGβ concentrations are of prognostic 
value in PFTC, as has been shown in many other non-trophoblastic cancers (Alfthan et al. 
1992; Carter et al. 1994; Carter et al. 1995; Gillott et al. 1996; Vartiainen et al. 2001; 
Hotakainen et al. 2002; Louhimo et al. 2002; Louhimo et al. 2004a; Louhimo et al. 2004b). 
Tumors secreting hCGβ are more aggressive and studies on bladder cancer have revealed a 
higher level of resistance to RT and a higher propensity to metastasize among tumors 
secreting hCGβ (Iles et al. 1996). The true function of hCGβ is unknown. It cannot stimulate 
LH/hCG receptor alone, and therefore the effect of hCGβ has to be mediated through some 
other pathway (Pierce and Parsons 1981). It may act as an autocrine growth factor by 
inhibiting apoptosis in vitro (Butler et al. 2000), but it does not increase the rate of cell 
replication. There are suggestions that it could block the transforming growth factor beta 
(TGFβ) receptor and by that way, apoptosis (Iles 2006). If that is true, this receptor could be 
a target for anti-tumor vaccines and therapy (Delves et al. 2006). 
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In conclusion, serum hCGβ and CA125 are useful markers in the diagnosis and follow-up of 
PFTC and hCGβ is a good marker of prognosis. Among patients with high serum hCGβ 
levels more aggressive treatments could be used and maybe in the future they could benefit 
from anti-tumor vaccines and therapy. 
The role of infectious factors on the risk of PFTC (III, IV) 
The results of the present study involving serological analyses indicate reasons and 
background other than CTR or HPV infections for PFTC. 
 
The idea of evaluating the significance of CTR and HPV infections in cases of PFTC was 
based on earlier case reports of tuberculous salpingitis being a possible promoter of PFTC 
(Gungor et al. 2003) and on studies on the connections between CTR, HPV and other 
gynecological cancers, mostly cervical cancer (Koskela et al. 2000; Anttila et al. 2001; 
Paavonen et al. 2003). 
 
The results of some studies have suggested a connection between PID and ovarian cancer 
(Risch and Howe 1995), but in a study by Parazzini et al. (1996) no association between 
ovarian carcinoma and PID was found. The only seroepidemiological study (146 cases, 192 
controls) concerning CTR infection and ovarian cancer revealed that women with higher 
levels of CTR antibodies to serovar D had a 90% greater probability of having ovarian 
cancer (Ness et al. 2003). We did not find an association between an earlier CTR infection 
and PFTC. These results are in accordance with those reported by Parazzini et al. (1996). 
We assessed serum CTR antibodies using the MIF method, which has been a tool in 
epidemiological research on chlamydial infection since 1970 (Wang and Grayston 1970) and 
is a sensitive and most specific method for laboratory diagnosis of CTR infection, and 
regarded as the gold standard method for epidemiological research. 
 
Among studies of the risk factors of ovarian cancer, theories concerning ascending factors 
such as talc (Cramer et al. 1982; Whittemore et al. 1988), asbestos (Graham and Graham 
1967), infectious agents or perhaps uterine growth factors (Riman et al. 1998) causing 
ovarian cancer have been widely proposed, but the mechanism and relevance of these 
factors still remain poorly understood. 
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Earlier studies have also revealed an association between HPV and gynecological cancers 
(Table 9). Human papillomavirus causes cervical cancer (Bosch et al. 1995) and it has also 
been linked to vulvar (Madeleine et al. 1997) and vaginal (Daling et al. 2002) as well as anal 
cancers (Daling et al. 2004). The results of studies on the link between ovarian cancer, 
endometrial cancer and HPV infection are very conflicting. There are studies connecting 
HPV (mostly HPV16) and endometrial cancer (Lai et al. 1992; Anwar et al. 1996; Zimna et 
al. 1997; Hisada et al. 2001; Ip et al. 2002) and HPV16 and ovarian cancer (Lai et al. 1992; 
Anwar et al. 1996; Hisada et al. 2001; Ip et al. 2002; Wu et al. 2003). However, there are 
many studies that have not revealed an association between HPV and endometrial 
(Czerwenka et al. 1996; Hording et al. 1997) or ovarian cancer (Leake et al. 1989; McLellan 
et al. 1990; Beckmann et al. 1991; Anwar et al. 1996; Chen et al. 1999). 
 
Few studies have been conducted concerning serological evidence of the connection 
between HPV and gynecological cancers others than cervical cancer (Strickler et al. 1998; 
Hisada et al. 2001) and only a non-significant association has been discovered. No earlier 
study has involved evaluation of the serological connection between HPV infection and 
PFTC, but a study of HPV DNA expression in PFTC revealed no HPV DNA in PFTC cases 
(Heselmeyer et al. 1998). 
 
We measured antibodies to VLPs as markers of exposure to HPV. Serological assays are 
useful in demonstrating associations in epidemiological studies, although molecular methods 
are more sensitive. The sensitivity of serological assays using detection of viral DNA as a 
reference varies between 50% to 75% and the specificity is 95–99% (Dillner et al. 1996; 
Kjellberg et al. 1999). This may lower the possibility of detecting marginally raised levels of 
serum HPV antibodies. Levels of antibodies to HPV have been detected to persist in 
prolonged follow-up (af Geijersstam et al. 1998) and there is no consistent association 
between HPV seropositivity and age (Wikström et al. 1995; Dillner et al. 1996). 
 
In the present study all serum samples for measurements of CTR and HPV antibodies were 
taken postoperatively in order to reflect the situation at the time of diagnosis of PFTC. The 
HPV16 seroprevalence rates were 22% and 21% in cases and controls, respectively, which is 
relatively high when compared with results in other studies (Cuzick et al. 2000). These 
aspects ensure that our diagnostic methods for evaluating the effect of an earlier HPV 
infection on PFTC are adequate, and the results do not suggest that HPV contributes to the 
Discussion 
  68 
 
 
development of PFTC. These are also the primary studies on this subject. However, there 
might have been some selection bias among control cases that could have influenced our 
results in studies III and IV, as the control samples were drawn from female employees at 
HUCH Hospital Area and from female patients seen for a benign colon disease or from 
patients operated upon because of benign ovarian cysts. In addition, as the PFTC material 
was relatively small, it may also have had an effect on the results. 
Second primary cancers after first PFTC 
Second primary cancers are cancers occurring after a prior cancer. They may be attributable 
to treatment (RT and CT) of the first primary cancer. They may also reflect shared etiologic 
factors, environmental exposure, host characteristics, and combinations of influences, 
including common genetic background or gene-environment interactions, and interaction of 
CT with RT (Travis, 2006a). Chemotherapy sometimes induces leukemia characterized by 
short latency after a first primary malignancy. Radiotherapy can induce bone marrow 
malignancies and solid tumors, the most sensitive organs being the breast and thyroid. In 
contrast to secondary leukemias, the latency period of therapy-associated solid tumors is 
much longer, usually ≥ 10 years (Travis et al. 1996) and the risk seems to be sustained. 
 
In the present multicenter study we observed increased risks of bladder, breast, colorectal 
and lung cancer, and non-lymphoid leukemia after PFTC. The clustering of lung and bladder 
cancer may suggest a shared smoking etiology. The increased risk of these cancers may also 
be a reflection of earlier RT, and some risk increase could be a reflection of earlier CT with 
alkylating agents (Travis et al. 2002). The excess of second primary colorectal and breast 
cancers after PFTC could indicate a shared genetic etiology (Travis et al. 2006b). 
 
These findings are consistent with the results of earlier studies on second cancers after 
gynecological cancers (Boice et al. 1985; Curtis et al. 1985; Storm and Ewertz 1985; Travis 
et al. 1996; Travis et al. 1999; Ohno et al. 2006). However, there are no earlier studies on 
second primary cancers after first PFTC, most likely because of the rarity of the disease. 
Studies on concomitant presentation of breast cancer, other gynecological cancers and colon 
cancer among patients with PFTC may suggest a similar hormone responsiveness of those 
cancers or similar genetic backgrounds (Yoonessi 1979; Alvarado-Cabrero et al. 1999; 
Baekelandt et al. 2000). In our study the excess risk of breast cancer became apparent more 
than ten years after PFTC diagnosis and the SIR was not highest in the youngest age groups, 
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findings that could be explained by an effect of ionizing radiation, and probably unlikely to 
be explained by genetic susceptibility (Pukkala et al. 2006b). 
 
In conclusion, to the best of our knowledge, the incidence of second primary cancers after 
first PFTC has not been reported previously. In the present study PFTC patients had a 40% 
increased risk of developing a new primary cancer, compared with the normal population. In 
part, the excesses of these second primary cancers may reflect common hormonal 
responsiveness of these cancers, in part the effects of earlier treatments and in part, lifestyle 
habits. In the study, common genetic susceptibility for breast cancer and PFTC was not 
detected, as the SIR for breast cancer was not highest among younger patients and the 
excess risk of breast cancer occurred relatively late. The late occurrence of second primary 
cancers reflects the effects of earlier RT. The excesses of breast, colorectal, lung and bladder 


















On the basis of the results these studies the following conclusions can be drawn: 
1. The incidence of PFTC increased in Finland during 1953–1997. The increase was 
highest in the main cities, but the relative rise was highest in rural areas. The incidence 
was highest in social classes I and II and among academic professions, and lowest 
among women in rural areas and in women working in farming, forestry and fishing. 
2. Parity is a protective factor for PFTC, as is previous sterilization. Previous hysterectomy 
is not protective as regards PFTC. 
3. In multivariate analysis, serum concentrations of hCGβ, and histology and stage were 
independent prognostic factors for PFTC. An increased serum hCGβ value is a marker 
of worsened prognosis of PFTC. 
4. Past Chlamydia trachomatis infection is not related to PFTC. 
5. Human papillomavirus infection is not related to PFTC. 
6. Second primary cancers among PFTC survivors are bladder, breast, colorectal and lung 
cancers, and non-lymphoid leukemias, reflecting late effects of radiotherapy and 
chemotherapy, and maybe a shared smoking etiology. A common genetic or hormonal 
background may also be possible.
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SOCIODEMOGRAPHIC DETERMINANTS OF INCIDENCE OF PRIMARY
FALLOPIAN TUBE CARCINOMA, FINLAND 1953–97
Annika RISKA1, Arto LEMINEN1* and Eero PUKKALA2
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Primary fallopian tube carcinoma is very rare. In Western
countries, it accounts for about 1% of all female genital ma-
lignant tumors. Its etiology remains poorly known, but high
parity is considered to be protective. We studied determi-
nants of incidence of primary fallopian tube carcinoma in
Finland. Incidence rates for primary fallopian tube carci-
noma, according to the population based Finnish Cancer
Registry, from 1953– 97 were assessed by age, year of diag-
nosis, and type of residential area. Standardized incidence
ratios (SIRs) for the years 1971– 95 were calculated by occu-
pation and social class variables taken from the 1970 Popu-
lation Census. There were 485 cases of primary fallopian tube
carcinoma registered during 45 years. The age-adjusted inci-
dence rate increased from 1.2/1,000,000 in 1953–57 to 5.4/
1,000,000 in 1993–97. This 4.5-fold increase in incidence rate
corresponds to a 7-fold increase in the number of new cases.
The increase is attributable to the age group beyond 55
years, the peak incidence occurring between 60–64 years.
Although the relative increase in incidence rate has been
larger in rural areas than in cities, the rate in the latter
remains 2-fold. Women in the 2 highest social classes had a
1.8-fold incidence (95% CI  1.2–2.6) as compared to the
lowest social class. Women in agriculture and those not
working outside the home had only half the cancer incidence
of those in academic or clerical occupations. The incidence of
primary fallopian tube carcinoma increases in Finland. Evi-
dently, the incidence has increased simultaneously with the
affluence of urban life. Part of the variation in incidence
correlates with variation in parity.
© 2003 Wiley-Liss, Inc.
Key words: primary fallopian tube carcinoma; incidence; social
class; occupation
Primary fallopian tube carcinoma (PFTC) is a very rare but
highly aggressive disease, reported to comprise 0.1–1.1% of all
female genital malignancies.1 PFTC was described for the first
time by Renaud in 1847.2 Although its etiologic factors are largely
unknown, they have been considered to be similar to those of
ovarian carcinoma. Histologically, most PFTCs are pure adeno-
carcinomas, the main type being serous adenocarcinoma. Occa-
sional cases of endometrioid, clear cell, transitional cell, and glassy
cell carcinomas have been reported.3
Finland is an industrialized country with 5.2 million inhabitants.
Most Finns live in urban communities. Finland is characterized by
a relatively homogenous population and an effective nearly free-
of-charge healthcare system. The nationwide population-based
cancer registry allowed us to study incidence characteristics of
PFTC over a period of 45 years in Finland.
MATERIAL AND METHODS
More than 99% of all cancer cases have been reported to the
Finnish Cancer Registry 1953.4 In the 1990s, about 95% of the
cases were microscopically confirmed, and about 1% of the cases
based on death certificate only.5 The Registry obtains information
from hospitals and other institutions with inpatient beds, general
practitioners, and pathology and cytology laboratories. The Finn-
ish Cancer Registry also receives copies of all death certificates in
which cancer is mentioned. Notification of new cancer cases to the
Cancer Registry is mandatory by law. From this register, we
collected all patients reported to have PFTC in 1953–1997. The
incidence rates, age-standardized to the world population,6 were
calculated by calendar period and urbanization level of the place of
residence.
The methods for calculating the standardized incidence ratios
(SIRs) in relation to occupation and social class have been de-
scribed in detail by Pukkala .7 Briefly, Statistics Finland organized
an official census of the Finnish population in 1970.8 The ques-
tionnaire included information on occupation, which was coded
into more than 400 occupational categories. Four social classes
were defined on the basis of education, occupation, industrial
status, and industry groupings.8,9 Financially dependent persons
(e.g., housewives and students) were classified by the occupation
of their supporter.
The four social classes were defined as follows:
1. Managers and other higher administrative or clerical employ-
ees, farmers owning more than 50 hectares of land;
2. Lower administrative or clerical employees, small-scale en-
trepreneurs, farmers owning 15–49.9 hectares of land;
3. Skilled and specialized workers, farmers owning 5–14.9
hectares of land;
4. Laborers, farm and forestry workers, institution inmates,
farmers owning 5 hectares of land, retired persons, whose
former occupation was unknown.
The cancer records of the Finnish Cancer Registry from
1971–95 for persons born in 1906–45 were linked with the census
data. The expected numbers of cases were calculated by multiply-
ing the stratum-specific number of person-years by the respective
calendar period and birth cohort-specific incidence rate of all
Finnish women. The SIR values were the ratio of the observed to
the expected number of cases. Confidence intervals (CI) were
defined with the assumption that the observed number of cases
followed Poisson distribution.
RESULTS
From 1953–97, 485 patients with PFTC were identified. Fifteen
cases of the PFTC were found during the 5-year period 1953–57
and 108 during 1993–97, indicating a 7-fold increase in the num-
ber of new cases. The age-adjusted incidence increased in the
1980s and 1990s (Table I). In rural areas, the incidence was lower,
but the relative rise was higher than in cities (Fig. 1). The main
increase was in the oldest age groups (Fig. 2). During 1953–67 the
peak incidence occurred in groups aged 50–54 years, whereas
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Finland. Fax: 358-9-4717-3640. E-mail: arto.leminen@hus.fi
Received 24 May 2002; Revised 4 October 2002; Accepted 10 October
2002
DOI 10.1002/ijc.10970
Int. J. Cancer: 104, 643–645 (2003)
© 2003 Wiley-Liss, Inc.
Publication of the International Union Against Cancer
during 1983–97 the incidence was highest between 60–64 years of
age.
There were 268 PFTC cases (all being a part of the total sample)
diagnosed in 1971–95 in women born 1906–45, for which infor-
mation on social class and occupation were available from Popu-
lation Census 1970. The SIRs markedly increased toward higher
social classes: the ratio of the combined SIR of Classes I and II
compared to that of Class IV was 1.8 (95% CI  1.2–2.6) (Table
II). Occupational branches “health care, technical, physical sci-
ence, social science, humanistic, and artistic occupations” and
“administrative and clerical work” were associated with high SIRs
for PFTC, while “farming, forestry and fishing” was associated
with a low risk, as were economically inactive women (Table III).
From specific occupations, significantly high SIRs were observed
for private secretaries (SIR 4.4, 95% CI  1.4–10), nurses (4.0,
95% CI  2.1–7.0), hairdressers and barbers (3.9, 95% CI 
1.3–9.2), and book-keepers and accountants (3.6, 95% CI  1.6–
7.1).
DISCUSSION
Our results show a 2-fold increase in the incidence of PFTC
during the last 15 years. At the end of the study period, the
incidence was 5.4/1,000,000. In the United States during the
period 1995–99 the SEER program reported an age-adjusted inci-
dence rate of 3.3/1,000,000 among Caucasian women.10 In Den-
mark, the incidence rate around 1980 of 2.9/1,000,00011 was quite
close to the respective Finnish rate. The age patterns in Denmark
and in Finland resemble each other, with the peak incidence
occurring between the ages of 60–64 years, whereas in the US, the
peak incidence was highest between the ages of 70–74 years.10
In our study, the incidence rate was greatest in urban areas and
in higher social classes. Professions with a high level of education
or with compulsory health control, such as medical care personnel,
had an increased risk of PFTC, which could be a consequence of
a higher identification rate due to greater alertness and routine
visits to gynecologists.
Because no dramatic changes in the diagnostic procedures of
PFTC have occurred in recent decades, improved procedures can-
not explain the rising incidence of this cancer. From the 1950s–
1980s, however, carcinomas were more often detected to be inop-
erable during laparotomy. As only biopsies were taken from those
inoperable cases, it was often impossible for the pathologist to
differentiate between ovarian and tubal carcinoma, leading to
misclassification of the tubal tumor as ovarian carcinoma. Ovarian
and tubal carcinomas share many features. In organogenesis, they
both develop from the Müllerian duct and are histologically nearly
identical. Clinically, they have a tendency toward invasive behav-
TABLE II – NUMBER OF PRIMARY FALLOPIAN TUBE CARCINOMA CASES
OBSERVED DURING 1971–1995 AMONG WOMEN BORN BETWEEN 1906
AND 1945 BY SOCIAL CLASS1
Social class Observed SIR (95% CI)2
I 25 1.27 (0.81–1.87)
II 95 1.28 (1.04–1.57)
III 114 0.89 (0.74–1.06)
IV 34 0.73 (0.51–1.02)
1All women in Finland  1.0.–2Standardized incidence ratio.
TABLE III – PRIMARY FALLOPIAN TUBE CARCINOMA CASES OBSERVED
DURING 1971–1995 AMONG WOMEN BORN BETWEEN 1906 AND 1945 BY
THE MAIN OCCUPATIONAL CATEGORIES1
Occupation Observedn SIR (95% CI)
2
Academic3 37 1.63 (1.15–2.25)
Administrative and clerical 35 1.60 (1.12–2.23)
All economically active persons 180 1.11 (0.96–1.28)
Transport and communications 6 1.09 (0.40–2.37)
Whole population 268 1.00 (0.88–1.12)
Services 32 1.00 (0.69–1.42)
Sales professions 16 0.98 (0.56–1.59)
Industrial and construction work 27 0.95 (0.63–1.38)
Economically inactive4 88 0.83 (0.66–1.02)
Farming, forestry, and fishing 27 0.79 (0.52–1.14)
1All women in Finland  1.0.–2Standardized incidence ratio.–
3Health care, technical, physical science, social science, humanistic,
and artistic occupations.–4Largely housewives.
TABLE I – ANNUAL NUMBER OF NEW CASES AND FEMALE POPULATION
AT RISK, AND INCIDENCE RATES PER 1,000,000 FOR PRIMARY
FALLOPIAN TUBE CARCINOMA IN FINLAND BY PERIOD OF DIAGNOSIS
Period n Population Rate1
1953–57 15 11,011,700 1.2
1958–62 31 11,508,000 2.3
1963–67 47 11,888,100 3.3
1968–72 40 11,933,500 2.5
1973–77 39 12,174,800 2.4
1978–82 46 12,378,000 2.7
1983–87 69 12,655,100 3.6
1988–92 90 12,869,900 4.3
1993–97 108 13,119,000 5.4
1Adjusted for age to the world standard population.
FIGURE 1 – Incidence rates per/1,000,000 of primary fallopian tube
cancer in different areas in Finland expressed in 15-year periods from
1953–97, adjusted for age to the world standard population. Main
cities: Helsinki, Tampere, Turku. Number of cases in each category are
expressed in the figure.
FIGURE 2 – Age-specific incidence rates per/1,000,000 of primary
fallopian tube cancer in Finland expressed in 15-year periods from
1953–97.
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ior, early dissemination throughout the peritoneal cavity, and poor
overall prognosis. PFTC tends to be even more aggressive than
ovarian cancer, and in less than 4% of cases is the diagnosis made
before primary surgery.11,12
PFTC and ovarian cancer have a similar etiology. Exposure to
high levels of gonadotropins, incessant ovulation, and infertility
increase the risk of ovarian cancer, whereas high parity, breast
feeding, the use of oral contraceptives, tubal ligation, and hyster-
ectomy seems to provide protection.13–20 Recent studies have also
found evidence that BRCA1 and BRCA2 germline mutations
increase the risk of PFTC as well as of ovarian carcinoma.21–24 The
pelvic inflammatory disease (PID) appears to be a risk factor for
development of ovarian carcinoma,25,26, and an association be-
tween PID and PFTC has also been suggested.27The observed
incidence pattern of PFTC matches the pattern of parity in Finland;
the average number of children has decreased and is highest
among economically inactive women and women in
agriculture.7So far, however, no case-control studies have been
published concerning PFTC and PID and parity.
In conclusion, the incidence of PFTC in Finland has risen
markedly during the last decades and is clearly associated with
higher socioeconomic status. Etiological factors explain part of the
increase, but other explanations must be explored to elucidate the
variation in its entirety.
REFERENCES
1. Nordin AJ. Primary carcinoma of fallopian tube: a 20-year literature
review. Obstet Gynecol Surv 1994;49:349–61.
2. Ricci JV. Neoplasms of the tubes. In: Ricci JV. One hundred years of
gynecology. Philadelphia: Blakiston, 1945. 498–501.
3. Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carci-
noma of the fallopian tube: a clinicopathological study of 105 cases
with observations on staging and prognostic factors. Gynecol Oncol
1989;35:236–9.
4. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control in
a population based cancer registry. Experience in Finland. Acta Oncol
1994;33:365–9.
5. Finnish Cancer Registry. Institute for statistical and epidemiological
cancer research: cancer incidence in Finland 1996 and 1997. Cancer
statistics of the national research and development centre for welfare
and health. Helsinki: Cancer Society of Finland, 2000.
6. Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer
incidence in five continents. vol. 5. Lyon: IARC, 1987.
7. Pukkala E. Cancer risk by social class and occupation: a survey of
109,000 cancer cases among Finnish of working age. Contributions in
Epidemiology Biostatistics. vol. 7. Basel: Karger, 1995.
8. Central Statistical Office of Finland. Population Census 1970: occu-
pation and social position. Official Statistics of Finland VI C:104, vol.
IX. Helsinki: Central Statistical Office of Finland, 1974.
9. Rauhala U. Social structure of the Finnish society. Social Review 6.
Helsinki: Ministry of Social Affairs and Health, 1966.
10. SEER Program. 12 Geographic areas for 1995–1999. Bethesda, Mary-
land: National Cancer Institute, Cancer Statistics Branch, 2001.
11. Pfeiffer P, Mogensen H, Amtrup F, Honore E. Primary carcinoma of
fallopian tube. Acta Oncol 1989;28:7–11.
12. Rosen AC, Sevelda P, Klein M, Graf AH, Lahousen M, Reiner A,
Auerbach L, Vavra N, Rosen HR. A comparative analysis of man-
agement and prognosis in Stage I and II fallopian tube carcinoma and
epithelial ovarian cancer. Br J Cancer 1994;69:577–9.
13. Jereczek B, Jacek J, Kobierska A. Primary cancer of the fallopian
tube: report of 26 patients. Acta Obstet Gynecol Scand 1996;75:
281–6.
14. Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization,
hysterectomy and the subsequent occurrence of epithelial ovarian
cancer. Am J Epidemiol 1991;134:362–9.
15. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ,
Rosner B, Hennekens CH, Speizer FE. Tubal ligation, hysterectomy,
and risk of ovarian cancer. JAMA 1993;270:2813–8.
16. Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ,
Rosner B, Hennekens CH, Speizer FE. A prospective study of repro-
ductive factors and risk of epithelial ovarian cancer. Cancer 1995;76:
284–90.
17. Risch HA, Marett LD, Howe GR. Parity, contraception, infertility,
and the risk of epithelial ovarian cancer. Am J Epidemiol 1994;140:
585–97.
18. Rossing MA, Daling JR, Weiss NS. Ovarian tumors in a cohort of
infertile women. N Engl J Med 1994;331:771–6.
19. Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer
Group. Characteristics relating to ovarian cancer risk: collaborative
analysis of 12 US case-control studies II. Invasive epithelial ovarian
cancers in white women. Am J Epidemiol 1992;136:184–203.
20. Whittemore AS. The risk of ovarian cancer after treatment for infer-
tility (letter; comment). N Engl J Med 1994;331:805–6.
21. Paley PJ, Swisher EM, Garcia RL, Agoff N, Greer BE, Peters KL,
Goff BA. Occult cancer of the fallopian tube in BRCA-1 germline
mutation carries at prophylactic oophorectomy: a case for recom-
mending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001;
80:176–180.
22. Zweemer RP, van Diest PJ, Verheijen RHM, Ryan A, Gille JPJ,
Sijmons RH, Jacobs IJ, Menko FH, Kenemans P. Molecular evidence
linking primary cancer of the fallopian tube to BRCA1 germline
mutations. Gynecol Oncol 2000;76:45–50.
23. Tonin P, Moslehi R, Green R, Rosen B, Cole D, Boyd N, Cutler C,
Margolese R, Carter R, McGillivray B, et al. Linkage analysis of 25
Canadian breast and breast-ovarian cancer families. Hum Genet 1995;
95:545–550.
24. Rose PG, Shrigley R, Wiesner GL. Germline BRCA2 mutation in a
patient with fallopian tube carcinoma: a case report. Gynecol Oncol
2000;77:319–20.
25. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber
B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL. Tubal
ligation and risk of ovarian cancer carriers of BRCA1 and BRCA2
mutations: a case control study. Lancet 2001;357:1467–70.
26. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of
epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995;
4:447–51.
27. Paavonen J. Chlamydia and cancer. Gynecol Forum 1998;2:17–20.
28. Peters WA III, Andersen WA, Hopkins MP, Kumar NB, Morley GW.
Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol
1988,71:757–62.
645FALLOPIAN TUBE CARCINOMA IN FINLAND

II




Tumor Biol 2006;27:43–49 
DOI: 10.1159/000090155 
Preoperative Serum hCG  as a 
Prognostic Marker in Primary Fallopian 
Tube Carcinoma 
A. Riskaa    H. Alfthanb    P. Finneb, c     J. Jalkanena    T. Sorvaria    U.H. Stenmanb
A. Leminena
Departments of aObstetrics and Gynaecology, and bClinical Chemistry, Helsinki University Central Hospital, 
Helsinki, and cSchool of Public Health, University of Tampere, Tampere, Finland 
(p = 0.052). The corresponding disease-free 5-year sur-
vival was 38 and 20%, respectively (p = 0.014). Patients 
with CA 125 values above 1,017 kU/l had an overall 5-year 
survival of 39% as compared with 14% for those with 
lower values (p = 0.009), while the disease-free survival 
was 37 and 23%, respectively (p = 0.096). Serum TATI 
was not a prognostic marker. Serum concentrations of 
hCG  and CA 125 correlated signifi cantly with stage 
(p = 0.049 and p = 0.050, respectively). In multivariate 
Cox proportional hazards regression analysis, only 
hCG  , stage and histology emerged as independent 
prognostic factors. Conclusions: Clearly elevated serum 
concentrations of hCG  and CA 125 predict survival in 
fallopian tube carcinoma, but in multivariate analyses, 
only hCG  is a prognostic factor independent of stage 
and histology. 
Copyright © 2006 S. Karger AG, Basel 
Introduction
 Primary fallopian tube carcinoma (PFTC) is a rare 
gynaecological carcinoma constituting 0.1–1.1% of all 
neoplasms of the female genital tract  [1] , but its inci-
dence is increasing. In Finland, it has increased from 
1.2/1,000,000 in 1953 to 5.4/1,000,000 in 1997  [2] . Only 
4% are correctly diagnosed preoperatively and most of 
Key Words 
Primary fallopian tube carcinoma   Tumour-associated 
trypsin inhibitor   Human chorionic gonadotropin 
Abstract
Objectives: It was the aim of this study to evaluate the 
prognostic value of the pretreatment serum concentra-
tions of the   -subunit of human chorionic gonadotropin 
(hCG  ), CA 125 and tumour-associated trypsin inhibitor 
(TATI) in primary fallopian tube carcinoma (PFTC). Meth-
ods: The pretreatment serum concentrations of hCG  ,
CA 125 and TATI were analyzed in serum samples from 
60 women with a mean age of 61 years, treated for PFTC 
between 1985 and 2000. Of the 91 patients treated during 
this period, 31 were excluded because no serum sample 
was available. The patients were followed-up for recur-
rence and survival until February 14, 2003. The prognos-
tic value of the serum markers were compared with 
those of stage, grade and histological type. Results: The 
median survival time was 27 months and the overall 5-
year survival rate 33%. Stage and size of the residual 
tumour ( ! 1 vs.  6 1 cm) predicted both overall and dis-
ease-free survival (p  ! 0.050). Histology (serous vs. oth-
ers) (p = 0.023) also infl uenced overall survival. Overall 
5-year survival was 38% when serum hCG  was below 
3.5 pmol/l, while it was 18% when the level was higher 
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the cases are detected at an advanced stage. Despite ad-
vances in therapy, the prognosis is poor, the overall 5-year 
survival rate being 33–57%  [3–6] . The size of the residu-
al tumour, clinical stage, histological grade and age of the 
patient have been shown to affect prognosis  [3, 7–9] . 
 Serum tumour markers are very valuable for monitor-
ing the clinical course of gynaecological cancers and CA 
125 plays an important role in diagnosis and follow-up of 
PFTC as well as in ovarian carcinoma  [6, 10] . Changes 
in CA 125 levels during the course of disease refl ect the 
response to therapy, and in a recent study, a CA 125 lev-
el above 756 U/ml (75th percentile) was found to be an 
independent prognostic factor for disease-free survival 
(DFS) and overall survival in PFTC  [8] . There are no re-
ports of the prognostic value of other tumour markers in 
PFTC. 
 Human chorionic gonadotropin (hCG) is a glycopro-
tein consisting of two subunits, i.e. the   - and   -subunit. 
hCG is a very useful marker for monitoring pregnancy, 
pregnancy-related disorders and trophoblastic disease, 
but it is very rarely useful in non-trophoblastic malignan-
cies  [11] . In these, the free   -subunit of hCG (hCG  ) in 
serum is fairly often elevated, e.g. in ovarian carcinoma, 
elevated serum hCG  levels have been observed in 30–
40% of the patients  [12–14] . Furthermore, hCG  is an 
independent prognostic factor in ovarian, colorectal and 
renal cell carcinoma  [14–16] . Elevated serum levels of 
hCG  correlate with excretion of the core fragment of 
hCG  , a degradation product of hCG  into urine  [17] , 
and elevated urinary levels of the core fragment of hCG  
refl ect the prognosis in vulvar and cervical carcinoma  [18, 
19] . 
 Tumour-associated trypsin inhibitor (TATI) is a mark-
er that is elevated in various cancers. Expression of TATI 
is associated with expression of tumour-associated tryp-
sin. Trypsin expression is generally associated with an 
aggressive disease. TATI refl ects trypsin expression and 
serum TATI has been shown to be an independent prog-
nostic marker for ovarian  [14, 20] , renal  [16] and bladder 
cancer  [21] . 
 The purpose of the present study was to clarify the 
prognostic value of preoperative hCG  in patients with 
PFTC using a highly sensitive and specifi c immunofl uo-
rometric assay. As reference markers we used CA 125 and 
TATI. 
Patients and Methods 
 Patients 
 Ninety-one consecutive patients treated for PFTC in our hos-
pital between 1985 and 2000 were studied. Patient data were re-
trieved by detailed chart review. The clinical characteristics of the 
patients are shown in  table 1 . The patients did not receive chemo-
therapy prior to surgery. Thirty-one of 91 patients (34%) were ex-
cluded from the study because a preoperative serum sample was 
not available. In order to exclude selection bias, we studied the 
overall survival of patients with and without preoperative hCG  
values and there was no statistically signifi cant difference (p = 
0.929), median survival being 29 and 36 months, respectively. The 
distribution of stage (p = 0.294), grade (p = 0.789), tumour size 
(p = 0.105), size of the residual tumour (p = 0.929) and histological 
type (serous adenocarcinomas vs. others; p = 0.165) did not differ 
between the groups. 
 The patients were followed up for recurrence and survival until 
February 14, 2003. Preoperative serum measurements of hCG  , 
CA 125 and TATI were available in 60, 57 and 59 cases, respec-
tively. Samples were drawn 1–75 days (median 15 days) before 
surgery. Mean age of the patients was 61 years (range 40–83). Stag-
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1 10 28 46
Residual tumor size, cm
None 21 35
! 0.5 1 2
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1–2 3 5
1 2 25 42
Peritoneal carcinosis 8 13
No data 1 2
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ing was performed according to the FIGO criteria with pelvic and 
para-aortic lymphadenectomy whenever possible. Stage, grade, his-
tological fi ndings, tumour size and size of the residual tumour were 
recorded ( table 1 ). In 8 cases, surgery was limited to explorative 
laparotomy (histological sampling) either because of an unresect-
able condition or peritoneal carcinosis. In 1 case, the size of the 
residual tumour was not recorded. All patients except 2 received 
platinum-based combination chemotherapy as adjuvant therapy: 1 
patient denied chemotherapy and another died before chemother-
apy could be started. Nine patients had other previous cancers: 5 
of them breast cancers, 2 gastrointestinal cancers and 2 other can-
cers of unknown origin. All of them were cured before the diagno-
sis of PFTC. No patients with a previous cancer were known to 
have any genetic background. Sixty-seven patients out of 91 died. 
Of those 67 patients who died during the follow-up, 62 died of their 
cancer, 1 of chemotherapy, 3 of other diseases and in 2 the cause 
was unknown. 
 Methods 
 hCG  in serum was quantifi ed with an in-house time-re-
solved immunofl uorometric assay  [22] with a detection limit of 
0.5 pmol/l. Cross-reaction of hCG in the assay for hCG  is  ! 0.1%. 
Inter-assay coeffi cient of variation is  ! 12% in the hCG  , range 
2–3,000 pmol/l. The upper reference limit based on the 97.5th per-
centile for apparently healthy women was 2.0 pmol/l. The serum 
concentrations of hCG  are not age dependent  [23] . The median 
pretreatment serum hCG  level was 1.25 pmol/l. For the purpose 
of evaluating the prognostic value of hCG  before surgery, the 75th 
percentile of the pretreatment level (3.5 pmol/l) was selected as the 
cut-off level  [8] . 
 CA 125 was measured by an immunoradiometric assay (Cento-
cor, Malvern, Pa., USA) until October 1995. After that, quantita-
tion was performed on an automatic analyzer (Immuno1 ® , Bayer, 
Tarrytown, N.Y., USA). Correlation between the two assays was 
good (r = 0.91). A cut-off value of 35 kU/l was used for both as-
says. The median pretreatment value was 355 kU/l and the 75th 
percentile pretreatment level used for prognostic analysis was 
1,017 kU/l. 
 TATI was measured by radioimmunoassay (Orion Diagnostica, 
Espoo, Finland), and a cut-off value of 2 nmol/l (13   g/l) was used. 
The median pretreatment level was 1.6 nmol/l. 
 Statistical Methods 
 The    2  test was used to compare distributions of categorical 
variables between patients with serum marker measurements and 
those without. For comparing frequencies of elevated serum mark-
er levels between stages, the    2  test for trend was used. Follow-up 
of the patients with preoperative serum samples started at the time 
of diagnosis and ended at the time of death (n = 43) or at the latest 
on February 14, 2003 (n = 17), when survival was checked with the 
Population Register Centre in Finland. The median follow-up time 
for all patients was 30 months (range 0.3–173) and for those alive 
it was 60 months (range 37–168). In analysis of overall survival, 
death due to any cause was defi ned as an event. When analyzing 
DFS, the event was relapse of the disease. 
 Probability of survival was estimated according to the Kaplan-
Meier method. Differences in survival probabilities between groups 
were assessed using the log-rank test. Multivariate modelling of 
survival probability was performed using Cox proportional hazards 
regression analysis  [24] . Cox regression was also used univariately 
for calculation of the relative risks of dying. Serum marker concen-
trations were analyzed and transformed to binary variables by test-
ing values between the 70th and 80th percentiles. These cut-offs 
gave similar results, and results for the 75th percentile are shown. 
Two-sided p values  ! 0.05 were considered statistically signifi cant. 
Results
 Serum Marker Concentrations 
 The serum concentrations of hCG  were elevated in 
37% of all cases as compared to 90% of CA 125 and 20% 
of the TATI values. For prognostic analysis, we used the 
75th percentile for all markers  [8] . The frequencies of 
Table 2. Number of samples with elevated serum concentrations of hCG, CA 125 and TATI according to 
stage
hCG CA 125 TATI
>3.5 pmol/l 
(75 percentile)
>2 pmol/l >1,017 kU/l 
(75 percentile)
>35 kU/l >1.6 nmol/l 
(75 percentile)
>2 nmol/l
n % n % n % n % n % n %
Stage
I 0/7 0 1/7 14 0/7 0 4/7 57 0/7 0 0/7 0
II 1/8 12 2/8 25 1/8 12 6/8 75 2/8 25 1/8 12
III 10/34 29 14/34 41 9/31 29 28/31 90 9/33 27 7/33 21
IV 4/11 36 5/11 45 4/11 36 11/11 100 4/11 36 4/11 36
Total 15/60 25 22/60 37 14/57 25 49/57 86 15/59 25 12/59 20
Figures denote elevated number/total number of samples.
 Riska  /Alfthan  /Finne  /Jalkanen  /Sorvari  /
Stenman  /Leminen  
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marker values exceeding the 75th percentile in various 
disease stages were similar for the three markers studied 
( table 2 ). 
 Survival Analyses 
 The overall 5-year survival rate was 33% and it was 
related to stage (p = 0.050). The disease-free 5-year sur-
vival was also 33%, which refl ects the aggressiveness of 
the disease. The size of the residual tumour was an im-
portant prognostic factor; the overall 5-year survival for 
patients with a residual tumour  ! 1 or  6 1 cm was 51 and 
20%, respectively (p = 0.003). In patients with a serous 
carcinoma, the overall 5-year survival rate was 37% com-
pared with 17% in those with other tumour types (p = 
0.023). In Kaplan-Meier analysis, the most important 
prognostic factors for disease-free 5-year survival were 
the size of the residual tumour (p = 0.013) and stage (p = 
0.014). 
 The overall 5-year survival was 38% when hCG  was 
below the 75th percentile and 18% when it was higher 
(p = 0.052) ( fi g. 1 ), while the disease-free 5-year survival 
was 38 and 20%, respectively (p = 0.014) ( fi g. 2 ). Patients 
with serum CA 125 values above the 75th percentile also 
had signifi cantly shorter overall 5-year survival, i.e. 14 vs. 
39% (p = 0.009) ( fi g. 3 ), and a disease-free 5-year surviv-
al of 23 and 37%, respectively (p = 0.096). Clearly elevat-
ed serum concentrations of TATI were rare and this 
marker did not have prognostic value. 
 Cox Regression Analysis of Prognostic Factors 
 In a univariate Cox regression model, the size of the 
residual tumour (p = 0.004), serum CA 125 (p = 0.012) 
and stage (stage IV, p = 0.018) were signifi cantly associ-
ated with overall survival, while serum hCG  (p = 0.019), 
stage III–IV (p = 0.020), stage IV (p = 0.025) and size of 
the residual tumour (p = 0.019) were all associated with 
DFS ( table 3 ). When all the variables were fi tted as mul-
tiple variables in the same model, only hCG  and the 
histology of the tumour were independent prognostic fac-
tors for overall survival and only hCG  for DFS ( ta-
ble 4 ). Stage and size of the residual tumour were strong-
ly correlated (p  ! 0.001) disturbing each other in the mul-
tivariate analysis, and therefore, the latter was excluded 
from the Cox model. In a backward stepwise Cox multi-
variate analysis, hCG  , stage and histology emerged as 
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p = 0.052
 Fig. 1. Effect of preoperative serum hCG concentration on over-






















0 2 4 6 8 10 12
Years after diagnosis
hCG <3.5 pmol/l
26 died, 17 censored
β
hCG 3.5 pmol/l
12 died, 3 censored
β ≥
p = 0.014
 Fig. 2. Effect of preoperative serum hCG concentration on DFS 
in PFTC patients. 
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Table 3. Univariate Cox regression model of prognostic factors in PFTC
Factor Overall survival Relapse-free survival
risk ratio 95% CI p value risk ratio 95% CI p value
Size of residual tumour 2.72 1.38–5.37 0.004 2.37 1.16–4.85 0.019
CA 125 >1,017 kU/l 2.44 1.22–4.90 0.012 1.83 0.87–3.86 0.109
Stage IV versus other stages 2.29 1.15–4.58 0.018 2.32 1.11–4.85 0.025
Stage III–IV 2.03 0.93–4.41 0.073 3.08 1.19–7.96 0.020
hCG >3.5 pmol/l 1.94 0.98–3.82 0.057 2.30 1.14–4.62 0.019
Age >65 years 1.29 0.68–2.45 0.432 1.00 0.49–2.02 0.998
Grade 3 0.84 0.45–1.56 0.589 0.74 0.38–1.43 0.374
Table 4. Multivariate Cox regression model of prognostic factors for overall survival and DFS in PFTC
Factor Overall survival DFS
risk ratio 95% CI p value risk ratio 95% CI p value
Histology 3.17 1.27–7.95 0.013 1.60 0.59–4.31 0.349
hCG >3.5 pmol/l 2.80 1.03–7.63 0.043 3.07 1.04–9.03 0.041
Stage IV 2.17 0.95–4.95 0.065 1.90 0.79–4.54 0.149
CA 125 >1,017 kU/l 1.91 0.83–4.39 0.127 1.52 0.62–3.69 0.352
Size of residual tumour 1.86 0.79–4.36 0.152 1.49 0.60–3.66 0.387
Age >65 years 1.65 0.77–3.50 0.193 1.06 0.47–2.35 0.886
TATI >1.6 nmol/l 0.57 0.21–1.52 0.260 0.69 0.25–1.86 0.462
Grade 3 0.48 0.22–1.03 0.060 0.54 0.24–1.21 0.136
Table 5. Signifi cance of prognostic factors when fi tted in Cox back-
ward stepwise regression model as multiple variables
Factor Overall survival p value
risk ratio 95% CI
Histology 2.71 1.26–5.83 0.010
Stage IV 2.47 1.21–5.02 0.012
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 Fig. 3. Effect of preoperative serum CA125 concentrations on over-
all survival in PFTC patients. 
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Discussion
 An elevated serum concentration of hCG  has been 
shown to be an independent prognostic factor in many 
carcinomas  [15, 16, 25, 26] and especially in ovarian car-
cinoma  [14] . Therefore, we studied whether it also pre-
dicts prognosis in PFTC, which in many respects resem-
bles ovarian carcinoma. There are only a few reports on 
prognostic markers in PFTC  [8, 26] and our study is the 
fi rst to investigate the prognostic role of hCG  in this 
disease. As the cut-off for analysis of prognosis, we used 
the 75th percentile, which has been used in an earlier 
study on CA 125  [8] , but results with cut-offs of the 80th 
and 70th percentiles were similar. Our results show that 
serum hCG  , stage and histology are the strongest inde-
pendent prognostic factors in PFTC. 
 CA 125 was also a signifi cant prognostic factor for 
overall survival, which is in accordance with results from 
an earlier study by Hefl er et al.  [8] . However, in our study, 
CA 125 correlated strongly with stage and was therefore 
not an independent prognostic factor for DFS although 
the risk ratio in univariable analysis was similar to that 
in the study of Hefl er et al.  [8] . In our study, as in Hefl er’s 
study, the number of patients is quite small, and this may 
explain the differences in DFS between these two studies. 
Interestingly, serum TATI was not a prognostic factor for 
PFTC, although it has been shown to be an independent 
prognostic factor for ovarian carcinoma  [20] , especially 
in stage III disease  [28] . In ovarian cancer, TATI expres-
sion is associated with expression of tumour-associated 
trypsin  [29] , which is not known to occur in PFTC. This 
may refl ect a difference in the biology of these tumours. 
 The mean age of 61 years of the patients in the present 
series is similar, while the stage distribution was some-
what different from that reported in other studies  [1, 3, 
9] ; only 10% of our patients had stage I disease as com-
pared to 20–42% in earlier studies  [3, 4, 26] . Well-differ-
entiated tumours were observed in 8%, while 32% had 
grade 2 and 58% grade 3 tumours, which is in concor-
dance with earlier studies  [4] . The distribution of histo-
logical subgroups is also comparable with that in earlier 
studies  [29, 30] , with 80% serous adenocarcinomas. The 
presence of another carcinoma before PFTC has also 
been reported in other studies: 11% in the study of Eddy 
et al.  [30] , and 17 of 115 (15%) in the study of Alvarado-
Cabrero et al.  [31] , 6 of which (5%) being breast cancers. 
In our study, there were 9 cases (15%) of a second malig-
nancy, 5 of them breast cancers. So far, these are the only 
studies reporting on the simultaneous occurrence of these 
carcinomas. The responsiveness of both tubal and breast 
epithelium to ovarian hormones may provide a theoreti-
cal background for this association  [30] . Interestingly, 
like breast cancer, PFTC has been linked to mutations in 
the BRCA-1 gene  [32] . 
 The strong correlation between serum hCG  and prog-
nosis is intriguing. Some mechanisms through which 
 hCG  could affect tumour aggressiveness have recently 
been elucidated. hCG  may exert antiapoptotic activity 
 [33] , and suppression of hCG  expression reduces tu-
mour growth of hCG  -expressing tumours  [34] . Further-
more, immunization with hCG  vaccines has provided 
promising results in patients with colon carcinoma  [35] . 
It is tempting to speculate that these mechanisms could 
explain why elevated serum levels of hCG  are associ-
ated with adverse prognosis in PFTC as well as in many 
other malignancies. 
 Elevated levels of serum hCG  have been observed in 
many nontrophoblastic tumours and most often in pan-
creatic (72%) and biliary carcinomas (86%)  [17] , which 
both are rapidly progressive cancers with very poor prog-
nosis. In ovarian carcinoma, the 5-year survival was 
found to be 80% if serum hCG  was normal and only 
22% when hCG  was elevated and, in those with stage 
III and IV and minimal residual disease, 5-year survival 
was 75% if the hCG  level was normal and 0% if it was 
elevated  [14] . Also in PFTC, hCG   is a strong prognostic 
factor and contrary to stage and grade, it can be deter-
mined before surgery. However, so far, a limitation in the 
use of hCG  is the paucity of suffi ciently sensitive com-
mercially available assays. 
 The number of patients in our study is limited, because 
PFTC is so rare. In comparison with other studies con-
cerning PFTC, it is one of the largest. Because of the ag-
gressiveness of this disease, we found it very important 
to evaluate the prognostic value of the tumour markers 
hCG  and CA 125. 
 In conclusion, both hCG  and CA 125 predict sur-
vival in PFTC, but in our study, only hCG  provided 
prognostic value additional to that based on stage and 
histology. Thus, serum hCG  is a potential marker for 
the selection of patients with PFTC for experimental 
treatment modalities. If hCG immunotherapy proves to 
be useful, it will be important to study whether tumour 
responsiveness to this therapy can be evaluated on the 
basis of the serum concentrations of hCG  . 
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A B S T R A C T
We conducted a retrospective seroepidemiological study to evaluate the relationship
between past chlamydial infection and primary fallopian tube carcinoma (PFTC). Post-
operative serum samples were drawn from 79 consecutive patients treated for PFTC in
1985–2000. For each case two controls were selected. Serum samples were analysed for
IgG antibodies to different C. trachomatis serotype pools and to C. pneumoniae. Seropositivity
in general or serum antibody levels to different C. trachomatis serovars or C. pneumoniae
did not differ between PFTC patients and controls. The lack of association between
anti-chlamydial antibodies and PFTC suggests that past chlamydial infection does not
play a role in the etiopathogenesis of PFTC. However, because chlamydial infection is
common at young age and PFTC develops decades later, we cannot definitively exclude
the possibility that C.trachomatis contributes to the development of PFTC.
 2006 Elsevier Ltd. All rights reserved.
1. Introduction
Primary fallopian tube carcinoma (PFTC) is a rare but aggres-
sive disease, comprising 0.1–1.1% of female genital malignan-
cies.1 The age-adjusted annual incidence in Finland has
increased from 1.2 per 1,000,000 women in 1953 to 5.4 per
1,000,000 women in 1997.2 The incidence has increased espe-
cially among women in higher social classes and among
those living in urban areas.2 The aetiological factors are lar-
gely unknown, but may be similar to those of ovarian cancer.
Chlamydia trachomatis infection is the most common sexu-
ally transmitted bacterial infection (STI),3 causing salpingitis
and pelvic inflammatory disease (PID).4,5 Chlamydiae are com-
mon intracellular bacteria and can cause chronic or persis-
tent infections.6 Chronic infections may predispose to
malignant growth.7 C. trachomatis has already been linked to
cervical carcinoma.8,9 History of PID has been linked to ovar-
ian carcinoma.10–12 Thus, an association between C. trachoma-
tis and PFTC is biologically plausible. The purpose of this
study was to evaluate the role of C. trachomatis in PFTC.
2. Patients and methods
The study population consisted of 79 consecutive patients
treated for PFTC at the Department of Obstetrics and Gynae-
cology, University Hospital, Helsinki, between 1985 and 2000.
Data were collected by systematic chart review. The patients
had not received chemotherapy prior to surgery. Staging
was performed according to the International Federation
of Gynecology and Obstetrics (FIGO) criteria. Pelvic and
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para-aortic lymphadenectomy was performed whenever pos-
sible. Stage, grade, histological findings, tumour size, and size
of the residual tumour were recorded. Serum samples were
drawn at a median of 36 d (interquartile range 28–55 d) after
primary surgery. For each case, two controls were selected
randomly from women matched for age at serum sampling
(±5 years), and who had no cancer diagnosis. For the five
youngest patients the age criterion had to be somewhat re-
laxed due to lack of suitable controls. Because two blood sam-
ples were drawn from the same control subject by mistake,
two cases had only one control. Thus, the total number of
controls was 156. Ninety-one serum samples were from con-
trol patients from the Helsinki City Maternity Hospital, oper-
ated for a benign gynaecological disease. Sixty-one control
archival serum samples were from patients coming to an
examination for a benign colon disease (30 controls) or were
female employees at Helsinki University Hospital (35 con-
trols). The time periods were on average 4 years apart. Collec-
tion of control serum samples was performed with the
approval of the Ethics Committee of the Department of
Obstetrics and Gynaecology, Helsinki University Hospital. All
samples were stored at 25 C and analysed simultaneously.
Themean ages of the patients and controls were 61.2 years
(range 40.0–82.8 years) and 61.5 years (range 24.5–87.0 years),
respectively. Clinical and histopathological characteristics are
shown in Table 1.
2.1. Chlamydia serology
Chlamydia trachomatis- and C. pneumoniae-specific IgG antibod-
ies were assayed by a micro-immunofluorescence method
(MIF)13 using pooled serovars (GFK, CJHI, BED) of C. trachomatis
(Washington Research Foundation, Seattle, WA, United States
of America (USA)) and serovar Kajaani 6 for C. pneumoniae as
control antigens, and fluorescein isothiocyanate (FITC)-conju-
gated anti-human IgG (Kallestad, Chaska, MO, USA) as conju-
gate.13 The serum samples were analysed at two-fold
dilutions forC. trachomatisandat four-fold dilutions forC. pneu-
moniae. Titres ofP16 were considered positive for C. trachoma-
tis. Titres ofP32 were considered positive for C. pneumoniae.
2.2. Statistical analysis
A statistical power of 80% was planned to detect a hypothes-
ised difference at a two-tailed significance of P < 0.05. The
power calculations were based on a hypothesised odds ratio
(OR) of 2.88 and a prevalence of C. trachomatis antibodies of
14% in the general population.14 Thus, 135 controls would
be needed for the cases. Univariate and multivariate ORs with
95% confidence intervals (CIs) and two-sided P-values were
estimated by conditional logistic regression.15 Statistical cal-
culations were performed using Stata 8.0 (Stata Corp, College
Station, Tex) and SPSS 12.0 (SPSS Inc, Chicago, III) software.
3. Results
Seropositivity to the different C. trachomatis serovars and to C.
pneumoniae in PFTC patients varied from 13.9% to 21.5%. In
control subjects seropositivity varied from 10.3% to 21.8% (Ta-
ble 2). The overall prevalence of C. trachomatis IgG antibodies
to one or more serotype pools in PFTC patients and controls
was 20% and 16%, respectively (P = 0.42). Serum IgG antibod-
ies to the different C. trachomatis serovars or to C. pneumoniae
were not associated with PFTC (Table 3). The presence of ser-
um IgG antibodies to more than one serotype pool did not in-
crease the risk of PFTC (Table 4). The study population was
divided into age quintiles to study the effect of age on sero-
positivity, but again there was no correlation. However, pa-
tients with elevated C. trachomatis IgG titres to serotypes
BED were younger than control subjects, 39 years versus 56
years (P = 0.038). When comparing PFTC patients and con-
Table 1 – Clinical characteristics of 79 patients with
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Peritoneal carcinosis 10 (13)
No data 4 (5)
Table 2 – Seropositivity to different chlamydia trachomatis
serovars and to chlamydia pneumoniae in PFTC (N = 79)
and control patients (N = 156)
Cases, n (%) Controls, n (%)
C. trachomatis
CJHI 13 (16) 17 (11) p = 0.2
GFK 13 (16) 23 (15) p = 0.7
BED 11 (14) 16 (10) p = 0.4
C. pneumoniae 17 (21) 34 (22) p = 0.9
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trols, a trend towards elevated C. trachomatis IgG antibody ti-
tres to one or more serotype pools was seen among younger
PFTC patients, whereas such trend was not seen among
young controls, but this did not reach statistical significance
(P = 0.115). Stage, histology or grade showed no association
with seropositivity to C. trachomatis or C. pneumoniae and
PFTC.
4. Discussion
This study is the first of an association between exposure to C.
trachomatis and subsequent PFTC. The potential role of spe-
cific infectious agents as risk factors of PFTC is unknown.
There have been some case reports of tuberculous salpingitis
being a possible promoter of PFTC.16 No evidence was found
of the role of past history of chlamydial infection as a risk fac-
tor of PFTC. Thus, the results of this study were somewhat
disappointing and unexpected. C. trachomatis is an intracellu-
lar bacterium and a major cause of salpingitis and PID. PID
may lead to pyosalpinx, sactosalpinx, fallopian tube adhe-
sions and obstruction, leading to ectopic pregnancy or tubal
factor infertility.17,18 One of the mechanisms by which chla-
mydia may be involved in carcinogenesis is through chronic
persistent inflammation. Inflammation involves rapid cell
division, DNA repair, oxidative stress, and high tissue concen-
trations of cytokines and prostaglandins, all of which can play
a role in carcinogenesis.19 Another important factor in carci-
nogenesis may be the anti-apoptotic effect of chlamydia.20
Koskela and colleagues8 have published sero-epidemiological
evidence that infection with C. trachomatis confers an in-
creased risk of subsequent development of invasive squa-
mous cell carcinoma of the uterine cervix. The presence of
serum IgG antibodies to serotype G increased the risk 6.6-fold.
In addition, antibodies to more than one serotype tended to
further increase the risk.9 A number of investigators have
found an elevated risk of ovarian carcinoma associated with
a past history of PID.10,11,19 Risch and Howe found an in-
creased risk of ovarian carcinoma among women who had
prior PID (OR 1.5).11 The relationship between PID and ovarian
carcinoma was strongest in women who had had PID at an
early age, and in nulliparous or infertile women. The risk of
ovarian cancer increased with the number of PID episodes.
In contrast, Parazzini and colleagues found no link between
ovarian carcinoma and history of PID.21 However, cancer inci-
dence correlations suggest common aetiological factors for
cervical and ovarian cancer.22 Furthermore, tubal ligation
and hysterectomy protect against ovarian cancer, supporting
the theory of ascending aetiological factors.23 In the present
study the risk of PFTC was not increased among those with
chlamydial antibodies. This is difficult to explain. If there is
an inflammatory agent ascending from the cervix to the ova-
ries, one would expect to see an association with fallopian
tube carcinoma.
Data on the natural history and kinetics of C. trachomatis
antibodies are limited. Puolakkainen and colleagues showed
that C. trachomatis IgG antibodies measured by means of an
indirect immunofluorescence technique persisted at stable
levels in 43% of the women involved for up to 6 years; 43%
of the women showed a decrease in IgG titres, and 13%
showed an increase.24 Chlamydial infections are rare among
older women. In the present study, the mean age of the pa-
tients was 61.2 years. Chlamydial IgG antibodies were mea-
sured by MIF, which is considered the gold standard.22 It is
not known whether the negative results in the present study
can be explained by decreasing serum chlamydial antibody ti-
tres. There are no studies on the possible protective effect of
tubal ligation or hysterectomy on PFTC. If tubal ligation does
not protect women from PFTC, this would support the nega-
tive results of the present study.
In conclusion, the presence of serum anti-chlamydial anti-
bodies was not associated with PFTC. However, because chla-
mydial infection is common in young women and PFTC
develops several decades later, one cannot exclude the possi-
bility that it contributes to the development of PFTC.
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Chlamydia pneumoniae 1.0 0.5–1.9
a CI = Confidence interval.
Table 4 – Risk by number of positive C. trachomatis serotype pools in PFTC patients and controls, univariate analysis
Percent positive
Number of serotype pools Cases n (%) Controls n (%) Odds ratio 95%CI p-value
0 63 (80) 131 (84) 1.0
1 3 (4) 5 (3) 1.2 0.3–5.4 0.7
2 5 (6) 9 (6) 1.1 0.4–3.6 0.8
3 8 (10) 11 (7) 1.5 0.6–3.9 0.4
Total 79 (100) 156 (100)
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Objective To evaluate the role of human papillomavirus (HPV)
types 6, 11, 16, 18, 31 or 33 infection in primary fallopian tube
carcinoma (PFTC).
Design A retrospective case–control study.
Setting Department of Obstetrics and Gynaecology, Helsinki
University Hospital, Finland.
Population Seventy-eight consecutive women with PFTC
diagnosed between 1985 and 2000 were studied. For each case,
two healthy controls were selected.
Methods Serum immunoglobulin G antibodies to HPV types 6,
11, 16, 18, 31 and 33 were measured from women with PFTC
and their healthy controls.
Main outcome measures Analysis of HPV 6, 11, 18, 31 and 33
seropositivity among women with PFTC and controls.
Results Seropositivity rates of non-oncogenic or oncogenic HPV
types did not differ between cases and controls, odds ratios being
1.04–1.30 for oncogenic HPVs and 1.08–1.19 for non-oncogenic
HPVs, similarly. We did not find any multiplicative joint effect in
PFTC by antibodies to more than one oncogenic HPV type;
neither did we find any antagonistic effect among women with
antibodies to non-oncogenic and oncogenic HPV types.
Conclusions Our results do not suggest any link between PFTC
and serological evidence for HPV infection.
Keywords Chlamydia trachomatis, herpes simplex virus type 2,
human papillomavirus, primary fallopian tube carcinoma.
Please cite this paper as: Riska A, Finne P, Koskela P, Alfthan H, Jalkanen J, Lehtinen M, Sorvari T, Stenman U, Paavonen J, Leminen A. Human papillomavirus
infection and primary fallopian tube carcinoma: a seroepidemiological study. BJOG 2007;114:425–429.
Introduction
Primary fallopian tube carcinoma (PFTC) is a rare but highly
aggressive disease, comprising 0.1–1.1% of all female genital
malignancies.1 In Finland, the number of new cases of PFTC
is rapidly increasing, now being seven-fold compared with
1953–1957.2 Its aetiology is largely unknown but may be
similar to that of ovarian carcinoma, as both arise from the
müllerian duct. Studies on the absence or presence of human
papillomavirus (HPV) DNA in carcinomatous epithelial
ovarian tissue or endometrial tissue are conflicting.3–7 HPV
is a necessary cause of cervical cancer.8 Antibodies to HPV
virus-like particles (VLPs) correlate with the presence of
HPV DNA in cervical neoplasia.9 To the best of our know-
ledge, a possible link between HPV serology and PFTC has
not been studied. One study has analysed 12 PFTC cases by
comparative genomic hybridisation but revealed no presence
of HPV genomes.10 The objective of our study was to find out
whether there is any serological evidence of the role of HPV
infection in PFTC.
Materials and methods
Postoperative serum samples were collected and stored at
–20C until analysed from 78 consecutive women treated for
PFTC at the Department of Obstetrics and Gynaecology, Uni-
versity Hospital, Helsinki, between 1985 and 2000. The study
was approved by the Ethics Committee of the Department of
Obstetrics and Gynaecology, Helsinki University Hospital.
Patient data were retrieved by detailed chart review. The
women had not received chemotherapy prior to surgery. Stag-
ing was performed according to the International Federation




of Obstetrics and Gynecology criteria. Pelvic and para-aortic
lymphadenectomy was performed whenever possible. Stage,
grade, histological findings, tumour size and size of the residual
tumourwere recorded. Serum samples were drawn at amedian
of 36 days (interquartile range 28–56 days) after primary sur-
gery. For each case, two controls were selected from hospital-
ised women fulfilling the following criteria: matched age at
serum sampling (±5 years) and no cancer diagnosis. For three
cases, the age matching rule had to be violated, and controls
with a larger age difference were included. Ninety postopera-
tive control serum samples were collected fromwomen attend-
ing Helsinki City Maternity Hospital, and 66 control serum
samples were drawn from the Serum Bank of Helsinki Univer-
sity Hospital (12 archival serum samples from women oper-
ated for benign ovarian cysts, 19 samples from women seen
for a benign colon disease and 35 archival serum samples
from female hospital employees).
The mean age of the women and controls was 61.9 years
(range 43.0–82.8 years) and 63.7 years (range 24.5–86.9
years), respectively. Selected tumour characteristics of the
PFTCs are shown in Table 1.
Laboratory methods
Immunoglobulin G (IgG) antibodies to oncogenic HPV types
16, 18, 31 and 33 and to non-oncogenic HPV types 6 and 11
were determined by the standard enzyme-linked immunosor-
bent assay (ELISA) method using HPV VLP capsid proteins
as antigen and disrupted homologous capsids as the control
antigen.11,12 The assay included on each ELISA plate both
positive and negative controls. Optical density (OD) values
were normalised relative to the results of positive control
(internal standard) sera. Cutoff levels were defined as the
mean + 3 SD of OD values of sera from 38 virgin women.
The cutoff levels for HPV 6, 11, 16, 18, 31 and 33 were 0.167,
0.142, 0.149, 0.125, 0.150 and 0.141 OD, respectively.
The HPV 16 VLPs were obtained from the Laboratory
of Cellular Oncology, National Cancer Institute, National
Institutes of Health, Bethesda, USA; types 11 and 6 VLPs
(L1) were obtained from Merck Research Laboratories, West
Point PA, USA; HPV 31 and 33 L1 VLPs, expressed in
Spodoptera frugiperda insect cells, were kindly provided by
Dr Kirnbauer, Vienna General Hospital, University of Vienna
Medical School, Austria. The HPV 18 VLPs were obtained
from GlaxoSmithKline Biologicals in Rixensart, Belgium.
The reported sensitivity of the serologic assays for detection
of antibodies to HPV VLPs has been 50–75%,13,14 and the
reported specificity is high.15
Chlamydia trachomatis IgG serology was measured by
a peptide ELISA (C. trachomatis IgG EIA; ANILabsystems,
Helsinki, Finland). This assay is based on synthetic peptides
derived from the C. trachomatis-specific variable domain of
major outer membrane protein.16 The assay is an indirect
solid-phase enzyme immunoassay with horseradish peroxi-
dase as the marker enzyme. Signal to cutoff >1.4 was regarded
as a positive result.
IgG antibodies to herpes simplex virus type 2 (HSV-2) were
analysed by a commercial ELISA (Biokit SA, Barcelona,
Spain) using purified baculovirus-expressed glycoprotein G2
as the antigen. The sample absorbance was divided by the
cutoff value, and values >1.0 were regarded positive.17 Both
C. trachomatis and HSV-2 antibodies in serum are reliable
markers of sexual behaviour.11,18,19
Statistical analysis
Differences in seropositivity between cases and controls were
assessed using the chi-square test. Univariate and multivariate
odds ratios (ORs) with 95% confidence intervals (CIs) were
estimated by conditional logistic regression.20 Two-sided P
values below 0.05 were considered statistically significant.
Statistical calculations were performed using Stata 8.0
(STATA Corp., College Station, TX, USA) and SPSS 12.0
software (SPSS Inc., Chicago, IL, USA).
































Peritoneal carcinosis 10 (13)
Unknown 4 (5)
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Results
Seroprevalence rates of different HPV types did not differ
between women with PFTC and controls (Table 2). In
women with PFTC, the seropositivity for the non-oncogenic
types (HPV 6 and 11) was 10 and 13%, respectively. The
seropositivity rates for the oncogenic types HPV 16, 18, 31
and 33 were 22, 6, 14 and 10%, respectively. In the control
subjects, the corresponding seropositivity rates to HPV 6 and
11 were 10 and 11% and to HPV 16, 18, 31 and 33 were 21,
5, 13 and 11%, respectively. The seropositivity rates to more
than one HPV types were not different between cases and
controls.
The OR of PFTC for one of the oncogenic HPV types was
0.96 (95% CI 0.46–2.02) in the absence of HPV 6/11 anti-
bodies and 0.57 (95% CI 0.11–2.85) in the presence of HPV
6/11 antibodies. When there were antibodies to more than
one oncogenic HPV type, the OR was 0.88 (95% CI 0.32–
2.46) in the absence of HPV 6/11 antibodies and 1.44 (95% CI
0.37–5.61) in the presence of HPV 6/11 antibodies. The ana-
lyses were adjusted for HSV-2 and C. trachomatis antibodies
(Table 3). All HPV-specific risk estimates of PFTC were non-
significant (Table 4).
Discussion
We found no evidence of the role of HPV, C. trachomatis or
HSV-2 infection in PFTC. HPV causes cervical carcinoma,21
and it has also been linked to vulval,22 vaginal23 and
anal carcinomas.24 Kaufman et al.25 identified HPV DNA in
advanced epithelial ovarian carcinoma tissue in 10 of 12
women, but Chen et al.4 could not confirm these results,
and later studies have also given conflicting results.3–5,7,25–27
Fewer studies have been conducted on endometrial malignan-
cies,3,5,26–28 and the results are even more inconsistent. Studies
have suggested that HPV could ascend up to the ovaries
and fallopian tubes by sperm.4 However, HPV may only be
a ‘passenger’, and neither endometrium28 nor fallopian tube
epithelium may support HPV replication.
Although molecular methods are more sensitive, serologi-
cal assays are useful to show associations in epidemiological
studies. There is only one study where HPV DNA expression
in PFTC has been evaluated.10 The investigators did not find
HPV DNA in women with PFTC, which is in accordance with
our results.
We measured antibodies to HPV VLPs as markers of expos-
ure to HPV. In women testing positive for HPV 16, 18 or 33
DNA in cervical samples, serum antibody response to HPV
capsids of the corresponding HPV type has been found
among 65, 69 and 75%, respectively.14 This may lower the
possibilities in detecting very marginally raised levels of serum
HPV antibodies. It is known that in women, seroconversion
against HPV VLPs occurs within a few months following
acquisition of HPV 16 DNA and that serum antibody levels
remain stable over long periods of time.15 In our study, the
HPV 16 seroprevalence rates were 22% in women with PFTC
and 21% in controls. In other studies, the prevalence of
HPV antibodies in control subjects has varied between 10
and 20%.29
In Western countries, the incidence of PFTC has increased
during the past decades.2,30 In Finland, the incidence has
increased especially among women in higher social classes
and among those living in urban areas. It would be tempting
Table 2. Seropositivity to different HPV types, C. trachomatis and
HSV-2 in women with PFTC and in controls
Cases, n 5 78 Controls, n 5 156 P value
n (%) n (%)
HPV
HPV 6 8 (10) 15 (10) 0.88
HPV 11 10 (13) 17 (11) 0.66
HPV 16 17 (22) 33 (21) 0.91
HPV 18 5 (6) 8 (5) 0.69
HPV 31 11 (14) 21 (13) 0.89
HPV 33 8 (10) 17 (11) 0.88
C. trachomatis 14 (18) 28 (18) 0.90
HSV-2 19 (24) 34 (22) 0.66
Table 3. Adjusted ORs for PFTC by seropositivity to high-risk HPV types or low-risk HPV types




Cases, n Controls, n OR (95% CI)*
0 No 47 91 1.00 (reference group)
0 Yes 5 12 0.80 (0.27–2.42)
1 No 14 28 0.96 (0.4–2.02)
1 Yes 2 7 0.57 (0.11–2.85)
2–4 No 6 13 0.88 (0.32–2.46)
2–4 Yes 4 5 1.44 (0.37–5.61)
*Adjusted for seropositivity to HSV-2 and C. trachomatis.
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to speculate that the increase is associated with increased
prevalence of gynaecological infections. Infertility, nulliparity
and age of the women have also been considered as risk fac-
tors.31 The aetiological factors have not been clearly defined,
but chronic inflammation has been implicated. In one study,
22% of the women with PFTC had history of salpingitis,32 and
tuberculous salpingitis has also been suggested to be a possible
promoter of PFTC.33 A number of investigators have found
an elevated risk of ovarian carcinoma associated with a history
of pelvic inflammatory disease, but we did not find any asso-
ciation between serum antibodies to C. trachomatis and
PFTC.34
In conclusion, our retrospective seroepidemiologic case–
control study is the first to examine a possible link between
serum antibodies to HPV and PFTC. The results do not sug-
gest that HPV contributes to the development of PFTC.
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V
Parity, tubal sterilization, hysterectomy and risk of primary
fallopian tube carcinoma in Finland, 1975–2004
Annika Riska1*, Reijo Sund2, Eero Pukkala3, Mika Gissler2 and Arto Leminen1
1Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland
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We studied the possible relationship among parity, female steriliza-
tion, hysterectomy and the risk of primary fallopian tube carcinoma
(PFTC) in a case–control study in Finland in cases occurring
between 1975 and 2004. A total of 573 PFTC cases were identified
from the Finnish Cancer Registry, and10 age-matched controls per
case were randomly selected from the Finnish Central Population
Registry. In multivariate analysis (including 189 PFTC cases and
1764 controls) parity was protective: the odds ratio (OR) for 1–2
deliveries was 0.63 (95% CI 0.44–0.91) and for 3 deliveries, 0.32
(95% CI 0.19–0.52). The OR for sterilization was 0.74 (95% CI
0.42–1.30) and for hysterectomy 1.27 (95% CI 0.73–2.21). Our find-
ings suggest a possible hormonal background as regards the devel-
opment of PFTC.
' 2006 Wiley-Liss, Inc.
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Primary fallopian tube carcinoma (PFTC) is a very rare but
aggressive disease, reported to comprise 0.1%–1.1% of all female
genital malignancies in Western countries.1 In Finland the age-
adjusted incidence has been rising during the last few decades and
is now 0.5/100,000 women.2 About one third of patients with PFTC
will be alive 5 years after diagnosis.3 Environmental and lifestyle
factors may play important roles as regards the risk of PFTC.2
There are several studies on the protective effect of sterilization
(tubal ligation) on the risk of ovarian cancer.4–6 A similar effect of
hysterectomy on ovarian cancer has also been observed.4,5,7 There
are no studies on the effect of these procedures on PFTC. There
have been various theories for these observations concerning ovar-
ian cancer,8 including a screening effect,9 a decrease in uterine
growth factors that could be involved in ovarian cancer develop-
ment,10 the effect of retrograde menstruation,11 changes in blood
flow to the ovaries,5 which could have an influence on plasma hor-
mone levels and ovarian function, and blockage of exposure to
ascending environmental agents, such as talc.12 Parity (up to 5
deliveries) is protective as regards ovarian cancer but age at first
birth has no major impact.13 In endometrial cancer, stronger pro-
tection with increasing number of deliveries and with increasing
age at first birth has been detected.14 Because both the ovaries and
fallopian tubes develop from the M€ullerian ducts, they could
behave similarly in some respects.
Finland is an industrialized country with 5.3 million inhabitants,
most of whom live in urban communities. The country has an effective
healthcare system, 75% of which is publicly financed, and the user
charges are relatively low. The nationwide population-based Finnish
Cancer Registry, the Hospital Discharge Registry (HILMO) and the
Finnish Central Population Registry (CPR) allowed us to carry out a
reliable case–control study on the effect of parity, sterilization, hyster-
ectomy and previous cancer on PFTC in Finland from 1975 to 2004.
Material and methods
We selected from the Finnish Cancer Registry all women
reported to have had PFTC in 1975–2004 (n 5 573). The Registry
obtains information from hospitals and other institutions with in-
patient beds, general practitioners, pathology and cytology labora-
tories, and from death certificates with cancer diagnoses. More
than 99% of all cancer cases have been reported to the Registry
since 1953.15 In the 1990s, about 95% of the cases were micro-
scopically confirmed, and about 1% of the cases were based on
death certificate data only.16
The CPR has covered information on all residents of Finland
since 1967, and their relatives since 1973.17 Ten age-matched
female controls (61 month) (n 5 5473) were selected from the
CPR for each PFTC patient. The control subjects had to be alive at
the time when diagnosis of the PFTC patient was completed. The
dates of birth of children of PFTC patients and control subjects
were collected from the CPR.
The CPR administers the Finnish system of unique identifiers
(IDs). It was started in 1964, and by 1967 all Finnish citizens and
permanent residents had received their own ID. These IDs are
used in practically all Finnish registries, and they were used as
linkage keys to combine information from various registries in
this study.
The sterilization, hysterectomy and salpingectomy data were
obtained from HILMO, which has operated since 1967 and is main-
tained by STAKES, the National Research and Development Centre
for Welfare and Health.17 The Registry contains summary informa-
tion on patients discharged from all public and private hospitals.
Virtually all discharges from inpatient wards are registered, and the
accuracy of the main diagnosis is more than 95% at the three-digit
level when comparing the principal diagnosis in HILMO and the di-
agnosis in medical records at discharge.18 Recording of surgical
events started in 1986; the completeness and accuracy of recording
is reasonably good.19 During the period 1986–1996 surgical proce-
dures were recorded according to the classification of surgical pro-
cedures issued by the Finnish Hospital League,20 and from 1997
according to the Nordic Classification of Surgical Procedures intro-
duced in 1996, also covering day surgery episodes.21
Reliable data on sterilizations were available from 1975, and on
the events of hysterectomies and salphingectomies from 1986. Only
events occurring more than half a year before the PFTC diagnoses
(or the corresponding day for controls) were included. The numbers
of children were derived by using data obtained from the CPR,
which is able to reliably identify live-born children of women born
after the mid-1930s. Age at first delivery could also be calculated
by using the date of birth of the oldest child of each mother.
It can be expected that the risk of PFTC decreases if salpingec-
tomy has been performed. Therefore, we excluded all 8 women
with an operation code for unilateral or bilateral salpingectomy
before the day of PFTC diagnosis. After this exclusion, 565 PFTC
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patients and 5473 control women remained. Since sterilization
data were not available until 1975, only the women born after
1925 were included for sterilization analyses (375 cases and 3587
controls), assuming that a sterilization procedure is no longer nec-
essary for women aged 50 years or more. Hysterectomy data were
available from 1986. Women born before 1936 were dropped
from the hysterectomy analyses, to be certain that all hysterecto-
mies during the analysis period would be registered (189 cases
and 1764 controls remained in the analysis). For parity and multi-
variate analyses the same restrictions as for hysterectomy analyses
were used, to be certain that data concerning children were avail-
able from the CPR.
In Finland, from 1975 to 2003, a total of 222,068 sterilizations
were performed, and from 1986 to 2003, 184,212 hysterectomies
were performed. From 1975 until 1990 the number of steriliza-
tions per year increased, but since then it has decreased every
year. The rapid increase of sterilizations during the time period
1984–1987 was a result of changes in the sterilization legislation
in 1985, making the law more liberal and family planning-ori-
ented. The frequency of hysterectomies per year rose steadily
from 1986 (7325 hysterectomies) to 1998, but later the tendency
has been decreasing (Fig. 1).
The Ministry of Social Affairs and Health gave permission to
use the confidential register data in scientific research, after con-
sulting the register keepers and the data protection authority.
Analyses
The risk ratios in terms of odds ratios (ORs) were calculated,
with 95% confidence intervals (CIs), by using univariate and mul-
tivariate conditional logistic regression for 1:m matched sets.22
The statistical software packages Survo MM (www.survo.fi) and
Stata release 8 (www.stata.com) were used in data processing and
analyses.
Results
The strongest protective factor as regards PFTC was parity:
parous women had an OR of 0.54 (95% CI 0.39–0.75) when com-
pared with nulliparous women in the univariate analysis. An
increasing number of deliveries resulted in stronger protection
against PFTC and the older age at first birth was also protective
(Table I).
Altogether, 375 PFTC patients and 3587 controls were included
in the analysis of sterilization effects. Fifteen PFTC patients and
230 controls had undergone sterilization. In the univariate analy-
sis, there was a statistically borderline-significant decrease in the
risk of PFTC among women who had undergone sterilization (OR
0.58, 95% CI 0.33–1.00) (Table I). The protective effect was stron-
ger among those who were younger at the time of sterilization.
There were 189 PFTC patients and 1764 control women, all
born after 1935, included in the analysis related to hysterectomy.
The univariate OR as regards hysterectomy was 1.14 (95% CI
0.66–1.98) (Table I).
Twenty-three cases of previous breast cancer (50% of all previ-
ous cancers) among patients with PFTC and 135 cases among the
controls were detected. The OR for PFTC after previous breast
cancer was 1.69 (95% CI 1.08–2.67) and after other cancers, 1.23
(95% CI 0.79–1.91).
Multivariate analysis
The multivariate analysis included women born after 1935.
When parity, sterilization, hysterectomy and previous breast can-
cer were included in the same model, parity was the only statisti-
cally significant protective factor as regards PFTC. The protection
became stronger with increasing number of deliveries: OR for 1–2
deliveries 0.63, 95% CI 0.44–0.91; and for 3 deliveries 0.32,
95% CI 0.19–0.52 (Table II). Sterilization nonsignificantly
reduced the risk of PFTC (OR 0.74, 95% CI 0.42–1.30). Hysterec-
tomy was more common among PFTC patients than their controls
(OR 1.27, 95% CI 0.73–2.21). Previous breast cancer increased
the risk, but nonsignificantly (OR 1.63, 95% CI 0.70–3.77).
Discussion
Our study is the first in which the effects of parity, sterilization
and hysterectomy on PFTC have been evaluated. It is well known
that parity reduces the risks of ovarian, endometrial and breast
cancer.13,14,23 In our material, parity was strongly protective and a
higher number of deliveries increased the protection. An older age
at first birth was also protective. A similar beneficial effect of
older age at first birth has been detected in endometrial cancer,14,24
but the influence of age at first birth on ovarian cancer is unclear.
Some investigators have reported an increase in risk as regards
older age at first birth25 and others an increased risk associated
with younger age at first birth.25 A recent Finnish report revealed
no correlation between age at first birth and ovarian cancer risk.13
There are several theories concerning the protective effect of preg-
nancies. The results of animal studies suggest that progestagen-
induced apoptosis of transformed ovarian surface epithelial cells
may underlie the observed protective effect of pregnancy on the
risk of ovarian cancer.26 The endosalpingeal lining of the fallopian
tube is hormonally reactive and the higher levels of progestagens
during pregnancy could lower the risk of PFTC by inducing apo-
ptosis of transformed epithelial cells.
We found borderline-significant protection against PFTC after
sterilization. This result is in accordance with the results of several
studies indicating a protective effect of sterilization on ovarian
carcinoma.6,11,27 The theory of blockage of ascending carcino-
genic agents such as talc,11,28 contraceptive foams or gels,29
viruses30 or uterine growth factors31,32 by sterilization has largely
been studied in connection with ovarian cancer, but factors other
than ascending agents may be required to explain the protective
effect of sterilization on the risk of PFTC.
Hysterectomy did not give protection against PFTC; rather it
increased the risk, but insignificantly. The marginally increased
risk of PFTC among hysterectomized women could be based on
hormonal features, such as raised levels of FSH. High levels of
gonadotrophins, mainly FSH, have been hypothesized to stimulate
malignant transformation of ovarian epithelial cells31,33,34 and
also fallopian tube epithelium in vitro.35 Elevated concentrations
of gonadotrophins could induce vascular endothelial growth factor
expression and that way accelerate tumour growth, at least in
ovarian epithelial cells.36
In our analyses previous breast cancer was not a risk factor for
PFTC, but a positive trend was seen. Early menarche and late
FIGURE 1 – The annual number of registered sterilizations and
hysterectomies in Finland, 1975–2003.
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menopause may increase the risk of breast cancer. Long-term
cyclic exposure to ovarian hormones is a risk factor for this cancer
and the long-term effect of a full-term pregnancy is protective.37
This is in line with our results. Nulliparity is a risk factor for
PFTC and for breast cancer. There are studies indicating clustering
of breast cancers and PFTC in the same patients.38,39 Several
investigators have detected a higher prevalence of BRCA1 and
BRCA2 mutation among PFTC patients than in the general popula-
tion.40–43 During surgery, prophylactic bilateral salpingectomy
has been proposed for women at risk of familial breast-ovarian
cancer,44 especially those carrying BRCA1 mutations.45 Our
results point in the same direction.
Our nationwide, population-based material represents the largest
case–control study concerning PFTC. The number of controls per
cancer patient is large, allowing maximal possible power in our
analyses. In Finland, the Cancer Registry has been functioning since
1953 with coverage of 99% of all cancer cases, and coverage and
accuracy of recorded surgical procedures in the Hospital Discharge
Registry is also good. Hence, we can exclude selection bias and
major misclassification information bias related to the registration
of conditions and interventions among hospital patients.
PFTC is a rare malignancy. Our findings suggest a possible hor-
monal background associated with PFTC, especially a pregnancy-
related background. Sterilization may reduce the risk of PFTC,
while hysterectomy seems not to offer any protection. Further
investigations are needed to clarify the role of hormones, espe-
cially the importance of pregnancy hormones, in the pathogenesis
of PFTC.
TABLE II – ODDS RATIOS (OR) FROM MULTIVARIATE ANALYSIS OF FACTORS ASSOCIATED WITH PFTC
(189 CASES, 1764 CONTROLS)
Cases Controls OR 95% CI1
Parity
No deliveries 51 280 1.00 Reference
1–2 deliveries 111 994 0.63 0.44–0.91
3 or more deliveries 27 490 0.32 0.19–0.52
No sterilization 174 1539 1.00 Reference
Sterilization 15 225 0.74 0.42–1.30
No hysterectomy 173 1633 1.00 Reference
Hysterectomy 16 131 1.27 0.73–2.21
No previous breast cancer 182 1727 1.00 Reference
Previous breast cancer 7 37 1.63 0.70–3.77
1CI, confidence interval.
TABLE I – UNIVARIATE ANALYSIS OF FACTORS ASSOCIATED WITH PFTC
Cases, n (%) Controls, n (%) OR1 95% CI2
All women 565 5473
No previous cancer 519 (91.9) 5151 (94.1) 1.00 Reference
Previous cancer 46 (8.1) 322 (5.9) 1.42 1.03–1.98
Type of previous cancer
No previous cancer 519 5151 1.00 Reference
Breast cancer 23 135 1.69 1.08–2.67
Other cancer 23 187 1.23 0.79–1.91
Women born 19251 375 3587
No sterilization 360 (96.0) 3357 (93.6) 1.00 Reference
Sterilization 15 (4.0) 230 (6.4) 0.58 0.33–1.00
Age at sterilization
No sterilization 360 3357 1.00 Reference
<40 years 4 115 0.30 0.11–0.84
40 years 11 115 0.85 0.45–1.61
Time since sterilization
No sterilization 360 3357 1.00 Reference
<10 years 11 108 0.93 0.48–1.81
10 years 4 122 0.29 0.11–0.79
Women born 19361 189 1764
No hysterectomy 173 (91.5) 1633 (92.6) 1.00 Reference
Hysterectomy 16 (8.5) 131 (7.4) 1.14 0.66–1.98
Age at hysterectomy
No hysterectomy 173 1633 1.00 Reference
<45 years 9 63 1.36 0.66–2.79
45 years 7 68 0.95 0.42–2.12
Time since hysterectomy
No hysterectomy 173 1633 1.00 Reference
<10 years 9 102 0.84 0.41–1.69
10 years 7 29 2.19 0.93–5.16
No deliveries 51 (27.0) 280 (15.9) 1.00 Reference
Women with deliveries 138 (73.0) 1484 (84.1) 0.54 0.39–0.75
Age at first birth
No deliveries 51 280 1.00 Reference
<35 years 135 1428 0.52 0.37–0.74
35 years 3 56 0.30 0.09–1.00
Parity
No deliveries 51 280 1.00 Reference
1–2 deliveries 111 994 0.62 0.44–0.89
3 or more deliveries 27 490 0.30 0.18–0.49
1Odds ratios.–2CI, confidence interval.
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Primary fallopian tube cancer (PFTC) is a rare disease, and its
aetiological factors are poorly understood. Studies on PFTC in the
setting of 2nd primary malignant neoplasms can provide clues on
aetiology and also define the possible side effects of different treat-
ment modalities for PFTC. A cohort of 2,084 cases with first PFTC
was extracted from the data from 13 cancer registries from
Europe, Canada, Australia and Singapore and followed for second
primary cancers within the period 1943–2000. Standardized inci-
dence ratios (SIRs) were calculated and Poisson regression analy-
ses were done to find out the RRs related to age at, period of and
time since the PFTC diagnosis. There were 118 cancer cases ob-
served after first PFTC (SIR 1.4, 95%CI 1.1–1.6). Elevated SIRs
were seen for colorectal cancer (1.7, 95%CI 1.0–2.6), for breast
cancer (1.5, 95%CI 1.1–2.2), for bladder cancer (2.8, 95%CI 1.0–
6.0), for lung cancer (1.8, 95% CI 0.9–3.2) and for nonlymphoid
leukaemia (3.7, 95%CI 1.0–9.4). Significant risk increases were
detected for colorectal cancer during the 2nd to 5th year after the
first PFTC diagnosis, for breast cancer in follow-up 101 and for
nonlymphoid leukaemia during the 2nd to 10th year. The cluster-
ing of cancers of the lung and bladder in PFTC patients may
suggest shared smoking aetiology. The excess of colorectal and
breast cancers after PFTC may indicate a genetic aetiology.
' 2007 Wiley-Liss, Inc.
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multi-centre cohort study
Primary fallopian tube cancer (PFTC) is a rare disease, contrib-
uting 0.3%–1.6% of female genital tract malignancies in Western
countries.1–3 Studies from the United States indicated an incidence
rate of 0.4 per 100,000 in the 1980s; with the rate being higher
in Caucasian women including Hispanics than in African
Americans.4 In Finland, the age-adjusted incidence rate increased
from 0.1/100,000 in 1953–1957 to 0.5/100,000 in 1993–1997.3 In
Denmark, the incidence rate during a 5-year period around 1980
was 0.3/100,000.5 The 5-year survival rate has varied between
22 and 57% over times and regions.5–8
Little is known about aetiology of PFTC. More than 90% of the
cases are serous adenocarcinomas and the histological appearance
resembles that of ovarian serous carcinomas.1,4,9 Fallopian tube is
a hormone sensitive organ. The epithelial cells of fallopian tube
undergo changes during the menstrual cycle in response to changes
in hormonal levels, particularly oestrogen. PFTC has been gener-
ally treated as ovarian cancer since both tumors have similar
histologies and biological behavior.10 Studies have reported
clustering of breast cancers and PFTC in same patients.2,11,12
There are also several findings on higher BRCA1 and BRCA2
mutation prevalence among PFTC patients than in average healthy
population.13–16
The present investigation is a unique multi-centre study includ-
ing cancer data from 13 population-based cancer registries in
Europe, Australia, Canada and Singapore.
Material and methods
This study is part of an international multi-centre study of
second primary cancers coordinated by the International Agency
for Research on Cancer (IARC) including data from 13 cancer
registries in Europe, Australia, Canada and Singapore that have
been in operation for at least 25 years (Table I). Details of data
handling and standardization between the 13 participating regis-
tries have been described elsewhere.17,18 Coding of multiple
primaries in the cancer registries has followed a common set
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of rules proposed by the International Association of Cancer
Registries (IACR) and the IARC.19 This was possible as all partic-
ipating cancer registries currently use the IARC/IACR rules or a
local set of more extensive or detailed rules. According to the
rules, a primary cancer is one which originates in a primary site or
tissue and is thus neither an extension, nor a recurrence nor a
metastasis. Only one tumor shall be recognized as arising in an
organ or pair of organs or tissue unless the histology is different.
Second tumors occurring in the fallopian tube were however not
analyzed, because rules were not compatible between registries or
over time. Cancers of the brain and nervous system, bladder
cancer and nonmelanoma skin cancer have been registered differ-
ently in the various registries. In the present study, we followed
the same rules as applied in the series of volumes of Cancer
Incidence in 5 Continents.20
The data from the 13 cancer registries were checked carefully
for inconsistencies and missing information, with verification pro-
vided by the local registry when required. A small proportion of
subjects (0.06%) were excluded because of remaining missing or
inconsistent information. Furthermore, patients for whom the first
primary cancer diagnosis and death were recorded at the same
time or who had 2 first primary cancers recorded simultaneously
(same dates of diagnosis) were excluded (8%). After these exclu-
sions, there were 2,084 women with a first PFTC. No treatment
data for PFTC were available.
All cases of PFTC were followed up for second primary cancer
from date of first diagnosis (1943–2000) to date of second primary
cancer (1943–2000), date of death, date of migration or end of
follow-up (1992–2000). The number of second primary cancers
observed was compared with the expected number of cancers
calculated from accumulated person-years and rates among
females of first PFTC specific for each registry and 5-year age and
calendar-periods. The standardized incidence ratios (SIRs) were
stratified for time since PFTC diagnosis (<1year, 1–4, 5–9 and
101 years after the diagnosis first PFTC), for calendar-period
of PFTC (<1975, 19751) and for age at PFTC diagnosis (21–49
years, 50–59 years, 60–92 years). A Poisson regression analysis
was done for selected cancer sites to quantify the independent risk
ratios (RR) related to each variable.
Results
The study population of 2,084 women with a first PFTC
contributed 11,047 person-years of follow-up (median 2.5, mean
5.3, maximum 49.6 years). At the time of the PFTC diagnosis,
52% of women were 601 years-old, 24% were diagnosed before
1975 (Table I). The majority of cases were from Europe (87%).
The proportion of patients having a second primary cancer after
PFTC during the follow-up was 5.7% (Table I).
The SIR of second primary cancer in all sites combined after a
PFTC was 1.4 (95% CI 5 1.1–1.6) (Table II). Elevated risks were
seen for colorectal cancer (SIR 1.7, 95% CI 1.0–2.6), breast cancer
(SIR 1.5, 95% CI 1.1–2.2), bladder cancer (SIR 2.8, 95% CI
1.0–6.0), nonlymphoid leukaemia (SIR 3.7, 95% 1.0–9.4) and
lung cancer (SIR 1.8, 95% CI 0.9–3.2). There were no second
cancers with significantly decreased risk.
The SIR for second cancer (all sites combined) was highest if
the time since PFTC diagnosis was 101 years, age at PFTC diag-
nosis <60 years, or the year of PFTC diagnosis <1984 (Table III).
For breast cancer, a significantly elevated SIR of 2.3 (95% CI
1.2–3.8) was seen over 10 years after the diagnosis of PFTC
(Table III). Also in the multivariate analysis there was an indica-
tion of an increase of breast cancer cases 101 years after the
PFTC as compared with shorter follow-up times. The age or calen-
dar period of the diagnosis had no effect.
For colorectal cancer, a significant increase (SIR 2.1, 95% CI
1.3–4.9) was detected during the 2nd to 5th year after PFTC diag-
nosis (Table III). If the PFTC was diagnosed before the age of
60 years, the relative risk of colorectal cancer tended to be high
TABLE I – CHARACTERISTICS OF THE COHORT OF FIRST PRIMARY FALLOPIAN TUBE CANCER CASES
(PFTC) EXTRACTED FROM 13 CANCER REGISTRIES, AND NUMBERS OF SECOND PRIMARY
CANCERS FOLLOWING PFTC BY DECEMBER 31, 2000
Characteristics
PFTC Second primary cancer
n % n Cumulative incidence of
second primary cancers (%)
Age at PFTC diagnosis
21–49 394 18.9 26 6.6
50–59 601 28.8 39 6.5
60–92 1089 52.3 53 4.9
Calendar period of PFTC diagnosis
<1975 501 24.0 46 9.2
1975–1983 425 20.4 31 7.3
1984–1990 479 23.0 24 5.0
19911 679 32.6 17 2.5
Time since PFTC diagnosis (full years)
<1 472 22.6 15 3.2
124 972 46.6 42 4.3
5–9 297 14.2 17 5.7
101 343 16.4 44 12.8
Cancer Registry
Australia, New South Wales 72 3.4 7 9.7
Canada, British Columbia 112 5.4 12 10.7
Canada, Manitoba 40 1.9 4 10.0
Canada, Saskatchewan 30 1.4 1 3.3
Denmark 505 24.2 34 6.7
Finland 464 22.2 16 3.4
Iceland 12 0.6 0 0.0
Norway 277 13.3 12 4.4
Singapore 26 1.2 3 11.5
Slovenia 100 4.8 8 8.0
Spain, Saragoza 11 0.5 0 0.0
Sweden 378 18.1 20 5.3
UK, Scotland 57 2.7 1 1.7
Total 2084 100 118 5.7
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(combined SIR of age categories <50 and 50–59 years 2.2, 95%
CI 1.1–4.0). Multivariate analysis gave essentially the same result:
the RR 1–4 years after the PFTC was 3.3 as compared with fol-
low-up 101 years (95% CI 1.0–11) and the RR related to PFTC
diagnosed in ages 601 years or in 19911 as compared with
younger ages or earlier calendar periods, respectively.
In multivariate analysis for the remaining cancers combined
(after exclusion of breast and colorectal cancers) there was some
indication of a higher risk related to PFTC diagnoses before 1984.
Elevated risks after first PFTC were also detected for nonlymphoid
leukaemia during the 2nd to 10th year after PFTC diagnosis
(4 cases, SIR 6.9, 95% CI 1.9–17.8) and for bladder cancer in
follow-up 51 years (7 cases, SIR 4.2, 95% CI 1.4–9.7). There
were 2 cases of endometrial cancer and 2 cases of cervical cancer
all of them diagnosed within 1 year after the PFTC.
Discussion
The number of fallopian tube cancer survivors has increased
because of advances in earlier detection, treatment and supportive
care. Therefore the risk of second primary cancers has become
clinically more relevant. Our study––the largest one on second
primary cancers after the first PFTC reported so far––showed that
women with first PFTC had a 40% increased risk of developing a
new primary cancer as compared with the general population.
There were excesses in breast cancer, colorectal cancer, leukae-
mia, bladder cancer and possibly lung cancer.
Little is known about the aetiology and epidemiology of PFTC.
Its aetiology is largely unknown but may be similar to that of
ovarian carcinoma, since they both arise from the M€ullerian duct.
Previous studies have suggested that nulliparous women have an
TABLE III – OBSERVED NUMBERS (OBS) AND STANDARDIZED INCIDENCE RATIOS (SIR) FOR SECOND PRIMARY CANCER AMONG 2,084 WOMEN WITH
A FIRST PFTC, BY AGE AND CALENDAR PERIOD AT PFTC DIAGNOSIS AND BY TIME SINCE PFTC DIAGNOSIS
Factor
Cancer site (ICD-9)
All malignant (140–208) Female breast (174) Colorectal (153,154)
Obs SIR 95% CI Obs SIR 95% CI Obs SIR 95% CI
Age at PFTC diagnosis
<50 26 1.6 1.0–2.4 7 1.4 0.6–2.8 4 2.3 0.6–5.9
50–59 39 1.5 1.1–2.1 12 1.8 0.9–3.0 7 2.2 0.9–4.5
>60 53 1.2 0.9–1.6 14 1.4 0.8–2.4 9 1.3 0.6–2.5
Calendar period of PFTC diagnosis
<1975 46 1.5 1.1–2.0 11 1.6 0.8–2.9 8 1.8 0.8–3.6
1975–1983 31 1.5 1.0–2.1 9 1.8 0.8–3.4 5 1.7 0.6–4.0
1984–1990 24 1.2 0.8–1.8 7 1.3 0.5–2.7 5 2.0 0.6–4.6
19911 17 1.1 0.6–1.7 6 1.3 0.5–2.9 2 1.0 0.1–3.5
Time since PFTC diagnosis (years)
<1 15 1.2 0.7–2.0 5 1.5 0.5–3.4 2 1.2 0.2–4.4
1–4 42 1.5 1.1–2.0 9 1.2 0.5–2.3 10 2.7 1.3–4.9
5–9 17 1.0 0.6–1.5 5 1.1 0.4–2.6 2 0.8 0.1–3.0
101 44 1.6 1.2–2.2 14 2.3 1.2–3.8 6 1.5 0.5–3.2
TABLE II – OBSERVED NUMBERS OF SUBSEQUENT PRIMARY CANCER CASES, STANDARDIZED INCIDENCE
RATIOS (SIR) AND 95% CONFIDENCE INTERVALS (CI) AMONG 2,084 WOMEN WITH
A FIRST PRIMARY FALLOPIAN TUBE CANCER (PFTC)
Cancer site (ICD-9) Observed SIR 95% CI
All malignant (140–208) 118 1.4 1.1–1.6
Oral cavity, pharynx (140–149) 2 1.5 0.2–5.6
Oesophagus (150) 1 1.3 0.0–7.3
Stomach (151) 3 0.7 0.2–2.2
Small intestine (152) 1 3.5 0.1–20
Colorectal (153, 154) 20 1.7 1.0–2.6
Colon (153) 13 1.7 0.9–2.9
Rectum (154) 7 1.7 0.7–3.5
Liver (155.0, 155.1) 0 – 0–5.0
Gallbladder, bile ducts (156) 3 1.9 0.4–5.5
Pancreas (157) 4 1.3 0.4–3.3
Peritoneum (158) 0 – 0–28
Lung (162) 11 1.8 0.9–3.2
Bone (170) 0 – 0–34
Soft tissue sarcoma (171) 1 2.5 0.1–14
Melanoma of skin (172) 1 0.4 0.0–2.5
Other neoplasm of skin (173) 9 1.5 0.7–2.9
Breast (174) 33 1.5 1.1–2.2
Cervix uteri (180) 2 0.7 0.1–2.4
Corpus uteri (182) 2 0.3 0.0–1.3
Other female genital (179, 184) 2 1.8 0.2–6.7
Bladder (188, 189.3–4) 6 2.8 1.0–6.0
Kidney (189.0–2, 189.5–9) 2 0.9 0.1–3.1
Brain, nervous system (191–192) 0 – 0–3.3
Thyroid gland (193) 2 2.3 0.3–8.3
Hodgkin’s disease (201) 0 – 0–15
Non-Hodgkin’s lymphoma (200, 202) 2 0.9 0.1–3.1
Multiple myeloma (203) 1 0.8 0.0–4.4
Leukaemia (204–208) 5 2.6 0.8–6.0
Lymphoid (204) 1 1.2 0.0–6.5
Nonlymphoid (205–208) 4 3.7 1.0–9.4
Others 5 1.2 0.4–2.7
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increased risk of PFTC, as for ovarian and breast cancer.1,21,22
There are earlier studies reporting a concomitant presentation of
breast cancer, other gynaecological cancers and colon cancer
among patients with PFTC,2,12,23,24 suggested to reflect their simi-
lar hormone responsiveness.24 First degree relatives of 44 PFTC
cases had a suggestion of an increase in risk of ovarian cancer
(RR 5 2.2, 95% CI 0.4–6.3) and of early-onset breast cancer
(RR 5 2.4, 95% CI 0.6–6.1)14; germline BRCA1 mutations were
found in 5 (11%) patients with PFTC and BRCA2 mutations in 2
(5%) patients. In comparison, out of unselected ovarian patients
3.5% were found to have BRCA1 mutations13 and the prevalence
of BRCA1 or BRCA2 mutations in the general population is
0.1%–0.2%.15 Brose et al. reported a cumulative risk of 3.0%
(95% CI 1.3–4.7%) for PFTC among BRCA1 carriers as com-
pared with 0.025% in the general population.16 Other reports have
confirmed an increased risk of PFTC in BRCA1 or BRCA2 muta-
tion carriers.25–28 A population-based study from Sweden con-
firmed a very high risk (SIR 93, 95% CI 55–146) of PFTC in
Swedish families with both breast and ovarian cancer.29 In fami-
lies with a case of breast cancer diagnosed before the age of 35 the
SIR of PFTC was 5.5 (95% CI 1.0–16). In our study the excess
risk of breast cancer became apparent more than 10 years after the
PFTC diagnosis and the SIR was not highest in the youngest age
groups, findings that appear unlikely to be explained by genetic
susceptibility. The latency would fit better with a hypothesis of an
effect of ionising radiation.30
Studies have advocated either pelvic or whole abdominal radio-
therapy for treatment of PFTC, but because of low efficacy and a
high rate of serious complications this should no longer be used
except for palliation of specific symptoms.2,8,31–33 The total doses
used in the pelvic or total abdominal radiotherapy have ranged
from 25 to 70 Gy (median 50.0 Gy).34 There are no studies on the
effect of radiation therapy, used as a treatment for PFTC, on breast
or other second cancer risk. On the basis of studies concerning
second malignancies among survivors of ovarian cancer35 the risk
effect of radiation therapy on PFTC should be low. The dose
delivered to the breast during whole abdominal radiation therapy
for PFTC should be similar to the dose delivered to the contralat-
eral breast from tangential field treatments of the breast cancer. In
our data the excess of breast cancer, bladder cancer, colorectal
cancer and leukaemia could be in part late effects of pelvic or
abdominal radiation.
Studies on late effects of chemotherapy treatments for cancer
have revealed an increased risk of second primary leukaemia,
mainly acute myeloid leukaemia.36 The relative risk (RR) of leu-
kaemia after platinum-based chemotherapy for ovarian cancer was
4.0 (95% CI 1.4–11).37 For carboplatin the relative risk was 6.5
(95% CI 1.2–37) and for cisplatin 3.3 (95% CI 1.1–9.4). The effect
was dose related, with the RR reaching 7.6 (95% CI 2.3–25) at
doses of 1,000 mg or more of platinum. The platinum-based
chemotherapy has been the main adjuvant therapy for PFTC and
could therefore explain the high rates of nonlymphoid leukaemia
after PFTC. Since the 1990s taxanes have been combined with
platinum-based drugs in the treatment of PFTC, especially in
advanced disease with a residual tumor after the operation. There
are case reports of secondary acute myeloid leukaemias after the
treatment with taxanes.38,39
All cases of nonlymphoid leukaemia and the majority of excess
cases of breast cancer were diagnosed among PFTC patients
treated after 1975, i.e., the hypothesis that the elevated SIRs are
due to earlier cancer treatment protocols seems not to hold. There
were no nonlymphoid leukaemia cases immediately after the diag-
nosis of the PFTC, but only during the 2nd to 10th year after the
PFTC, which may indicate an effect of platinum-based chemother-
apy.37 The overall excess of breast cancer, colorectal cancer and
bladder cancer may reflect an effect of treatments with radiother-
apy and/or chemotherapy.
There were 2 cases of cervical cancer and 2 endometrial cancers
diagnosed within 1 year after the diagnosis of PFTC. These may
be related to the additional diagnostic and treatment activities due
to the PFTC.
Tobacco-smoking is a strong established risk factor for lung
cancer and bladder cancer; it has been estimated that 79% of lung
cancers and 32% bladder cancers around the year 2000 among
women in the Nordic countries would be avoided if cigarette
smoking were eliminated.40 The raised SIRs for those cancers as
second primary cancers after PFTC suggest that smoking may also
have a role in the aetiology of PFTC.
Our results are based on records collected from 13 cancer regis-
tries with different registration practises in multiple cancer coding.
Misclassification of metastases as new primary cancers does not
seem to have been a problem, since we observed reduced risk esti-
mates for sites frequently exposed to metastasis, such as liver,
bone and brain. This may reflect a conservative coding principle: a
cancer is not accepted as new primary cancer if there is any doubt
that it could be a metastasis.
The conclusion of this study is that history of a PFTC has an
effect on the subsequent risk of breast, colorectal, bladder and
lung cancers and nonlymphoid leukaemia. Although with the
largest PFTC patient cohort ever collected for this kind of study,
due to the rarity of this cancer and the lack of individual data on
risk factors and treatment it is difficult to determine how much of
the excess risks might be associated with shared genetic or life
habit factors and how much is related to treatment of the PFTC.
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